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ABSTRACT  
 
The folate receptor (FR) was identified in 1986 and has been established as a 
‘molecular Trojan Horse’ target for the uptake of folate-conjugated organic molecules 
into cells. The FR is overexpressed in many malignancies, including those of the ovary, 
uterus, breast, cervix, and prostate, yet it is reportedly under-expressed in normal 
healthy cells. This difference in expression and the high affinity/specificity of folate 
towards the folate receptor presents a promising drug delivery system. The aim of this 
research was to utilise folic acid as a targeting moiety and generate simple metal folate 
and novel folate-phenanthroline complexes with cytotoxic properties. 
 
A challenging set of chemical objectives were set and resulted in the successful 
generation of simple metal-folate and metal-folate-phen complexes (metal = Cu2+, 
Mn2+, Fe3+ and Zn2+). In contrast to reports in the literature, NMR and IR evidence 
indicates that the folate ligand coordinates the metal centre via a tridentate ONO {α-
COO-, γ-COO-, and Namide} binding mode. A challenging six-stage synthetic route yielded 
the novel folate-ethylenediamine-imidazole-phen (FIMP-et) ligand and the novel 
complexes [Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O and [Mn(FIMP-et)3].(ClO4)2.9H2O 
were subsequently isolated in high yield and purity. 
 
The complexes generated were then utilised in a series of biological studies using 
cellular models expressing the folate receptor. Our results suggest that the effects 
mediated by these complexes are not dependent on folate receptor expression. Western 
blot analysis and live cell analysis identified that [Cu(fol)(phen)(H2O)].3H2O, with or 
without the inclusion of folic acid, induced expression of proteins associated with 
proteasomal inhibition and apoptosis. In contrast, [Mn(fol)(phen)(H2O)].4H2O was 
ineffective in inducing proteasomal inhibition. Interestingly 
[Mn(fol)(phen)(H2O)].4H2O induces cell death through a mechanism independent of 
proteasomal inhibition, which may involve ROS-induced autophagy.   
 
This work advances the field of medicinal inorganic chemistry and has identified novel 
mechanisms of action for metal folate targeted inorganic complexes as potential 
chemotherapeutic agents, through proteasomal inhibition and ROS-induced 
autophagy.  
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I.1 Introduction to Chemotherapy 
 
The origins of chemotherapy stem from nitrogen mustard, a chemical warfare agent 
used in WWI and extensively researched by the Allies of WWII. Victims of the toxic 
gas were often noted to have profoundly low levels of white blood cells as well as a 
reduction in size of the lymph nodes1. In light of this, Doctors Louis Goodman and 
Alfred Gilman, two pharmacologists with the US Department of Defense, saw 
potential in the agent as a treatment for lymphoma, a disease often characterized by 
the malignant swelling of the lymph nodes. The gaseous agent was converted to a 
liquid product and named mustine – a compound which would go on to be the model 
for alkylating agents still used today in modern chemotherapy2.  
 
Shortly after this serendipitous discovery, Sidney Farber built upon the observations 
made by Goodman and Gilman and demonstrated that 4-aminopteroyl-glutamic acid 
(aminopterin) (Figure 1), a synthetic derivative of the B-vitamin folic acid, resulted in 
remissions in children with acute leukemia3–6. Aminopterin was found to compete with 
folate for the binding site of the dihydrofolate reductase (DHFR) enzyme preventing 
the uptake of folic acid and consequently halting DNA replication7–9. However, the 
difficult synthesis of aminopterin prompted researchers to modify the compound, 
resulting in the generation of methotrexate (Figure 1) - an antifolate drug still widely 
used today and the first drug shown to cure a metastatic tumor of choriocarcinoma10. 
The success of these initial chemotherapeutic agents encouraged chemists to seek new 
molecules that could inhibit cell replication entirely - The era of cancer chemotherapy 
had begun. 
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Figure 1: The chemical structures of aminopterin and methotrexate. 
 
Since the introduction of chemotherapy, the average rate of survival amongst adult 
cancer patients has increased from 35% in 1954 to 50% in 1975 and now to the latest 
(2018) average survival rate of 69%11,12. This increase in survival is largely due to 
earlier detection, improvements made in anticancer therapeutics, and the introduction 
of anticancer vaccines12. However, although there have been great advances in the field 
of chemotherapy, many of the chemotherapeutic agents in use today still suffer the 
same limitation as their predecessors, poor specificity. This is primarily because 
anticancer agents often utilize the high proliferation rates of cancer cells as their 
objective. However, this non-selective strategy ultimately results in the death of 
healthy cells that also proliferate rapidly, such as those of the gastrointestinal tract, 
hair follicles and the immune system13,14. The adverse side effects which often result, 
introduce dose limiting consequences for many chemotherapeutic agents and 
invariably undermine their use.  
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I.1.1 Introduction to Targeted Therapies 
The paragon of chemotherapy is the recognition of malignant cells by a therapeutic 
agent via the identification of a unique characteristic of malignant cells, and the 
preferential delivery of a chemotherapeutic agent to such cells to induce a precise 
cytotoxic effect. Many examples of the effective use of this strategy can be found in 
the literature, including targeted therapies in advanced stages of development and a 
small number in clinical use15–18.  
 
It is worth noting that although the development of targeted therapeutic agents was 
primarily initiated to direct the toxic effects to malignant cells only, in turn reducing 
damage to healthy cells19, targeted therapeutics also offer a plethora of other 
advantages. These include enabling otherwise membrane impermeable drugs to enter 
target cells via receptor mediated endocytosis and inducing advantageous 
modifications in cell behaviour by activating a receptor’s normal signaling pathway19. 
 
I.1.2 Folate-Targeted Chemotherapy 
 
In 1986, Kamen et al, a group from the University of Texas South-western Medical 
Centre reported that MA104 cells possess a high-affinity surface receptor for folates20. 
The group proposed that folate uptake may occur by: (i) binding to the surface 
receptor, (ii) internalisation via endocytosis and (iii) liberation from the receptor in an 
acidic endosome20. In the early 1990’s, Leamon and Low reported that the 
physiological process by which folate-drug conjugates enter folate receptor positive 
(FR+ve) cells is identical to that of folic acid. Furthermore, Leamon and Low stated 
that macromolecules can be non-destructively delivered into cells via folate receptor-
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mediated endocytosis if the macromolecules are covalently conjugated to folic acid 
prior to addition to cells expressing the folate receptor21–23. These discoveries led to 
the development of chemotherapeutic folate targeting, Often referred to as “molecular 
Trojan horses”, covalent folate conjugates can leverage the high affinity/specificity of 
folate towards the folate receptor (FR)23. Later in 1999, Leamon et al determined that 
macromolecules attached to folic acid by either the α or γ glutamyl linkage could 
associate with FR bearing cells at virtually identical levels24. However, it is worth 
noting that the different pKa values of the α and γ carboxylic acid moieties of the 
glutamate tail of folic acid result in different reactivities25.  
 
In 2013, Chen et al, successfully elucidated the crystal structure of the human  folate 
receptor α (FRα) in complex with folic acid at 2.8 Å resolution (Figure 2). They 
reported that the human FRα has a globular structure stabilized by eight disulphide 
bonds. It was reported that the folate pteroate head binds deep within the receptor 
pocket, leaving its glutamate moiety exposed outside of the pocket entrance, allowing 
it to be conjugated to drugs without unfavorably affecting FRα binding26. 
 
 
Figure 2: The binding interaction of folic acid and FRα as determined by Chen et al26. 
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In the same year, Wibowo et al published structures of human folate receptors α and 
β and described the molecular interaction of human FR with antifolates Alimta, 
aminopterin and methotrexate27. Wibowo added further that the pterin rings interact 
with residues deep within the binding pocket via π- π stacking and are stabilized by 
additional polar bonds27. The extensive interactions between the receptor and ligand 
explain the high folate-binding affinity and offer a template for the design of more 
specific drugs targeting the folate receptor system26. 
 
Of the numerous targeted therapeutic methodologies currently under development, this 
review of the literature will focus specifically on those utilizing the folate moiety to 
selectively target the FR which is over expressed on many cancer cell types28,29,38,30–
37. However, it is worth mentioning that the high FR expression observed in activated 
macrophages may also provide a means of preferentially targeting Mycobacterium-
infected macrophages, activated macrophages in inflammatory and autoimmune 
diseases (rheumatoid, inflammatory and osteoarthritis), and may also hold promise in 
the treatment of leishmaniosis39–48. 
 
I.2 Folic Acid: Structure, Function and Its Role in disease Progression 
 
Folic acid is a member of the family of B9 vitamins, its molecular structure can be 
subdivided into three components, consisting of a pteridine moiety, linked by a 
methylene bridge at carbon 6 to para-aminobenzoic acid (PABA), with an amide bond 
to a glutamic acid moiety (Figure 3)49. The terms ‘folate’ and folic acid are often used 
interchangeably but it should be noted that folic acid as depicted in Figure 2 is a 
pharmacological agent and does not occur in nature49. The term ‘Folate’ is generic and 
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used to refer to a number of members of the B9 vitamin family. For the purposes of 
this thesis, the terms folate (i.e. the deprotonated form of folic acid) and folic acid may 
be used interchangeably throughout. 
 
 
Figure 3: The structure of folic acid highlighting the three central components; the 
pteridine ring, para-aminobenzoic acid (PABA) and the glutamate tail. The α and γ 
carboxylic acid moieties are indicated. 
 
Folic acid is used in vitamin supplements and in cell culture media due to its chemical 
stability, but within cells it is first reduced to dihydrofolate (DHF) and then to 
tetrahydrofolate (THF) mediated by dihydrofolate reductase (DHFR) (Scheme 1)49. 
Endogenous folic acid is not found in human cells; it is derived entirely from dietary 
sources, with 5-methyltetrahydrofolic acid (5-methylTHF) being the major folate 
derived from dietary sources and the dominant folate found in the blood of humans 
and rodents49. 
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Scheme 1: Folic acid is reduced to dihydrofolic acid (DHF), which is in turn reduced 
to tetrahydrofolic acid (THF) in reactions mediated by dihydrofolate reductase 
(DHFR). 5-Methyltetrahydrofolic acid (5-methylTHF) is the major folate found in 
blood (modified from Zhao et al)49.  
 
Folates play an essential role in critical biosynthetic processes in mammalian cells. 
These one-carbon donors are required for purine nucleotide and thymidylate synthesis 
and, hence, are essential for the de novo production of RNA and DNA. Folates are also 
required for vitamin B12-dependent synthesis of methionine, from which S-
adenosylmethionine is formed, required for methylation of DNA, histones, lipids and 
neurotransmitters49. A deficiency in folate uptake results in the impairment of 
methylation of deoxyuridylate to thymidylate and initiates a process that can lead to 
megaloblastic anemia50. Insufficient folate intake (less than 400 μg) in pregnant 
women is associated with neural tube defects (NTD) which are abnormalities that may 
occur in the brain, spine, or spinal column of a developing embryo and are present at 
birth. The two most common forms of NTD are spina bifida (in which the fetal spinal 
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column doesn't close completely) and anencephaly (in which most of the brain and 
skull do not develop)51,52. 
 
1.2.1 Folate Uptake into Cells and Tissues 
 
The cellular uptake of folate is mediated by three distinct transporters; the proton 
coupled folate transporter (PCFT), the reduced folate carrier (RFC), and folate receptor 
(FR). The PCFT is the main transporter of folate in low pH environments, such as the 
intestine53. The RFC is the predominant folate transporter expressed in normal adult 
tissue, mediating the uptake of reduced folates and the antifolate drug, methotrexate 
with relatively high affinity (Km for 5-methylTHF in the range of 3-7 µM; Km for 
methotrexate from 1 – 5 μM)38,54,55. However, it has a very low affinity for folic acid 
(Ki approx. 150-200 µM)56. The RFC is ubiquitously expressed in the intestine, 
hepatocytes, choroid plexus and renal epithelial cells. It facilitates transplacental 
transport of folates and folate transport across the blood-brain barrier57–60. 
 
The FR is a glycopolypeptide with high affinity for binding and transporting 
physiological concentrations of folate into cells. The human FR family comprises of 
four isoforms –α, -β, -γ and -δ. Of the four, FRα and FRβ are 
glycosylphosphatidylinositol (GPI)-linked membrane bound proteins, while the third, 
FRγ, is a secretory protein. The fourth isoform, FRδ, has been identified only from 
genome database mining, however neither its tissue expression nor functionality have 
been determined61. Both FRα and FRβ exhibit limited expression in healthy tissues 
such as placenta, kidney, bladder and the choroid plexus. In the kidney, FRα is 
implicated in folate transcytosis from luminal cavities to the interior environment, 
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whilst in the placenta, both FRα and FRβ function to maintain maternal-to-fetal folate 
transport. Furthermore, the presence of FRα in choroid plexus is critical to maintain 
folate homeostasis and for the transfer from plasma to the cerebrospinal fluid27,38.  
 
However, most FRs are expressed on the apical surface of healthy, polarized epithelial 
cells and are therefore inaccessible to circulating FR-targeted agents administered 
intravenously. An exception to the rule is the kidney, in which FRα expressed in the 
proximal tubules will bind to receptor targeted agents which are filtered from the blood 
stream. It has been suggested that the kidneys should be protected against the cytotoxic 
effects of FR-targeted agents, such as nanoparticles, liposomes and macromolecules, 
as they are excluded from glomerular filtration due to their size61. 
 
FRα is consistently overexpressed in non-mucinous adenocarcinomas of the ovary, 
uterus, breast, cervix, colorectal, prostate, brain, nose and throat26,27,62. It exhibits a 
high affinity (Kd < 10-9 M) for folic acid, a binding affinity ~10 times greater than any 
other reduced form of the vitamin or the anti-folate drug, methotrexate38. It is 
estimated that 95% of ovarian carcinomas overexpress FRα and that a strong 
correlation exists between FRα expression and both stage of tumour progression and 
histological grade63. In instances of lung cancer, the leading cause of cancer death 
worldwide, non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancers 
and has been shown to express FRα to a high extent64,65. It is hypothesised that the 
overexpression of FRα in malignant cells confers a growth advantage to tumours by 
increasing folate uptake, in turn increasing DNA synthesis and affecting cell 
proliferation via alternative cell signalling pathways32. The overexpression of FRα 
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may hold potential as both a therapeutic and prognostic target in a number of different 
cancers, especially ovarian, colorectal and breast65–67. 
 
FRβ is expressed on activated synovial macrophages which are present in large 
numbers in arthritic joints, where they play an active role in rheumatoid arthritis. 
Furthermore, pathologies such as multiple sclerosis68, Crohn’s disease69, ulcerative 
colitis70, psoriasis71, osteomyelitis72, and even atherosclerosis73 are also believed to 
be caused or aggravated by activated macrophages which express FRβ74.  
 
I.2.2 Mechanism of Folate Uptake via the Folate Receptor 
 
The physiological process by which both dietary folate and folate-drug conjugates 
enter FR expressing cells is known as endocytosis. It involves the binding of folate or 
an exogenous folate-drug conjugate to FRα and the subsequent invagination of the 
plasma membrane around the receptor-ligand complex to form an intracellular vesicle 
or endosome. It is reported that the endosome acidifies to ~pH 5 through the action of 
proton pumps, inducing a conformational change in the receptor and the release of the 
active drug from the folate delivery system75 (Figure 4). However, the precise 
pathway(s) are still widely discussed76–79. 
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Figure 4: Uptake of folate-drug conjugates. The folate-drug conjugate is taken up by 
cells by binding of folate to the folate receptor. Invagination of the plasma membrane 
results in receptor mediated endocytosis. The acidic pH (~5) results in dissociation of 
the drug cargo and the folate receptor is recycled to the cell surface once more 
(modified from Leamon et al)75. RFC: reduced folate carrier. 
 
Receptor-mediated endocytosis offers an advantageous uptake system as it is non-
destructive to the folate-drug conjugate and, as the folate receptor is known to recycle 
regularly between the cytosol and cell surface, an increased drug concentration can be 
obtained within the cell53,80. Given the restricted expression of FR isoforms 
(particularly FRα) on healthy tissue, in addition to its high affinity for folic acid, folate-
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mediated drug delivery is advantageous to overcoming unwanted drug toxicity as well 
as offering the benefit of increased drug concentration in target cells. 
 
I.3 Coordination Chemistry  
 
Medicinal inorganic chemistry is still considered a youthful discipline by many, 
contrary to the historical use of metals in medicine in the civilizations of Mesopotamia, 
Egypt, India, and China81–83. The antimicrobial agent, salvarsan (a mixture of 3-amino-
4-hydroxyphenyl-arsenic(III) compounds), developed by Paul Ehrlich as an effective 
treatment against syphilis in 1912 is widely regarded as the birth of modern 
chemotherapy and often cited as the beginning of metallodrug development84. 
 
Yet it was the discovery of the platinum-based anticancer drug, cisplatin, in which 
medicinal inorganic chemistry truly found success85. Cisplatin has been employed in 
the treatment of various solid neoplastic malignancies including sarcomas and 
carcinomas such as small cell lung cancer, testicular, ovarian, cervical, endometrial, 
bladder, head and neck, gastroesophageal and germ cell cancers/tumours86,87. It has 
proven highly effective against testicular cancer in combination with other agents such 
as bleomycin with cure rates up to 85%88.  
 
Cisplatin is still extensively utilised, being a major component in first, second and third 
line treatment regimens for the aforementioned cancer types89. The clinical success of 
cisplatin and its derivatives is immense, as they are among the most effective 
anticancer cytotoxins available and are currently utilized in 50% of all treatment 
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regimens for solid tumours. This constitutes the most impressive contribution to the 
use of metals in modern cancer chemotherapy.  
 
I.3.1  Contemporary Modes of Action of Metallodrugs 
 
Cisplatin and its platinum-based derivatives represent the classical metal-based 
therapy, inducing its cytotoxicity via DNA damage. Platinum based compounds have 
been reported to enter cells via the copper transporter, Ctr1 and undergo hydrolysis 
within the cell, producing a potent electrophile capable of reacting with the nitrogen 
donor atoms on nucleic acids and cross-link to the N7 reactive centre on purine 
residues of deoxyribonucleic acid, in turn halting cell division and resulting in 
apoptotic cell death. The 1,2-intrastrand cross-links of purine bases with cisplatin 
account for roughly 90% of adducts formed and have been reported to contribute to 
the toxicity of cisplatin90,91.  
 
However, due to the undesirable adverse side effects and potential drug resistance 
associated with cisplatin and related platinum-based drugs, there has been increased 
interest in nonclassical platinum complexes whose mechanism of action may be 
distinct. Complexes containing other metals, such as copper, not only offer the 
prospect of biological activity involving DNA interaction/damage but also the 
potential to interact with biomolecules such as proteins and the potential to interfere 
with anomalies associated with metabolic processes such as oxidative 
balance/imbalance (Figure 5)92. 
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Figure 5: The proposed sites of action of metal-based drugs in mammalian cells. 
Copper(II) and platinum(IV) complexes have been reported to interact with DNA 
either directly or via ROS generation, resulting in DNA cleavage and ultimately 
apoptosis. Metals such as manganese(III), copper(II), and ruthenium(II) reportedly 
induced ROS related-mitochondrial damage and autophagy. Finally copper(II) and 
other metals such as gold(II), nickel(II) and zinc(II) have been found to induce 
proteasomal damage, resulting in apoptosis93,94,103–112,95–102. 
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I.3.1.1  Reactive oxygen species (ROS) induced DNA damage 
 
The activity of transition metal complexes is largely associated with the generation of 
ROS and the subsequent damage to proximal proteins and DNA. For example, the 
hydroxyl radical (•OH), formed through Fenton or Haber–Weiss reactions catalyzed 
by the reduction of Mn to Mn-1 in the presence of oxygen and a ready electron source, 
such as glutathione, is credited as the most likely agent of DNA cleavage93–95. This 
reaction, in turn, results in the oxidation of bases (most notably guanine, to form 8-
oxoG); the generation of other radicals that result in DNA crosslinks (particularly G 
and methylated-C), and double or single strand breaks in the phosphoester bonds 
between specific nucleotides in DNA113.  
 
I.3.1.2  ROS-induced autophagy 
 
Autophagy is the self-catabolic process of sequestering and delivering damaged 
organelles and protein aggregates from the cytoplasm into lysosomes for 
degradation114. Autophagic cell death is morphologically associated with the induction 
of autophagic vacuole formation and involves a biochemical process where organelles 
are digested in double membrane autophagasomes115. In contrast, apoptosis, (more 
commonly encountered when working with metal complexes) is characterized by 
exposure of phosphatidylserine on the external membrane, formation of mitochondrial 
permeability transition pores, caspase 3 activation, chromatin condensation, blebbing, 
and oligo-nucleosomal DNA fragmentation116,117.  
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Among the effector mechanisms involved in the control and regulation of cell death 
pathways, including autophagy and apoptosis, is the cellular redox status. The redox 
status in the cell is determined by the balance between the rates of production and 
breakdown of reactive oxygen and/or nitrogen species (ROS/RNS), including free 
radicals such as superoxide (O2
.-), hydroxyl radical (•OH), and non-radicals capable of 
generating free radicals (i.e., H2O2)
118. 
 
In recent years, metal complexes have reportedly induced cell death by means of ROS-
induced autophagy. For example, in 2009, Paris et al reported that a copper(II) 
dopamine complex (Cu.DA) induced autophagic death in RCSN-3 cells (transformed 
rat ganglion cell line). Fluorescent microscopy shows that Cu.DA (100 µM) induced 
the formation of double-membraned autophagic vacuoles around mitochondria, 
evident by co-localisation of GFP-LC3 (a protein involved in the formation of 
autophagosomes) and the mitochondrial calcium marker Rhod-2AM. The authors 
proposed that the autophagic events preceded late apoptotic death, due to late 
oligonucleosomal DNA fragmentation observed. These results are in agreement with 
reports showing that autophagy precedes apoptosis119. Additionally, complexes of 
copper(II), manganese(II), ruthenium(II), and platinum(II) have been reported to 
induce similar effects96–104. 
 
I.3.1.3  Proteasome Inhibition 
 
In recent years, the disruption or inhibition of the Ubiquitin-Proteasome System (UPS) 
has been identified as a novel mechanism of several transition metal complexes. The 
UPS is responsible for intracellular protein homeostasis and is the predominant 
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regulator of the degradation of proteins involved in cell cycle control, gene 
transcription, DNA repair, and apoptosis induction and helps to maintain normal 
cellular function120. Deregulation of this pathway has been reported in various forms 
of cancer such as breast, colorectal, lung and prostate, and appears to promote cancer 
development through a plethora of mechanisms121. 
 
The initial link between metals and inhibition of the proteasome was first identified in 
2004 by Daniel et al who reported that copper(II) salts (10 µM), regardless of 
counterion, were consistently capable of irreversibly inhibiting proteasome activity in 
cell-free conditions by more than 80% whereas free organic ligands {such as 
hydroxyquinoline (8-OHQ) and 1,10-phenanthroline (phen)} could not. Free 
copper(II) ions failed to reproduce the same proteasomal effects in whole cells, 
reducing proteasome activity by 30% at 10 µM, possibly due to poor cellular 
uptake/inability to access the proteasome. However, coordination to phen or 8-OHQ 
not only facilitated uptake into whole cells to induce proteasome-inhibitory effects but 
also completely inhibited proteasome activity at 10 µM. Since 2004, a number of 
articles reporting similar findings have also been published122–126. 
 
The implication of metal induced ROS generation in the inhibition of proteasome 
activity has also previously been investigated. Daniel et al noted that co-incubation of 
CuCl2 in the presence of the anti-oxidant, N-acetylcysteine (NAC; 100 mM) had no 
effect on the ability of copper to inhibit the purified 20S proteasome127. Similarly, 
Santoro et al reported that copper-treated samples (5 µM) were unable to catalyse 
production of ROS in the presence of the reducing agent, Dithiothreitol (DTT; 29 µM). 
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Both authors concluded that proteasome inhibition was a result of direct binding of 
Cu(II) ions to the proteasome and not a result of ROS generation.  
 
Other metals such as gold, nickel and zinc have also been reported to induce 
proteasome inhibition, evident by accumulation of K48-linked ubiquitinated proteins 
and the upregulation of proteasome-related substrates such as p21 and p27105–112. 
Interestingly, a platinum pyrithione (PtPT) complex reported by Zhao et al was found 
to target proteasomal deubiquitinating enzymes (DUBs) UCHL5 and USP14 rather 
than DNA, suggesting a different mode of action than cisplatin107.  
 
It must be stated that although the described mechanisms have been found to induce 
cell death, it is entirely likely that numerous pathways and/or mechanisms are involved 
in the eventual cell death. It is now becoming more apparent that transition metal-
based drugs are multi-faceted and multi-modal, and that their mechanism of action 
goes far beyond DNA damage.  
 
I.4  Folate targeting of inorganic complexes 
 
As described in Section I.3.1.1, cisplatin and its successors interfere with replication 
and/or the mitotic processes of tumour cells. In this way, they achieve potency by 
damaging cancer cells more than they damage healthy cells. While this approach has 
been successful, it is known to cause significant side effects, such as nephrotoxicity, 
neurotoxicity, leukopenia, and thrombocytopenia, as well as nausea, vomiting, and 
hair loss. Just as the design of organic chemotherapeutics has shifted from potent 
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alkylators and inhibitors of DNA synthesis to more tailored, subtle reagents, the design 
of novel metallotherapeutics now requires a targeted approach128.  
 
1.4.1 Coordination complexes of folic acid 
 
The application of FRα-targeted molecules is not new; there have been many articles 
and papers published regarding the conjugation of folates to known organic drug 
molecules such as taxol, paclitaxel and doxorubicin to improve drug targeting129–131. 
The advantageous chemotherapeutic potential of folate-targeted inorganic 
nanoparticles such as mesoporous materials132–134, gold-nanoshells135–137, quantum 
dots (QD)138–140, and magnetic nanoparticles141–143 has also been established. Along 
with these, the applications of other folate-targeted nanomaterials including liposomes, 
micelles, dendrimers, oligonucleotides and carbon nanotubes (CNT) have been 
reviewed in detail elsewhere14,34,144. 
 
However, there is a void in the literature regarding the coordination chemistry of folic 
acid and the conjugation of folic acid to metal-based molecules and even less regarding 
their chemotherapeutic capabilities. A review of the literature returned fewer than forty 
relevant articles concerning metal-folate complexes, many of which focus on the 
synthesis and characterisation of metal-folate complexes but do not report results from 
biological investigations. 
 
The coordination chemistry of folic acid (Figure 3), is poorly characterised. Metal 
complexes of pteridines are not common since they are highly π electron deficient 
heterocycles but they are known to form some complexes involving their nitrogen and 
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oxygen atoms (which can exist in either a carbonyl group or an iminol group depending 
on which tautomeric state prevails)145. The binding properties of glutamic acid, on the 
other hand, are well established and it is known to form thermodynamically stable 
complexes with a range of metals146. Very few publications report the direct 
coordination of folic acid to a metal even though such complexes may have interesting 
biological activity and selectivity towards FRα-overexpressing cells. Table 1 
summarizes the formulation, mode of coordination and any reported biological 
properties for the metal folate/folic acid complexes, and relevant related compounds 
that were sourced in the literature. 
22 
 
Table 1: Formulae, mode of coordination and biological properties for the metal folate/folic acid complexes. 
 
 
Formulae Binding mode of the folate/folic acid Biological activity Reference 
M2(folate).nH2O (M = Mn
2+
, Co
2+, Ni2+, Cu2+, 
Zn2+, Cd2+ and Hg2+ ; n = 1-3,5 or 15) 
Bidentate bridging via α and γ carboxylate 
groups 
Antifungal and antibacterial activity 147 
 
[Ag2(folate)].3H2O 
 
Bidentate bridging via α and γ carboxylate 
groups 
 
Not reported 
 
 
148 
[(VO)2(folate)(NH4)2(SO4)2] 
Bidentate bridging via α and γ carboxylate 
groups 
Antioxidant and anti-DNA damage 
capabilities. 
149 
Ln2(folate)3.nH2O (Ln = La
3+ to Gd3+, except 
Pm3+; n = 6-9.5) 
Bidentate bridging via α and γ carboxylate 
groups 
Not reported 150 
M(folate)2.nH2O (M = Cu
2+ or Fe3+; n = 2 or, 
respectively) 
Bidentate chelating via the α and γ 
carboxylate groups 
M(folate)2.nH2O absorbed more efficiently in 
rodent blood than metal-free folic acid 
151 
M(folate).nH2O (M = Mn
2+, Fe2+, Co2+, Ni2+, 
Cu2+, Zn2+; n = 4-6) 
Bidentate chelating via the α and γ 
carboxylate groups 
Not reported 148,150 
M(folate).4H2O (M = Ca
2+ or Sr2+) 
Bridging Bidentate via α and γ carboxylate 
groups 
Sr(folate).4H2O is a non-toxic bone promoter 
152 
[Cu(MTX)(H2O)] (MTX
2- = the doubly 
deprotonated methotrexate) 
Tridentate (α and γ carboxylate groups and 
the amide nitrogen of the glutamate moiety) 
Nuclease activity and cytotoxicity 153 
[UO2(folate)2](EV)2 (EV
+ = the cation of the 
basic triphenylmethane dye ethyl violet) 
Chelating via α carboxylate and amide 
nitrogen of the glutamate moiety 
Not reported 154 
 
[cis-Ru(2,2’-bipy)2(folic acid)]2+ 
 
Chelating via N5 and N10 nitrogen atoms 
 
Not reported 
155,156 
 
[cis-Pt(NH3)2(H2O)2(tetrahydrofolate)] 
 
Chelating via N5 and N10 nitrogen atoms 
 
Dihydrofolate reductase and folate transport 
system inhibition in L1210 cell line 
157 
MLL’X2.2H2O (where M = Cu
2+, Cd2+, Mn2+, 
Fe3+, Ni2+, Pb2+ ; L = folate or niacin; L’= 
glycine, and X = NO3 or Cl
-), 
Bidentate chelating via α and γ carboxylate 
groups 
Weak-to-moderate cytotoxicity and 
antioxidant effects 
158 
{M2(folate)(N2H4)3(OH)2(H2O)2}n (M =Ni
2+ 
or Co2+) 
Bidentate bridging via α and γ carboxylate 
groups 
FR+ve selective cytotoxicity; where M = Co2+ 
- in-vivo antitumour activity in mice 
159,160 
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The earliest reported synthesis of a metal-folate complex found in the literature was 
published in 1947 by a group led by J.J. Pfiffner of Park-Davis and Company161. 
Interested in the application of folic acid as an “anti-anaemic factor”, the group focused 
on its isolation from liver and yeast. As part of their study, a silver salt of the B vitamin 
was synthesized; involving the reaction of an aqueous solution of folic acid with silver 
nitrate to generate a yellow microcrystalline product, which they formulated as 
[Ag2(folate)] on the basis of elemental analysis
161. 
 
In 2008, Abd El-Wahed et al reported the synthesis and thermal characterisation of 
simple binuclear transition metal-folate complexes with the general formula 
M2L.nH2O (where M = Mn
2+
, Co
2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ ; L = folate; n = 
1-3,5 or 15), generated by the reaction of sodium folate with the respective metal 
chlorides147. Here, the folate anion acts as a dicarboxylate ligand, with the metal ion 
coordinated to both the α and γ carboxylate groups of the glutamic acid moiety (Figure 
6). Furthermore, the group conducted antifungal and anti-bacterial testing on these 
simple metal-folate complexes and concluded that the cadmium(II), cobalt(II) and 
nickel(II) folate complexes exhibit activity against Penicillium, Trichoderma and 
Bacillus subtilis, while a mercury(II) folate complex was shown to exhibit high 
activity against Penicillium, Trichoderma and Escherichia coli147. The generation of 
[Ag2(folate)].3H2O, via a similar synthetic route as reported by J.J. Pfiffner et al, has 
also been reported recently148. 
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Figure 6: The proposed structures of various metal folate complexes synthesized by 
Abd El- Wahed et al147. (A) The structure of 4 coordinate complexes where M = Mn2+, 
Co2+, Ni2+, Cu2+, Zn2+, Cd2+ and Hg2+ and n = 1, 3, 15, 2, 0, 3 and 0, respectively. (B) 
The structure of the only six coordinate complex where M = Fe3+ and n = 7. 
 
In 2016, the synthesis and characterization of a similar simple vanadium(IV) folate 
complex [(VO)2(L)(NH4)2(SO4)2] was also published (Figure 7)
149. 
[(VO)2(L)(NH4)2(SO4)2] was isolated from the reaction of vanadyl(II) sulphate and 
folic acid in solution at pH 7-8, and the complex was found to exhibit antioxidant and 
anti-DNA damage capabilities149.  
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Figure 7: The structure of [(VO)2(L)(NH4)2(SO4)2]
149 
 
In 2009, Hamed et al reported mononuclear iron and copper folate complexes, with 
the general formula ML2.nH2O (M = Cu
2+ or Fe3+; L = folate; n = 2 or 3, respectively) 
whereby the metal ions are coordinated to two folate anions via the glutamate moiety 
which effectively acts as a bidentate ligand on the α and γ carboxylate groups (Figure 
8 (A))162. When treating white albino mice with 100 mg/kg of folic acid or the copper-
/iron-folate complexes, the authors found that the complexes were better absorbed in 
rodent blood than folic acid itself, which they believe may be due to the increased 
solubility of the metal-folate complexes. In addition, folate complexes with the general 
formula ML.nH2O (M = Mn
2+, Fe2+, Co2+, Ni2+, Cu2+, Zn 2+; L = folate; n = 4-6) have 
also been reported150. It is proposed that in these complexes the folate also acts as a 
bidentate ligand via the glutamate moiety, but their structures were not confirmed.  
 
In 2015, Rojo et al reported the synthesis and characterisation of calcium and strontium 
folates with the general formula ML.4H2O (M = Ca
2+ or Sr2+; L = folate), in which the 
folate also acts as a bidentate ligand via the glutamate moiety152. The strontium-folate 
complex, which was obtained by reacting a sodium salt of folic acid with strontium 
chloride, was found to overcome the toxic effects associated with free Sr2+ ions, a 
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problem associated with strontium ranelate, the established anti-osteoporosis treatment 
used to promote bone growth.  
 
Interestingly, in 2015 Nagaj et al reported the copper(II) complex of the antifolate 
agent methotrexate (MTX), an analogue of folic acid (Figure 1)153. Potentiometric 
titrations of MTX against CuCl2 yielded the neutral complex [Cu(MTX)(H2O)] 
(MTX2- = the doubly deprotonated methotrexate) at pH 7.5 and on the basis of NMR 
and IR spectral evidence the authors proposed that the MTX2- was bound to the 
copper(II) centre as a tridentate ligand via the α and γ carboxylate and the amide 
nitrogen functionalities (Figure 8 (B)). [Cu(MTX)(H2O)] was also shown to be an 
effective nuclease agent in the presence of added hydrogen peroxide and the complex 
was found to be approximately twice as cytotoxic against mouse colon carcinoma 
(CT26) and human lung adenocarcinoma (A549) cell lines than methotrexate itself. 
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Figure 8: (A) The proposed structure of the octahedral metal (M = Cu2+ or Fe3+) 
difolate complexes synthesized by Hamed et al162. (B) The proposed structure of the 
neutral complex [Cu(MTX)(H2O)] (MTX2- = dianionic methotrexate) isolated at pH 
7.5153. (C) The structure of [UO2(folate)2](EV)2 (EV = Ethyl Violet)
154. (D) The 
proposed structure of ΔR cis-bis(2,2’-bipyridine)-dichlororuthenium(II), [cis-Ru(2,2’-
bipy)2Cl2 coordinated to positions the N5 and N10 of folic acid
155. 
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While developing a novel analytical method for folic acid and its metabolites under 
physiological conditions, Xi et al isolated the 2:1 anionic folate-uranium (IV) complex 
salt [UO2(folate)2](EV)2 (where EV
+ = the cation of the basic triphenylmethane dye 
ethyl violet) in aqueous solution at pH 4.2-4.8154. The authors proposed that the folate 
ligands are coordinated to the uranium atoms in the UO2
2+ moieties via the nitrogen 
atom of the imido-group of the amino-carboxyl and the oxygen atom of the α -carbonyl 
to form stable five-membered chelate rings (Figure 8 (C)), as determined by charge 
density calculations. 
 
In 1992 Schwederski et al reported the synthesis of the ruthenium complex cation [cis-
Ru(2,2’-bipy)2 (FA)]2+ (FA = folic acid) in which they postulated, based on a limited 
analysis, that a neutral folic acid ligand was bound to the ruthenium as an α - 
iminocarbonyl chelate, via the carbonyl oxygen and a nitrogen atom of the pteridine 
moiety156. More recently, while investigating the interaction of ruthenium complexes 
with intracellular biomolecules, Scrase et al also reported the isolation of [cis-Ru(2,2’-
bipy)2(FA)]
2+ under physiologically relevant conditions155. The complex was 
characterised extensively by NMR and MS which revealed that the folic acid acts as a 
neutral chelating ligand involving a nitrogen atom from the pteridine group and the 
amine nitrogen of the para-aminobenzoic acid moiety (Figure 8 (D))155. 
 
These authors also repeated the synthesis of the complexes reported by Schwederski 
et al and confirmed that the two complexes were identical. Furthermore, the group 
experimented with altered protonation states of folic acid and confirmed that the 
binding of the neutral folic acid was contingent on its ability to act as the N-N chelate. 
The authors hypothesised that the total ruthenium content of treated cells could be 
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forty times greater than folate in molar concentrations and therefore, the resulting 
ruthenium-folate species could interfere with enzyme binding and the one-carbon 
transfer function of folates in cells. Therefore, given the low concentration of folates 
in cells, any sequestration of ruthenium will alter the cellular balance of folate. As 
folate metabolism has long been recognized as a key target for cancer therapy, 
understanding how ruthenium complexes interact with the folate pool may be of 
significance155.  
 
The N-N chelate mode of coordination had previously been reported by Vitol et al in 
a platinum(II) complex generated when the cis-diaminediaquaplatinum(II) cation was 
reacted with the reduced folate tetrahydrofolate carrier at pH 7 and 37 OC to generate 
the pure complex in 70% yield157. Elemental analysis, NMR and absorbance 
spectroscopies confirmed that the diamine platinum moiety was coordinated to the N5 
and N10 positions of the tetrahydrofolate. Although similar complexes were isolated 
for 5-methylhydrofolate, 5-formyltetrahydrofolate, methotrexate and aminopterin, the 
authors reported that folate and 7,8-dihydrofolate did not react with the diamine 
platinum cation successfully. The biological implications of these observations were 
also investigated and the cis-diaminediaquaplatinum (II)tetrahydrofolate complex was 
found to be a reasonably good inhibitor of dihydrofolate reductase (Ki = 4 µM) and of 
the folate transport system (50% inhibition at 200 µM) in the mouse lymphocytic 
leukaemia cell line (L1210). It is noteworthy that there is no apparent cell death caused 
by the cis-diaminediaquaplati-num(II)tetrahydrofolate complex at 200 µM during a 
folate transport inhibition study, suggesting that it would not be capable of exerting a 
cytotoxic response in the same way as cisplatin, possibly due to the lack of labile 
coordination sites in its structure. 
30 
 
In 2016, Fazary et al reported the synthesis and thermal characterisation of 1:1 
mononuclear folate and niacin complexes with secondary glycine ligation. The general 
formula MLL’X2.2H2O (where M = Cu
2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+ ; L = folate or 
niacin; L’= glycine, and X = NO3 or Cl-), generated by the reaction of the respective 
metal salts with glycine, followed by subsequent reaction with either a methanolic 
solution of niacin or an alkaline solution of folic acid. It is reported that the folate anion 
acts as a dicarboxylate ligand, with the metal ion coordinated to both the α and γ 
carboxylate groups of the glutamic acid moiety (Figure 9).  
 
 
 
Figure 9: The proposed structures of various metal folate complexes synthesized by 
Fazary et al158. (A) The structure of 6 coordinate complexes of the B vitamin niacin 
where M = Cu2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+ (B) The structure of six coordinate 
complexes of folic acid where M = Cu2+, Cd2+, Mn2+, Fe3+, Ni2+, Pb2+. 
 
Furthermore, the group conducted cytotoxicity studies using Hep-2 human laryngeal 
carcinoma, Daoy human medulloblastoma, MCF-7 human breast adenocarcinoma, and 
WiDr human colon adenocarcinoma cell lines, as well as antioxidant studies. The 
group reported that chromium(II) and lead(II) complexes of niacin and folic acid 
showed weak cytotoxic activities whereas all other mixed ligand complexes of the 
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vitamins exhibited moderate cytotoxic activities against the four cancer cell lines. The 
manganese(II) folate glycine complex, [MnFAGCl2].2H2O, was found to exhibit good 
antioxidant activity (76.36 % DPPH inhibition), whereas both cadmium complexes 
[CdFAGCl2].2H2O and [CdNAGCl2].2H2O exhibited poor inhibitory effects (23.85 
and 27.66 % DPPH inhibition, respectively)158. 
 
Two very interesting nickel(II) and cobalt(II) biomolecule-based coordination 
complex nanotubes (BMB-CCNT’s), with the molecular formula of the monomeric 
unit {M2(folate)(N2H4)3(OH)2(H2O)2} (M = Ni
2+ or Co2+) have recently been 
reported159,160. These BMB-CCNT’s were synthesised in good yield by a method 
involving ultrasonification of folic acid with the respective metal(II)chloride in a 1:2 
molar ratio and with the addition of 10 mL of aqueous hydrazine (at pH 10.5) in an 
ethanol/water mixture (20/80) followed by heating in an autoclave to 120 °C to yield 
the product. Similar attempts to generate the Zn2+, Ca2+, Fe2+ and Cu2+ analogues were 
unsuccessful, and the authors reported the recovery of only the corresponding metal 
oxides from these reactions. The structure of the {Ni2(folate)(N2H4)3(OH)2(H2O)2}n 
nanotubes (Figure 10) was confirmed by an array of physicochemical techniques.  
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Figure 10: The proposed structure of nickel(II) biomolecule-based coordination 
complex nanotubes (BMB-CCNT’s), with the molecular formula of the monomeric 
unit being {Ni2(folate)(N2H4)3(OH)2(H2O)2}n
159,160
. 
 
The folate ligand is bound to the Ni2+ ions via its carboxylate groups, which act as 
bidentate chelates and the nanotubes comprise a polymeric structure in which the metal 
ions are at the centre of octahedral coordination sphere with hydrazine ligands bridging 
neighbouring M2+ to each other and with hydrogen bonding involving the pteroic 
moiety of the folate forming a tape-like structure (Figure 10). To demonstrate the 
importance of the hydrazine in the role of the nanotube formation these workers also 
reacted folic acid with nickel(II) chloride in the presence of ammonia or sodium 
hydroxide instead of the hydrazine under the same experimental conditions160. Using 
transition electron microscopy (TEM) imaging the resulting complexes, for which the 
authors did not provide formulation data, were found to form non-nanotubular 
structures.  
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The {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes were tested for their activity against 
human cervical cancer HeLa cells (FR+ve), human lung adenocarcinoma cancer A549 
cells (FR-ve) and normal human embryonic lung fibroblasts HELF cells (FR-ve). The 
results showed that the {Ni2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes exhibited 
comparable cytotoxicity to cisplatin and that they are selective for the FR+ve HeLa 
cells ( IC50 = 0.586 µg/ml, 0.855 µg/ml and 10.139 µg/ml for the HeLa, A549 and 
HELF cell lines, respectively). The {Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes 
were also tested for their cytotoxicity and they were found to be even more selective 
for the FR+ve over FR-ve cells (IC50 = 0.1.47 µg/ml, 5.43 µg/ml and 20.32 µg/ml for 
the HeLa, A549 and normal human liver L-O2 cell lines, respectively). Further interest 
is derived in this class of material in that the inner tubes of the 
{M2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes can easily be loaded with clinical drugs 
such as cisplatin or doxorubicin to yield dual action therapeutics. Cellular uptake 
studies demonstrated that the drug loaded nanotubes, which are stable at physiological 
pH, enter cells through an FR mediated endocytic mechanism and that they are broken 
down to release the active components in the acidic environment inside the cell. The 
fundamental pharmacokinetic profiles and biodistribution of the 
{Co2(folate)(N2H4)3(OH)2(H2O)2}n nanotubes in mice are also reported along with its 
very promising in-vivo antitumour activity159.  
 
I.4.2  Folate-metal complex conjugates as targeted therapeutic agents 
 
As well as functioning as a ligand, folic acid can be conjugated to small or large 
biologically active metal complexes through direct folate coupling or folate coupling 
via a linker. The inclusion of a linker allows for effective unhindered binding of the 
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folate moiety to the FR and control over the lipophilicity of the folate conjugate, 
which are requirements for cellular internalization of the entire molecule through 
endocytosis (Figure 4). Furthermore, cleavable linkers, such as those containing 
disulphide bonds, can facilitate the release of the active payload from the folate carrier 
once the folate-metal complex conjugate encounters the acidic environment of the 
endosome163. Generally, unless otherwise stated, the synthesis of the compounds 
involves the following methods for conjugate formation: 
 
(i) the formation of an amide bond involving the reaction of a carboxylic acid group 
(α and/or γ) of the glutamate moiety of the folic acid with an amine (-NH2) 
functionality on the linker (generally an alkyl diamine molecule, PEG derivative or 
amino acid) which in turn can be bound to the coordination complex via a second 
amide bond (Figure 11); (ii) direct conjugation of folic acid to the active metal 
complex via an amide bond. Alternative strategies involve encapsulation of active 
metal complexes within folate-conjugated carriers. 
 
 
Figure 11: Structural design of a folate-metal complex conjugate comprising the folate 
targeted moiety, the optional linker and the amide bond formation to the active metal 
complex. 
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I.4.3  Platinum-based systems 
 
As mentioned previously, platinum-based drugs play a key role in treatment regimens 
of a range of cancers, but their applicability and efficacy are plagued by limitations 
regarding drug resistance and adverse toxic side effects. The selective delivery of such 
drugs via targeted strategies has recently been an area of intense research164–166. Table 
2 summarises the structural and biological profiles of the known platinum-folate 
conjugate systems. 
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Table 2. The structural and biological profiles for FR targeted platinum anticancer conjugates. 
FR Targeted Platinum-Based Anticancer Conjugates 
Conjugate type Linker 
Active 
component 
Cellular uptake studies In vitro activity In vivo activity Refs 
Folate-cisplatin 
Folate-carboplatin 
Aliphatic diamine 
Aliphatic amine 
Cisplatin 
Carboplatin 
Not reported Not reported Not reported 167 
Folate-PEG-
carboplatin 
polyethylene 
glycol 
Carboplatin 
Confirmed by confocal 
microscopy and FACS 
Reduced cytotoxicity 
in FR+ve M109HiFR 
cell line in 
comparison to non-
targeted analogue 
Not reported 168 
Cisplatin-folate-PEG-
g-PAsp-Ami micelles 
PEG-graft-α,β-
poly((N-amino-
acidyl)-
aspartmide] 
Cisplatin 
Confirmed by cytotoxicity 
assays in presence of excess 
folic acid 
Superior cytotoxicity 
compared to 
nontargeted 
Cisplatin-PEG-g-
PAsp-Ami micelles 
in FR+ve 
KB cell line. 
Athymic mice: similar results 
to in vitro study with low 
toxicity. 
169 
Carboplatin-folate-
liposome 
None Carboplatin 
Confirmed using IGROV-1 
cells (2-fold increase in 
cellular 
Accumulation compared to 
carboplatin) 
2-fold increase in 
cytotoxicity in 
IGROV-1 cells 
compared to 
carboplatin 
IGROV-1 ovarian tumour 
xenograft mice: Low toxicity 
and increased survival rate 
(83%) compared to 
carboplatin 
170 
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The systematic preparations of folate conjugates of cisplatin and carboplatin were 
recently reported167. The multi-step synthesis involved the direct attachment of 
diamine and dicarboxylate functionalities to the glutamate moiety of folic acid 
followed by reaction with the respective platinum(II) salts to yield five different 
derivatives (Figure 12). Although this approach yielded desirable structures, the folate-
complex conjugates were not studied for their cytotoxicity or FR uptake capabilities 
due to their poor solubility. 
 
Figure 12: The general synthetic scheme of folate-conjugates of cisplatin-like and 
carboplatin-like complexes167. 
 
To enhance the therapeutic potential of platinum anticancer drugs, conjugation to large 
polymeric carrier molecules such as polyethylene glycols (PEGs) which are known to 
increase their solubilities in water have been utilised165. Although this approach can 
significantly improve pharmacokinetics and tissue distribution of the drug, cell 
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permeability can remain a problem due to the relatively high molecular weights of 
such conjugates171. This presents a particular problem, as if platinum complexes are 
released in the extracellular medium, they can act as nonspecific electrophiles, 
resulting in their rapid inactivation by extracellular nucleophiles.  
 
To overcome this issue, Aronov et al synthesised a FA-PEG-Carboplatin conjugate 
(Figure 13) and studied its cellular uptake, cytotoxicity and rate of DNA platination172. 
The group also synthesized the fluorescent analogue FA-PEG-FITC (FITC = 
fluorescein isothiocyanate) to enable them to explore the effects of the conjugation on 
the cellular uptake of the PEG system using confocal microscopy and fluorescence-
assisted cell sorting (FACS). The reported synthesis of the FA-PEG-Carboplatin is an 
arduous six step procedure requiring significant purification and characterization. 
Indeed, the authors claim this to be the first complete chemical characterization of Pt-
PEG conjugates, a feat involving 1H NMR, 195Pt NMR, and 2D-[1H, 15N] heteronuclear 
single quantum correlation (HSQC) spectroscopy. 
 
 
Figure 13: The structure of the FA-PEG-Carboplatin conjugate172. 
 
Using a folate receptor-enriched murine lung carcinoma cell line, M109HiFR, Aronov 
et al conducted drug uptake and cytotoxicity studies as well as the determination of 
Pt-adduct formation. Results showed that the folate-targeted FA-PEG-Carboplatin 
conjugate was less cytotoxic than both its untargeted PEG-Carboplatin counterpart and 
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the free drug carboplatin, despite exhibiting increased drug uptake via endocytosis. It 
was found that the untargeted PEG-Carboplatin conjugate resulted in higher levels of 
DNA platination than the folate-targeted FA-PEG-Carboplatin conjugate, thus 
accounting for its low cytotoxicity. It was suggested that this unexpected phenomenon 
may be due to the folate receptor-mediated endocytic pathway, in which folate-
conjugates are not released into the cytosol but rather are directed to acidic lysosomes 
or endosomes, thereby restricting access to the nucleus. The findings suggest that the 
folate-targeted conjugate FA-PEG-Carboplatin may be unsuitable as a prodrug for the 
carboplatin family, as the conjugate appears to be neutralized or blocked during the 
folate receptor-mediated endocytosis process, resulting in entrapment of the prodrug 
in certain cellular compartments.  
 
In an attempt to reduce toxic side effects while enhancing its antitumor activity the 
incorporation of cisplatin into a polymeric folate conjugate with PEG-graft-α,β-
poly[(N-amino acidyl)-aspartamide] (Cisplatin-FA-PEG-g-PAsp-Ami) has also been 
studied recently (Figure 14)169. The targeted polymer-metal complex micelles were 
prepared by reacting cisplatin with FA-PEG-g-PAsp-Ami in distilled water for 24 
hours at 37 oC, followed by purification by dialysis and characterization by 
measurement of critical aggregation concentration, particle size and morphological 
observations. Cytotoxicity was determined in the oral cancer KB cell line (FR+ve), by 
treating the cells with the folate targeted Cisplatin-FA-PEG-g-PAsp-Ami and 
untargeted Cisplatin-PEG-g-PAsp-Ami complexes in folate deficient media for 24 h. 
The results showed that the folate-targeted complex was more cytotoxic (50% cell 
viability at 100 µg/ml concentration) than the non-targeted system (> 60% cell 
viability at 100 µg/ml concentration), due to folate receptor mediated endocytic uptake 
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of the compound. Additional inhibition assays involving excess folic acid supported 
the role of FR targeting for the Cisplatin-FA-PEG-g-PAsp-Ami (70% cell viability at 
100 µg/ml concentration in the presence of 1 mg/ml of added folic acid). In vivo testing 
in male athymic mice exhibited similar results, indicating that Cisplatin-FA-PEG-g-
PAsp-Ami micelles were well-tolerated by the mice. 
 
Figure 14: The proposed structure of a single unit of the folate conjugate Cisplatin-
FA-PEG-g-PAsp-Ami polymer169. 
 
 
In 2012, Chaudhury et al reported the intraperitoneal (IP) administration of a 
carboplatin folate receptor-targeted (FRT) liposomal system to increase the therapeutic 
efficacy and reducing toxicity of carboplatin for the purpose of IP treatment of ovarian 
cancer170. The authors discussed the limitations of IP administration of chemotherapy 
and the advantages of a drug delivery system such as an FR targeted liposomal system, 
which could deliver a drug payload into FR+ve ovarian cancer cells. Initial 
fluorescence studies on the ovarian adenocarcinoma cell line, IGROV-1, before 
injection showed a twofold increase in cellular accumulation of the folate-targeted 
platinum compared to the non-targeted carboplatin. Cytotoxicity studies showed that 
13 µM of folate-targeted carboplatin could induce cell death in 50% of IGROV-1 cells 
in vitro, while both the free drug and non-targeted conjugate required 24 - 45 µM, 
41 
 
respectively. In vivo studies, involving an intraperitoneally grown human IGROV-1 
ovarian tumour xenograft mouse model, identified that five out of six FR targeted 
carboplatin liposome treated mice (83%) survived to the end of the study. In contrast, 
groups treated with either the non-targeted carboplatin-liposome, carboplatin or saline 
control all died within 19-39 days post-tumour inoculation. Of the 83% mice that 
survived treatment, none showed weight-loss or metastasis. The authors concluded 
that intraperitoneal (IP) administration of folate-targeted carboplatin liposomes has the 
potential to extend the overall survival of ovarian cancer patients as well as 
maintaining therapeutic efficacy with reduced risk of regimen-related toxicities. 
 
I.4.4  Non-Platinum Systems 
 
The anticancer properties of gallium(III) compounds have been attracting attention 
since the 1970’s. The mechanism through which Ga(III) induces cell death (DNA 
binding/modification, enzyme inhibition and ion transport disruption) has been 
extensively investigated. However, the pharmokinetic properties, including renal 
retention time and cancer cell targeting of gallium salts, prevent their widespread 
chemotherapeutic use. To explore the cancer cell targeting abilities of gallium(III) 
complexes, Viola-Villegas et al studied the conjugation of gallium(III) complexes of 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), via a polyethylene 
glycol (PEG) linker, to the γ carboxylic acid moiety of folic acid (Figure 15 (A))173. 
The authors determined the IC50 concentrations for the gallium(III) containing 
compounds in both A2780/AD (FR+ve Adriamycin resistant ovarian cancer cell line) 
and CHO cells (FR-ve Chinese Hamster Ovary cell line), with the IC50 being lower in 
the A2780/AD cells in all cases. 
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These studies revealed two interesting results; (i) the metal free conjugate and its 
gallium complex were both toxic towards the FR-ve CHO cells and (ii) the metal-free 
γ-FA-PEG-HDOTA showed greater cytotoxicity (IC50 = 1.35 and 0.18 mM for the 
CHO and A2780/AD cell lines, respectively) than its coordinated counterpart, γ-FA-
PEG-Ga(HDOTA) ((IC50 = 2.93 and 1.85 mM for the CHO and A2780/AD cell lines, 
respectively). Researchers concluded that gallium was ‘leaking’ from the Ga-DOTA 
moiety, allowing the ligand to chelate other metals in the cellular environment. 
Additional stability studies carried out in HEPES buffer and RPMI 1640 media over 
72 hours coupled with HPLC and ICP techniques supported this theory. Unfortunately, 
as the non-complexed γ -FA-PEG-(HDOTA) showed greater cytotoxicity than its 
gallium-containing counterpart, the folate conjugate γ-FA-PEG-Ga(HDOTA) was 
considered to be unsuitable as an anti-cancer agent.  
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Figure 15: (A) The proposed structure of gallium(III) complexes coordinated via 
DOTA and a polyethylene glycol linker to the γ carboxylic acid moiety of folic acid, 
γ-FA-PEG-Ga(HDOTA) synthesized by Viola-Villegas, Vortherms and Doyle173. (FA 
= Folic acid, PEG = Polyethylene glycol, DOTA = 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) [193] (B) Proposed structure of the water-soluble folate 
conjugate of zinc tetraaminophthalocyanine (ZnaPc-folate) or ZnTAPcFA174. 
 
The water-soluble folate conjugate of zinc tetraaminophthalocyanine (ZnaPc-folate) 
was recently reported (Figure 15 (B))174,175. The study of the photophysical and 
photochemical properties of ZnaPc-folate revealed that an increase in the fluorescence 
quantum yield of the conjugate was accompanied by a decrease in the triplet and 
singlet oxygen quantum yields, a decrease that was not observed when ZnaPc was 
simply mixed with folic acid (in the absence of formal conjugation)174. Confocal laser 
scanning microscopy (CLSM) was employed to determine that ZnaPc-folate was 
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significantly internalised in the FR+ve KB cell line when compared to the FR-ve A549 
cells. Results from competitive binding studies using folic acid suggested a FRME 
cellular uptake mechanism175. Whereas ZnaPc-folate was found to be effectively 
inactive against KB cells in the absence of any photo-irradiation, irradiation with two-
photon excitation (TPE) of near-infrared (NIR) laser pulses caused a 10-fold decrease 
in cell viability when compared to the results for sulphonated aluminium phthalo-
cyanine (AlPcS), an approved photosensitizer for clinical applications under common 
one-photon excitation of red light175. The authors suggest that ZnaPc-folate represents 
a promising new generation of photosentizers for TPE-based photo-dynamic therapy 
(PDT). 
 
In 2015, Gou and colleagues explored the use of a folate-functionalised human serum 
albumin (FA-HSA) carrier system as an FR targeted delivery system for copper(II) 
complexes incorporating plumbagin, bipyridine and 1,10-phenanthroline ligands 
(Figure 16)176. Plumbagin is a natural small molecular naphthoquinone analogue 
isolated from the medicinal plant Plumbago zeylanica and which exhibits moderate 
anticancer activities in vitro and in vivo177–179.  
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Figure 16: Structures of various Cu(II) plumbagin polypyridyl complexes investigated 
by Gou et al176. Adapted from Gou et al176. 
 
To determine the biological action of the FA-HSA-Cu complex systems, the copper(II) 
complexes were incubated with the FA-HSA conjugate in PBS and DMSO (0.5%) for 
24 hours at room temperature. After incubation, FR+ve cell lines HeLa and MCF-7 
and FR-ve cell line WI-38 were treated with the FA-HSA-Cu complex systems for 48 
hours. It was found that the Cu(II) complexes themselves were equally cytotoxic 
towards the FR+ve and FR-ve cells lines (IC50 range = 3-8 µM), however the FA-
HSA-copper complex systems were approximately three times more active against the 
FR+ve cells (IC50 range = 0.98-3.67 µM) than the FR -ve cell line (IC50 range = 3.95-
6.95) µM. The FA-HSA-copper complex system incorporating the [Cu(PLN)(phen)]+ 
(where PLN = the plumbagin anion, (Figure 16 (3)) was the most cytotoxic and further 
studies revealed that it caused mitochondrial damage through production of reactive 
oxygen species (ROS) in HeLa cells and inhibited the activity of cyclin-dependent 
kinase-1 (CDK1) and the prosurvival Bcl-2 proteins, resulting in apoptotic cell death. 
The targeted therapeutic properties of the relatively few non-platinum folate-metal 
complex conjugates discussed have been summarized in Table 3.
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Table 3. The structural and biological profiles for FR targeted non-platinum anticancer conjugates. 
FR Targeted Non-Platinum Anticancer Conjugates 
Conjugate type Linker 
Active 
component 
Cellular uptake 
studies 
In vitro activity 
In vivo 
activity 
Refs 
γ-Folate-PEG-
Ga(HDOTA) 
polyethylene 
glycol 
Ga(HDOTA) Not reported 
γ-Folate-PEG-Ga(HDOTA) 
is 2-fold 
and 10-fold less cytotoxic 
than metal-free γ- Folate-
PEG-(HDOTA) in FR+ve 
A2780/Ad and FR-ve CHO. 
Not 
reported 
173 
Folate-HSA-
[Cu(PLN)(phen)]+ 
HSA [Cu(PLN)(phen)]+ Not reported 
Folate-HSA-
[Cu(PLN)(phen)]+ 
approximately 3 times more 
active against the FR+ve 
Hela and MCF- 
7 cells than the FR-ve WI-38 
cell line. 
Not 
reported 
176 
ZnaPc-Folate None 
ZnaPc-Folate 
upon photo-
irradiation 
FRME Confirmed by 
confocal laser 
scanning 
microscopy in 
competitive 
binding studies using 
folic acid involving 
FR+ve 
KB and FR-ve A549 
cells 
10-fold decrease in cell 
viability compared to results 
for sulphonated aluminium 
phthalocyanine (AlPcS), an 
approved photosensitizer for 
clinical applications under 
common one-photon 
excitation of red light 
Not 
reported 
174,180 
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I.4.5  Folate-metal complex conjugates as targeted diagnostic agents 
 
The advent of theranostic agents, which consist of a targeted drug coupled to an 
imaging agent, has been a key development in modern medicine, particularly in the 
treatment of cancer. This advancement would not have materialized if it was not for 
the significant successes achieved in the fields of molecular imaging and in the 
expansion of the knowledge-base of the synthesis of efficient targeting compounds175. 
 
Lanthanides, europium in particular, have luminescent properties when bound to 
organic, chelating ligands181. In addition, europium offers an array of advantages such 
as long emission times, enabling time-resolved measurements while narrow, intense 
absorption bands ensure high colour purity. Luminescent lanthanide complexes (LLC) 
such as europium complexes offer increased loading capabilities as they do not exhibit 
the self-quenching properties that are often observed in organic dyes. Such complexes 
often show high chemical, thermal, kinetic and photo-physical stability while 
exhibiting low toxicity when compared to gadolinium complexes commonly used as 
contrast agents in magnetic resonance imaging (MRI)182. Therefore, it is unsurprising 
that they may prove to be highly sensitive luminescent probes in biomedical studies. 
 
In 2012, Pavich et al synthesised a folic acid-europium chelate conjugate [FA-
phen)Eu(BTA)3] (FA-(phen) = Folate-spcer-1,10-phenanthroline conjugate; BTA = 
benzoyl trifluoroacetone) (Figure 17)183. NH2-Phen was incorporated into the 
coordination sphere to prevent quenching by the diketone BTA ligand. In addition, 
examining the absorption and luminescence spectra, as well as the luminescence 
excitation of the newly formed complex, the group conducted cellular uptake studies 
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using the FR+ve HeLa cell line. Cellular uptake of the conjugate was determined from 
the intensity of europium luminescence in the cell lysates and results indicated 
significant quantities of the europium conjugate (4.106 conjugate molecules per cell) 
were internalised. Furthermore, the addition of exogenous folic acid severely reduced 
cellular uptake of the conjugate by 68%, suggesting that uptake was FR-mediated183. 
These results and the observed promising luminescent timeframe of 110 μs may serve 
to spearhead the design of selective methods for time-resolved luminescent 
microanalysis based on conjugates of folic acid with europium complexes. However, 
the characterisation of the [FA-(phen)Eu(BTA)3] was poor and no data regarding the 
cytotoxicity or stability of the conjugate were reported. 
 
 
Figure 17: The chemical structure of the conjugate FA-(Phen)Eu(BTA)3. (Phen = 
1,10-Phenanthroline, BTA = benzoyl trifluoroacetone)183. 
 
The gadolinium(III) complex of DOTA is currently used as an extravascular contrast 
agent for MRI184. In 2015, Gros et al reported the synthesis and characterisation of a 
heterobimetallic copper(II) corrole/gadolinium(III) DOTA-folate complex (Figure 18) 
as a potential FR-targeted bifunctional contrast agent for MRI and positron emission 
tomography (PET) imaging of cancer185. The complex was obtained in high yield via 
a five-step synthetic method. Preliminary studies showed that the relaxivity of the 
heterobimetallic copper(II) corrole/gadolinium(III) DOTA-folate complex was higher 
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in comparison to the commercially available MRI contrast agent [Gd(DOTA)(H2O)]
-. 
The authors did not report any data for the toxicity, cellular uptake or FR specificity 
of the complex. 
 
Figure 18: The structure of the Cu corrole, Gd DOTA folate complex185. 
 
In the same year, Quici and colleagues reported the results of a more thorough study 
of the three water soluble europium complexes conjugated via 1,4,7,10-
Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the α-carboxylate, the γ-
carboxylate and N10 (the nitrogen of the para-aminobenzoic acid group) positions of 
folic acid (denoted Eu3+C1, Eu3+C2, Eu3+C3, respectively) as luminescent probes for 
the selective targeting of cancer cells (Figure 19)181. The α- and the γ-carboxylate 
conjugates Eu3+C1 and Eu3+C2 were generated, as a regioisomeric mixture, separated 
as pure isomers by HPLC and identified by ESI mass spectrometry. Eu3+C3 required 
a seven-step synthesis and it too was obtained in high purity. 
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Stability studies on all three conjugates were conducted by incubation in phosphate 
buffered saline (PBS), cell culture medium and rat serum at 37oC for 25 hr and revealed 
that varying media did not affect either conjugate luminescence or spectral shape. 
Results showed that the conjugates were stable after cell exposure and internalisation, 
with no apparent biotransformation and no significant interaction occurring with 
serum proteins.  
 
Cytotoxicity assays and internalisation studies conducted on a range of FR+ve ovarian 
cancer cell lines indicated that all three conjugates were only cytotoxic at 
concentrations above 300 μM and that internalisation was both concentration and time 
dependent. Internalisation studies using the FR-ve cell line A2780 showed no 
internalisation of the conjugates, suggesting that the uptake was folate receptor 
mediated. Furthermore, the conjugation site was found to be a critical factor with the 
binding affinity following the order Eu3+C2 > Eu3+C1 > Eu3+C3 in the SKOV-3 cell 
line, highlighting the importance of the pterin head and para-aminobenzoic acid body 
of folic acid in receptor recognition.  
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Figure 19: The chemical structures of three Europium complexes Eu3+C1, Eu3+C2 
and Eu3+C3 coordinated via DOTA to various conjugation sites of folic acid181. 
 
In a 2014 study Plush et al examined the influence that the length of the linker between 
the folate head and the lanthanide-DOTA chelate had on FR mediated uptake186. They 
synthesised and characterised water-soluble folate-targeted lanthanide probes (Ln(III) 
= Eu(III), Tb(III) or Gd(III)) in which the Ln(DOTA) moieties were connected to the 
folate heads via an aliphatic (–CH2-)n chain (where n = 1 or 5) (Figure 20).  
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Figure 20: Structures of the water-soluble folate-targeted lanthanide probes (Ln(III) 
= Eu(III) or Gd(III)) in which the Ln(DOTA) moieties were connected to the folate 
heads via an aliphatic (–CH2-)n chain (where n = 1 or 5)186 
 
More recently, in 2018, Plush et al reported the multistep synthesis, photophysical and 
cellular properties of four new imaging agents, folate and methotrexate labelled 
luminescent lanthanide complexes Eu-FA, Eu-MTX, Tb-FA and Tb-MTX (Figure 
21)187. Cellular uptake and cytotoxicity studies were performed on a panel of FR-ve 
non-malignant cells, and FR+ve and FR-ve malignant cells. Fluorescence was not 
observed in any of the FR-negative non-malignant cells. Furthermore, no enhanced 
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fluorescence was observed in FR-ve malignant cells A549 and PC-3 following 24 
hours incubation. However, the authors reported that all four Ln(III) complexes 
showed strong fluorescence emission in malignant FR+ve cells following 24 h 
incubation, indicating FR-mediated uptake of both MTX and folate conjugates. Eu-
MTX and Tb-MTX conjugates were found to induce significant antineoplastic activity 
in the FR+ve HeLa cell line within 48 hours. Cell death was also observed for the FA-
modified complexes, Eu-FA and Tb-FA, but to a reduced degree compared with that 
of MTX-modified complexes. Furthermore, Eu-MTX was found to be more cytotoxic 
than free MTX in solution, suggesting that there may be a synergistic effect between 
the Eu3+ ion and MTX. The authors concluded that the use of such complexes may 
allow for the visualisation and monitoring of the selective accumulation of cytotoxic 
agents within cancer cells which may offer significant advantages in the development 
of new therapeutics187.  
 
 
Figure 21: The structures of four lanthanide complexes; Eu-FA, Tb-FA, Eu-MTX and 
Tb-MTX. (A) Ln-FA (B) Ln-MTX (where Ln3+ = Eu3+ or Tb3+) in which the 
Ln(DOTA) moieties were connected to folic acid via a carbostyril antenna and 
ethylenediamine linker158  
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In addition to PET, single photon emission computed tomography (SPECT) is another 
highly sensitive cancer imaging technique which has attracted significant interest in 
the development of folate-based tracers to target FR expressing cancers188–190. For the 
development of folate-conjugates of such nuclear imaging agents, 99mTc has emerged 
as the preferred radionuclide for applications in SPECT. One of the best studied 
examples of such FR-targeted technecium radionuclides is 99mTc-EC20 in which 
99mTc(V) is complexed to a peptide (Cys-Asp-Dap-D-Glu-Pte) which is linked to a 
folate moiety (Figure 22 (A))191. Clinical trials found that 99mTc-EC20 was an excellent 
imaging agent, with very high tumour uptake192. It was also found that a single 
intravenous injection of 99mTc-EC20 resulted in detectable uptake in 68% of patients 
and was well tolerated by adult patients. Consequently, the authors suggested that 
99mTc-EC20 imaging was a safe, non-invasive procedure that may identify FRs in 
recurrent or metastatic disease without the need for biopsy192. However, due to the 
presence of high FR expression in the kidneys and bladder, accumulation of 99mTc-
EC20 caused problems with very significant renal uptake of radioactivity. It has been 
reported that this problem may be resolved to a significant extent by pre-treatment with 
antifolates such as Pemetrexed, however it may result in patients experiencing further 
stress193. In recent years there have been several attempts to improve the efficacy of 
99mTc-labeled folate conjugates by modifying the nature of the linkers, the chelating 
agents and the radiosynthon but the problem with high accumulation in the kidneys 
has persisted due to the highly hydrophobic nature of the 99mTc-labeled folate 
conjugates194,195.  
 
In 2017, Banerjee et al reported the synthesis and biological evaluation of a 99mTc-
labeled folate conjugate with the lipophilic [99mTcN(PNP)]2+ inorganic moiety {where 
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N(PNP)=N-(2methoxyethyl)-2-(diphenylphosphino)-N-(2-diphenylphosphino) 
ethyethanamine} (Figure 22 (B))196. The 99mTc-labeled folate conjugate was generated 
by conjugating a cysteine-based (O-S) bifunctional chelating group to the γ-carboxylic 
acid of folic acid to yield the targeted vector. This, in turn, acts as an O-S chelate upon 
complexation with [99mTcN(PNP)]2+, yielding the [99mTcN(PNP)]2+-folate conjugate 
(Figure 22 (B)). The conjugate was found to be significantly lipophilic (LogPo/w = 
0.87). Unfortunately, in vitro studies on FR+ve KB cells revealed that this new 99mTc-
labeled folate conjugate exhibited a ten-fold decrease in affinity for the FR than native 
folic acid. However, in vivo studies involving normal Swiss mice revealed that the 
[99mTcN(PNP)]2+-folate conjugate was effectively cleared by the kidneys which is in 
itself a significant development. The authors propose that the inclusion of an 
appropriate aliphatic spacer in the structure of the [99mTcN(PNP)]2+-folate conjugate 
as a possible route to improving the FR uptake of this class of potential radiotracer. 
Table 4 summarises the structural and biological profiles for folate-metal complex 
conjugates with targeted diagnostic potential. 
 
Figure 22: (A) Structure of folic acid radioconjugate, 99mTc-EC20192 (B) Structure of 
a new 99mTc-folic acid radiotracer prepared using [99mTcN(PNP)]2+ metal fragment197
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Table 4: The structural and biological profiles for folate-metal complex conjugates with targeted diagnostic potential. 
 
 
 
FR Targeted metal complexes as diagnostic agents 
Conjugate type Linker 
Active 
component 
Cellular uptake studies 
In vitro 
activity 
In vivo activity Ref 
[FA(phen)Eu(BTA)3] ethylenediamine 
[FA(phen)Eu(BT
A)3] 
Luminescence measurements in 
FR+ve HeLa cells and competitive 
binding studies 
with folic acid 
Not reported Not reported 183 
Europium complexes 
conjugated via DOTA to α- 
carboxylate, the γ-carboxylate 
and N10 positions of folic 
acid 
Tetraazacyclodode 
cane-1,4,7,10- 
tetraacetic acid 
(DOTA) 
 
Uptake in FR+ve SKOV-3 cells was 
conjugation 
Dependent (Eu3+C2>Eu3+C1> 
Eu3+C3) with no uptake in FR-ve 
A2780 cells. 
Non-toxic 
below 300 
µM 
Not reported 181 
FA-NH–(CH2)n-NH- 
[Ln(DOTA)] 
(Ln(III) = Eu3+, Tb3+ or Gd3+; 
n = 2 or 6) 
The diamine 
chain 
-NH–(CH2)n-NH- 
[Ln(DOTA)]3+ 
Effectively internalised by 
FR+ve HeLa cells with the shorter 
linker yielding 
superior uptake 
Not reported Not reported 186 
Heterobimetallic Cu(II) 
corrole/Gd(III) DOTA-folate 
complex 
ethylenediamine 
[Cu(corrole)]2+ 
and 
[Gd(DOTA)]3+ 
Not reported Not reported Not reported 198 
99mTc-EC20 
99mTc(V) is complexed 
to a 
peptide (Cys-Asp- 
Dap-D-Glu-Pte) 
which is linked to 
a folate moiety via 
a diamine group 
99mTc-EC20 
Extensively 
studied with very 
high cellular 
uptake in FR-ve 
cell lines in-vitro 
Low 
cytotoxicity 
Very high tumour uptake in 
a mouse model and in 
clinical trials. Significant 
FR mediated renal uptake. 
 
195,199 
[99mTcN(PNP)]2+-O-S-folate 
conjugate 
 
cysteine-based (OS) 
chelating group to the 
γ-carboxylate of 
folic acid. 
[99mTcN(PNP)]2+ 
10-fold less 
affinity for FR+ve 
KB-31 cells than 
folic acid 
Low toxicity 
In normal Swiss 
mice the conjugate was 
effectively cleared from the 
kidneys 
197 
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I.5 Conclusion 
 
As it stands, folate-targeted drug therapy is proving to be a rich vein of research into 
the diagnosis and treatment of many forms of cancer. This is emphasised by the 
continuous stream of literature regarding the topic published since the early 2000’s. 
However, there is a dearth of published material in relation to studies conducted on 
folate-targeted metal-based therapies over the same time frame. From the data 
available, it is apparent that the subject area is in its infancy and has the potential to 
contribute greatly to cancer research, both in therapeutics and diagnostics. 
 
Folic acid is an interesting ligand for metal complex formation, but its coordination 
chemistry is not well developed. Incorporating simple folate ligands into biologically 
active metal complex systems may offer a simple strategy for improving their selective 
uptake in FR+ve cells. This remains an avenue yet to be exploited with the issue of 
metal complex solubility presenting a significant challenge, as encountered in the work 
reported thus far.  
 
The success of the platinum drugs in treating a range of cancers is compromised by 
issues relating to toxic side effects, drug resistance and the lack of tumour selectivity. 
Promising recent results show that incorporation of drugs such as cisplatin and 
carboplatin into folate- or folate-carrier- systems has the potential to overcome these 
problems to some extent by improving their delivery and/or selectivity. Very few non-
platinum metal complex conjugates with folic acid have been reported in the literature, 
and most of the studies conducted to date lack substantial in vitro and/or in vivo data. 
Notwithstanding this, it is an avenue that offers significant potential to develop 
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targeted therapeutic approaches in areas such as chemotherapy and molecular imaging 
for diagnostics. 
 
If this approach is to be fully exploited there are experimental challenges to overcome. 
The synthesis, purification and characterisation of metal complex-folate (and/or folate-
carrier-) conjugates are quite often difficult, presenting problems in relation to 
biomedical applications. Furthermore, the expression levels of the folate receptor in 
different cell types has been a topic of significant interest with data in the literature 
being somewhat confusing and conflicting, and a situation that requires caution when 
assaying the selectivity of potentially active compounds. Notwithstanding these 
challenges, where over-expression of the folate receptor is well documented and a key 
cellular feature of diseases such as cancer, inflammation, tuberculosis and parasitic 
infection, the coupling of the biologically active inorganic complexes with folate 
receptor targeted capability is a highly desirable goal, offering the opportunity to avoid 
unwanted side-effects during diagnosis and treatment. 
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PROJECT RATIONALE 
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R.1 The rationale for the current project 
 
1,10-phenanthroline (phen) (Figure 23) is a heterocyclic organic compound which is 
known to form stable biologically active complexes with a range of metals200. Indeed, 
so called ‘metal-free’ phen has been characterised as exhibiting a range of biological 
capabilities in its own right. However, it is believed that phen sequesters trace metals 
with the resulting metal complexes believed to be the actual biologically active 
species. Ostensibly, the activity of phen-based complexes can be significantly 
modulated by modifying the structure of phen by either extending its backbone at the 
-5,6- position or by the substitution of the aromatic protons by suitable substituents 
(Figure 22)200. Metal-phen complexes exhibit significant potential as broad-spectrum 
agents capable of eliciting cytotoxicity towards diseases and infections manifested by 
cancer201–205, bacteria206–208, tuberculosis209 fungi210,211 and viruses200.  
 
Figure 23: Structure of 1,10-phenanthroline (phen) with numbering for substituents 
and examples of modified phen structures. 
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Our group has previously found that copper(II), manganese(II) and silver(I) complexes 
of 1,10-phenanthroline incorporating dicarboxylate ligands are of particular interest as 
they have been found to exhibit excellent in-vitro anticancer activity (some examples 
of these complexes are shown in Figure 24)201–204,212. Although the mechanism of 
action of this class of complex is not yet fully understood, it is known that the type of 
metal present and the choice of dicarboxylate ligands has a profound effect on their 
structure, physico-chemical and biological properties. To date all of the complexes 
examined have been found to be promiscuous, exerting their cytotoxic effects non-
selectively, causing damage to healthy as well as malignant cells. The goal now is to 
attempt to modify these complexes with a view to increasing their chemotherapeutic 
potential via greater selectivity for cancer cells.  
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Figure 24: The structure of some of the copper (A)201–203, manganese (B)203 and silver (C)213 phen-based dicarboxylate complexes 
previously studied.
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R.2  Aims and objectives of the current project 
 
The aims of the current project were:  
(i) To generate metal phenanthroline complexes with folate targeting moieties 
(where M = Cu2+, Mn2+, Fe3+, Zn2+ and Ag1+) 
(ii) To assess the FR-targeting capabilities and biological activity of selected 
novel metal-phenanthroline-folate complexes against FR+ve and FR-ve 
cell lines.  
 
To achieve these aims the main objectives of the project were: 
  
(i) To complete a comprehensive review of the literature to determine 
what is known about (a) the coordination chemistry of folic acid and 
the biological properties of metal-folate complexes and (b) the 
synthesis and biological profiles of metal complexes containing folate 
conjugated ligands. 
(ii) To exploit folic acid (through its glutamate moiety) as a potential 
dicarboxylate ligand in the synthesis of novel metal-folate-
phenanthroline complexes.  
(iii) To develop a method for the synthesis of folate-phen conjugates and 
their coordination to transition metals.  
(iv) To assess the cytotoxic activity of relevant complexes in FR+ve and 
FR-ve cell lines  
(v) To elucidate, where possible, aspects of the mechanism of action of the 
active compounds in cellular systems.   
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D.1   Novel metal complexes containing folate and 1,10-phenanthroline 
ligands 
 
As discussed in the introduction the coordination chemistry of folic acid has not been 
explored extensively to date, with just a small number of papers reporting its 
complexation to metals147,148,176,150,155,161,162,169,170,172,173 (Table 1). These reports in the 
literature describe the folate predominantly acting as a classical dicarboxylate ligand 
when reacted to form simple metal complexes. In such complexes the glutamate group 
of the folate is generally reported to doubly deprotonate and can form mononuclear, 
binuclear or polymeric complexes. Our group has previously reported extensively on 
the cytotoxic profiles of mono- or bi-nuclear and polymeric copper(II), manganese(II) 
and silver(I) complexes containing simple aromatic or aliphatic dicarboxylates that act 
as bridges between M2+(phen)n moieties (M = Cu or Mn; n = 1 or 2) (Figure 24). At 
the outset of this project a key objective was to employ the simple folate as a 
dicarboxylate ligand and attempt to generate bis-phenanthroline metal complexes 
similar to those previously studied. This section describes the attempts to synthesise 
simple metal-folate and metal-folate-phen complexes (where M = Cu2+, Mn2+, Zn2+, 
Fe3+ and Ag+; and phen = 1,10-phenanthroline). 
 
D.1.1 Synthesis of simple metal-folate complexes 
 
Abd El Wahed et al had previously described the facile synthesis of metal folate 
complexes with the general formula M2(folate).nH2O (where M = Mn
2+
, Co
2+, Ni2+, 
Cu2+, Zn2+, Cd2+ and Hg2+ ; L = folate; n = 1-3,5 or 15)147. The complexes were 
generated by the reaction of sodium folate with the respective metal chlorides. The 
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complexes were characterised as binuclear containing the folate anion as a 
dicarboxylate ligand, with the metal centres coordinated to the α and/or γ carboxylate 
groups of the glutamic acid moiety in a chelating mode (Figure 5). 
  
Following this approach, the mononuclear Cu2+, Mn2+, Fe3+ and Zn2+ complexes 1 - 4 
were generated in good yield by neutralising a methanolic suspension of folic acid with 
sodium hydroxide followed by addition of the respective metal chloride (Scheme 2). 
Complexes 1 - 4 were isolated as brown, yellow, red-brown and yellow powders, 
respectively, and they were formulated as mononuclear complexes as shown in Table 
5. The synthesis of the yellow binuclear complex [Ag2(folate)] had also been reported 
as far back as 1947 involving the reaction of an aqueous solution of folic acid with 
silver nitrate161. However, all attempts to generate a silver(I)-folate complex were 
unsuccessful in the current study.  
 
Furthermore, extensive attempts to generate the binuclear complexes reported by Abd 
El Wahed et al were unsuccessful. These attempts included:  
(i) Increasing the pH of the reaction to enhance the deprotonation of the 
carboxylate groups (from pH 7 to pH 9).  
(ii) Varying the solvent (water, ethanol, methanol, etc.) in an attempt to 
improve solubility.  
(iii) Altering the ratio of metal chloride and folic acid in the reaction (from 
1:1 up to 4:1). 
(iv) Omitting the final neutralisation step described by Abd El Wahed et al.  
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It is noteworthy that other authors have reported mononuclear complexes generated 
from reactions employing similar methods151. These complexes were characterised as 
containing folate with the glutamate acting as a bidentate chelate, and the general 
formula ML2.nH2O, where M = Cu
2+ or Fe2+; L = folate; n = 2 or 3, respectively (Figure 
7).  
 
Scheme 2: Synthetic route for complexes 1 – 4 
 
Table 5: Analytical data for simple metal-folates 1 - 4  
Complex 
Mw 
(g/mol) 
Yield 
(%) 
Found (Calc) % 
C H N M 
[Cu(fol)(H2O)3].H2O (1) 573.98 68 
39.65 
(39.76) 
3.80 
(4.21) 
17.42 
(17.38) 
11.29 
(11.07) 
[Mn(fol)(H2O)3].3H2O (2) 601.40 68 
37.85 
(37.95) 
4.20 
(4.69) 
16.30 
(16.08) 
9.37 
(9.13) 
[Fe(fol)(H2O)2(Cl)].4H2O (3) 637.76 71 
35.99 
(35.78) 
4.42 
(4.43) 
15.45 
(15.37) 
9.05 
(8.76) 
[Zn(fol)(H2O)3].3H2O (4) 611.85 62 
38.10 
(37.70) 
4.99 
(4.61) 
16.42 
(16.02) 
9.74 
(10.69) 
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Due to the poor solubility of complexes 1 – 4, their UV-visible spectra were recorded 
in the solid state. Samples were mounted on a quartz slide inside an integrating sphere 
(IS) and measured using diffuse transmission. The spectra of folic acid and complexes 
1 – 4 are shown in Appendix 1, 4 and 5. The UV–visible spectrum of folic acid exhibits 
absorbance bands at 220, 290, and 380 nm which may be assigned to (π→π*), (π→π*), 
and (n→π*) transitions respectively147,214. The absorption spectra of complexes 1 – 4 
exhibit similar features with two broad peaks between 282 – 290 and 383 -394 nm, 
respectively.  
 
The TGA thermograms of folic acid and complexes 1 – 4 were studied to 800 oC. The 
TG curve of folic acid showed that the organic ligand melts at 220 oC with 
simultaneous decomposition (Figure 25)147,151. The complexes 1 - 4 all showed thermal 
decomposition over three stages, corresponding to the loss of the uncoordinated and 
coordinated water and the loss/decomposition of the folate ligand, respectively.  
 
Figure 25: The thermogravimetric analysis (TGA) of folic acid and complexes 1 – 4.  
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Magnetic measurements were performed using the Gouy method. The calculated 
magnetic moment (µeff) values of complexes 1 and 2 {1.78 and 6.11 B.M., 
respectively} are typical for high spin divalent complexes . Complex 3 has a µeff value 
of 2.71 which suggests a low spin Fe3+ complex215. Furthermore, these values are all 
indicative of complexes that contain metal centres that are magnetically 
independent216. [Zn(fol)(H2O)3].3H2O (4), a diamagnetic complex, experiences 
repulsion for the applied magnetic field, appearing to lose mass (resulting in a negative 
value). Therefore, complex 4 does not exhibit a magnetic moment.  
 
The IR spectra for folic acid and complexes 1 – 4 are shown in Figure 26 and Appendix 
4 and 5 respectively. Complexes 1 – 4 all have very similar spectra which reflect 
similar structural characteristics for this series of complexes. The IR spectrum of folic 
acid exhibits a distinct absorption band at 1695 cm−1 due to the stretching vibration of 
ν(C=O) of the carboxyl group (Figure 26). The coordination of carboxylate groups to 
the metal centres is supported by IR spectral evidence for all three complexes with the 
appearance of a νasym (OCO) band {1607 - 1602 cm-1} and νsym (OCO) band {1410 – 
1401 cm-1} in their spectra (Table 6). The ΔOCO values for all the complexes (190 – 
203 cm-1) are indicative of carboxylate groups bound to the metal centre in a unidentate 
coordination mode217. Complexes 1 – 4 were found to have very limited solubility in 
water and common organic solvents which prevented conductivity studies and full 1H 
and 13C NMR spectral analysis.  
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Figure 26: IR spectrum of folic acid. 
 
Table 6: Characteristic carboxylate bands in the IR spectra of complexes 1 – 4 
Complex 
Band Assignment 
COO (assym) COO (sym) Δ OCO 
[Cu(fol)(H2O)3].H2O (1) 1606 1414 192 
[Mn(fol)(H2O)3].3H2O (2) 1607 1407 200 
[Fe(fol)(H2O)2(Cl)].4H2O (3) 1604 1401 203 
[Zn(fol)(H2O)3].3H2O (4)  1601 1398 203 
 
However, identification of the donor atoms involved in the simple metal folate 
complexes 1 – 4 can be explored using a 13C NMR technique. It is known that 
coordination of paramagnetic cations to donor atoms in a ligand results in the 
significant decrease or disappearance of 13C NMR signals related to neighbouring 
carbon atoms218. Thus, the interaction of folate with small volumes of CuCl2 solution 
(Cu2+:folic acid = 1:100) was investigated, with the decrease/loss of (i) both the α and 
γ carboxylate carbon signals (C1 and C2; Figure 27); (ii) C15 of the glutamate tail, and 
loss of the signal for the carbonyl carbon atom neighbouring the amide nitrogen on the 
glutamate moiety (C3) (Figure 27). These findings, in conjunction with the IR data, 
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support the presence of a tridentate ONO {α-COO-, γ-COO-, and Namide} binding mode 
for the folate ligand in this series of metal complexes. 
 
Furthermore, it was also found that the 13C NMR signals from the pteridine ring 
decreased or disappeared when the Cu2+ was added to the folic acid (Figure 27 (C)). It 
is not believed that this part of the folate molecule is involved in the binding to the 
metal. Similar results were reported by Nagaj et al153 for the neutral copper(II) 
complex [Cu(MTX)(H2O)] (MTX
2- = the doubly deprotonated antifolate agent 
methotrexate, an analogue of the folate di-anion) (Figure 8 (B)). Stacking interactions 
involving the self-association of heterocyclic aromatic compounds such as purines and 
pyrimidines, structurally related to folates, has been observed219–221. It was also 
previously reported by Poe et al that the stacking of folates at neutral pH resulted in 
the formation of a dimer consisting of two molecules in a “stretched out” 
configuration. Consequently, both pteridine and p-aminobenzoic acid rings may 
participate in stacking interactions in a head-to-tail arrangement222 (Figure 28). A 
similar ‘dimerisation’ process may also be occurring in the present study and may 
explain the decrease/disappearance of 13C NMR signals corresponding to the pteridine 
moiety.  
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Figure 27: A) Folic acid with numbered carbon atoms B) 13C NMR of folic acid in 
D2O and C) CuCl2.2H2O and folic acid (1:100) in D2O  
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Figure 28: The proposed folic acid dimer, showing the head-to-tail configuration, as 
described by Poe et al222. 
 
Proposed structures consistent with the physico-chemical data for complexes 1 – 4 are 
shown in Figure 29. These proposed structures are similar to the structure of the neutral 
copper(II) complex [Cu(MTX)(H2O)] which was reported by Nagaj et al
153. On the 
basis of similar 13C NMR and IR spectral evidence the authors also proposed that the 
MTX2- bound to the copper(II) centre as a tridentate ligand via the α and γ carboxylate 
and the amide nitrogen functionalities was also involved (Figure 8 (B)).  
 
The involvement of the amide nitrogen in the coordination chemistry of the folate 
ligand has also been reported in the case of the 2:1 anionic folate-uranium(IV) complex 
salt [UO2(folate)2](EV)2 (where EV
+ = the cation of the basic triphenylmethane dye 
ethyl violet). In [UO2(folate)2]
2- the folates are coordinated to the uranium atom in the 
UO2
2+ moiety as chelates via the nitrogen atom of the imido-group of the amino-
carboxyl and the oxygen atom of the α-carbonyl to form stable five-membered chelate 
rings (Figure 8 (C)). 
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Figure 29: Proposed structures for complexes 1 – 4 
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D.1.2  Reaction of simple metal-folate complexes 1 - 4 with 1,10-
phenanthroline  
 
D.1.2.1 Reactions of complexes 1 – 4 with 1,10-phenanthroline (phen)  
 
Attempts were made to react complexes 1 - 4 with the chelating ligand 1,10-
phenanthroline (phen) in an effort to generate the respective mononuclear bis-phen 
complexes (intended structure is shown in Figure 30). [Cu(fol)(H2O)3].H2O (1) was 
reacted with two equivalents of phen to yield complex 5 (Scheme 3). Complex 5 was 
isolated in high yield, as a lime-green powder, was partially soluble in warm DMSO 
only, and it was formulated as [Cu(fol)(phen)(H2O)].3H2O (5) (Table 7). All attempts 
to generate bis-phen derivatives of complex 1 were unsuccessful (regardless of the 
amount of phen used (up to 4 equivalents) in the reactions, reaction times or changes 
in other conditions). This fact supports the postulation that the folate is acting as an 
ONO tridentate ligand in complexes 1- 4, which precludes the coordination of more 
than one phenanthroline moiety to the copper centre. Furthermore, regardless of 
reaction conditions (time, solvent or the use of excess phen) exhaustive attempts to 
react phen with either [Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3), or 
[Zn(fol)(H2O)3].3H2O (4) yielded only unreacted complexes and metal-free phen.  
 
 
Scheme 3: Synthetic routes for complex 5  
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Figure 30: Intended structure for metal-folate-(bis-phen) complexes 
 
Table 7: Analytical data for complexes 5 - 8 
Complex 
Mw 
(g/mol) 
Yield 
(%) 
Found (Calc) % 
C H N M 
[Cu(fol)(phen)(H2O)].3H2O (5) 754.19 68 
49.45 
(49.37) 
3.78 
(4.28) 
17.70 
(16.71) 
8.43 
(7.35) 
[Mn(fol)(phen)(H2O)].4H2O (6) 763.59 98 
48.49 
(48.76) 
3.65 
(3.92) 
16.51 
(16.66) 
8.15 
(7.19) 
[Fe(fol)(phen)(Cl)].5H2O (7) 799.95 44 
46.42 
(46.54) 
4.31 
(4.28) 
16.73 
(15.76) 
7.15 
(6.98) 
[Zn(fol)(phen)(H2O)].4H2O (8) 774.04 84 
48.38 
(48.10) 
3.97 
(4.43) 
16.59 
(16.29) 
7.45 
(8.45) 
 
D.1.2.2  Reaction of metal bis-phenanthroline complexes with sodium folate 
 
In an attempt to generate binuclear folate complexes containing bridged bis-phen 
moieties (Mn+(phen)x) reactions of the chloride salts of [Cu(phen)2]
2+, [Mn(phen)2]
2+, 
[Fe(phen)3]
3+, and [Zn(phen)]2+ with di-sodium folate were explored. The 
[M(phen)x]
n+ chlorides were synthesised by reacting the metal chloride with two 
equivalents of 1,10 phenanthroline. The cations [Cu(phen)2]
2+ and [Mn(phen)2]
2+ were 
obtained as bis-phen derivatives, as previously reported223–225. [Zn(phen)]2+ was 
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obtained as a mono-phenanthroline analogue, as previously reported226. Although no 
tris(phen)iron(III) trichloro complex can be found in the literature, similar Fe(III) tris 
phen complexes with alternative counterions such as NO3 have been synthesised and 
characterised227.  
 
 Reaction of two equivalents of [Cu(phen)2]
2+
 with di-sodium folate did not yield the 
expected dinuclear bis-phen derivative but rather the mono-phen complex 
[Cu(fol)(phen)(H2O)].3H2O (5) was recovered in good yield (Scheme 4). Under 
similar conditions [Mn(phen)2]
2+, [Fe(phen)2]
3+ , and [Zn(phen)2]
2+ all reacted with di-
sodium folate to give analogous complexes, obtained as yellow, red and yellow 
powders, respectively. Complexes 5 – 8 were all partially soluble in warm DMSO and 
DMF and formulated as shown in Table 6. As observed with complexes 5, only one 
phenanthroline per metal centre was successfully incorporated into complexes 6 - 8.  
 
 
Scheme 4: Synthetic routes to complexes 5 – 8 involving the reaction of the respective 
[M(phen)x]
n+ chlorides (x = 1 or 2; n = 1 or 2) with di-sodium folate  
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Due to the poor solubility of complexes 5 – 8, their UV-visible spectra were also 
recorded in the solid state, and their spectra, along with those of folic acid and 1,10-
phenanthroline are shown in Appendix 6 - 7. The UV-Vis spectra of complexes 5 – 8 
are similar to those of complexes 1 – 4, with a new peak observed at 265 nm, indicating 
the presence of the 1,10-phenanthroline ligand.  
 
The IR spectra for folic acid and complexes 5 – 8 are shown in Figure 26 and Appendix 
6 – 7, respectively. Complexes 5 – 8 all have very similar spectra which reflect similar 
structural characteristics for this series of complexes. When compared to the spectra 
of complexes 1 – 4 (Appendix 4 - 5), the IR spectra of 5 – 8 are more complex and 
contain new absorption bands in the region of 840 – 844 cm-1 and 724 – 729 cm-1 
which are characteristic of the presence of the phen ligand in the complexes228. The IR 
spectrum of folic acid exhibits a distinct absorption band at 1695 cm−1 due to the 
stretching vibration of ν(C=O) of the carboxyl group (Figure 26). This ν(C=O) band 
disappears in the IR spectra of the four complexes with the appearance of νasym (OCO) 
bands {range: 1607 - 1602 cm-1} and a νsym (OCO) bands {range: 1410 – 1401 cm-1} 
(Table 8). The ΔOCO values for all four complexes (190 – 203 cm-1) are indicative of 
carboxylate groups bound to the metal centre in a unidentate coordination mode229.  
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Table 8: Characteristic IR bands of complexes 5 - 8  
Complex 
Band Assignment 
COO 
(assym) 
COO 
(sym) 
Δ 
OCO 
C-H 
Bending 
(phen) 
C-H 
Bending 
(phen) 
[Cu(fol)(phen)(H2O)].3H2O (5)  1603 1407 196 855 722 
[Mn(fol)(phen)(H2O)].4H2O (6) 1609 1410 199 847 727  
[Fe(fol)(phen)(Cl)].5H2O (7) 1602 1406 196 845 725 
[Zn(fol)(phen)(H2O)].4H2O (8)  1606 1393 213 852 730 
 
The TGA thermograms of folic acid and complexes 5 – 8 were studied to the 
temperature 800 oC. As previously indicated the TG curve of folic acid showed that 
the organic ligand melts at 220 oC with simultaneous decomposition (Figure 31)147,151. 
1,10-phenanthroline, on the other hand, shows a steep decomposition occurring in two 
defined steps (at 127 oC and 276 oC, respectively). The complexes 5 - 8 all showed 
thermal decomposition over three stages, corresponding to the loss of the 
uncoordinated and coordinated water and the loss/decomposition of the folate and 
phen ligands, respectively.  
 
Figure 31: Thermogravimetric analysis of folic acid, 1,10-phenanthroline (Phen) and 
complexes 5 – 8.  
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The room temperature magnetic moments of powdered samples of complexes 5 – 8 
were also recorded. Whereas the values for 5 and 6 (1.82 B.M and 5.32 B.M 
respectively) are indicative of high spin divalent complexes, the magnetic moment for 
7 (2.71 B.M) was slightly higher than expected (2.0 – 2.5) but indicative of a low spin 
Fe3+ complex215. Furthermore, these values are consistent with complexes with no 
significant exchange interactions between the metal centres.216 Divalent and 
diamagnetic complex 8 does not generate a magnetic moment. 
 
Proposed structures that fit the physico-chemical data of complexes 5 – 8 are shown 
in Figure 32. 
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Figure 32: The proposed structures of 1,10-phenanthroline derivatives of simple-
metal folates 5 – 8 
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D 1. 3   Conclusion 
All attempts to generate the binuclear complexes [M2(folate)(H2O)n] (M = Cu
2+, Mn2+, 
Fe3+, Zn2+ and Ag+) using previously published methods (and with significant 
modifications) were unsuccessful. Instead, these reactions, as undertaken in the current 
study, yielded the novel mononuclear complexes [Cu(fol)(H2O)3].H2O (1), 
[Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3), and [Zn(fol)(H2O)3].3H2O 
(4) in good yield (> 60%). In complexes 1 – 4 the folate acts, ostensibly, as a tridentate 
ONO ligand.  
 
Only the copper(II) complex [Cu(fol)(H2O)3].H2O (1) was found to react directly with 
1,10-phenanthroline. Attempts to generate the binuclear metal complexes 
[{M(phen)2}2(folate)] (M = Cu
2+, Mn2+, Fe3+ and Zn2+) via a reaction between the 
respective (Mn+(phen)2)-chloride salt and disodium folate yielded the novel 
mononuclear complexes [Cu(fol)(phen)(H2O)].3H2O (5), 
[Mn(fol)(phen)(H2O)].4H2O (6), [Fe(fol)(phen)(Cl)].5H2O (7), and [Zn(fol)(phen)(H-
2O)].4H2O (8) in moderate to high yields (40 – 97%). In complexes 5 – 8 the folate is 
again believed to act as a tridentate ONO ligand with only one phen coordinated to the 
copper centre. 
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D.2 The chemotherapeutic potential of the simple metal-folate complexes  
 
At the outset of the current project there were no reports in the literature of any 
cytotoxic profiles or folate receptor (FR) mediated cyto-selective studies involving 
simple metal complexes containing the folate ligand. However, in 2016 the novel FR-
selective coordination complex nanotubes with the general formula 
{M2(folate)(N2H4)3(OH)2(H2O)2}n (M = Ni
2+ or Co2+), which exhibit excellent 
anticancer therapeutic potential, were reported230,231. In these complexes the folate acts 
as classical bridging dicarboxylate ligand with the metal centres coordinated to the α 
and γ carboxylate groups of the glutamic acid moiety leaving the pterin ring 
unhindered in relation to its binding function in the pocket of the folate receptor.  
 
To explore the chemotherapeutic potential of the simple metal-folate complexes 
generated in the present study the copper and manganese complexes 
[Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5), [Mn(fol)(H2O)3].3H2O (2) 
and [Mn(fol)(phen)(H2O)].4H2O (6) were selected for biological assessment. The 
known cytotoxic cationic bis-phen complex cations [Cu(phen)2]
2+ and [Mn(phen)2]
2+ 
were also included in this study to gauge the impact of the folate ligand on the 
cytotoxic profiles of complexes 5 and 6. 
   
D.2.1  Determination of the biological activity of [Cu(fol)(H2O)3].H2O (1) 
and [Cu(fol)(phen)(H2O)].3H2O (2) 
 
As previously mentioned in section I.3.1, the exploration of the biological effects of 
simple metal folate complexes is in its infancy. Our work therefore sought to elucidate 
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the mechanism of action of these complexes and to determine if these simple metal 
folates had potential for development as cytotoxic agents. In addition, the presence of 
folate was used in an attempt to target the complexes through the folate receptor. Initial 
studies were undertaken to identify the potential cytotoxic and cytoselective 
capabilities of a simple copper(II) folate complex, [Cu(fol)(H2O)3].H2O (1) and its 
1,10-phenanthroline derivative, [Cu(fol)(phen)(H2O)].3H2O (2) (Figure 33) in FR-
overexpressing cell lines.  
 
 
Figure 33: The proposed structures of [Cu(fol)(H2O)3].H2O (1) and 
[Cu(fol)(phen)(H2O)].3H2O (5) 
 
D.2.2  Expression of folate receptor alpha protein levels in cell lines  
 
In order to test the specific targeting of complexes through the FRα and identify 
appropriate cell models for experimentation, the protein expression levels of the 
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receptor in several cell lines was measured using Western blot. Current literature 
available on the expression of the FRα is variable and makes it challenging to identify 
the most relevant cell models. For example, the breast cancer cell line MCF-7 has been 
reported to express normal levels of folate receptor232, while more recently this cell 
line has been reported to overexpress the receptor233. Indeed, some authors have even 
reported the use of the MCF-7 cell line as negative controls for folate receptor232,234–
236. Furthermore, in 2012 the well characterized cervical cancer cell line HeLa, was 
reported to express high FRα levels in one publication237 and low levels in a paper 
published in 2013238,239. 
 
SKOV-3 are commonly used as an FR+ve (FR-overexpressing) cell model240 and 
A549 are used as an FR-ve (FR-underexpressing) cell model180,241. RPE-1 cells were 
chosen as a non-malignant FR-ve cell line242. To determine if these cell lines do 
express the FR levels previously described, western blot analysis was carried out. 
SKOV-3 (human ovarian adenocarcinoma), A549 (human lung carcinoma), RPE-1 
(immortalised human retinal epithelial) and MelJuSo-UbG76V-YFP (human melanoma) 
were cultured in folate-free RPMI 1640 medium, harvested at 80% confluency and 
total protein isolated for western blot analysis. β-actin was used as a control, however 
due to the different expression of β-actin in these cell lines, Ponceau red staining was 
used as a positive control for gel loading.  
 
A549 cells were found to exhibit a detectable level of FRα protein, in agreement with 
the current literature243–245, despite the fact that they are commonly described as FR-
ve cell lines. Li et al did not identify any detectable mRNA for FRα in A549 cells, 
however tumour xenograft tissues expressing A549 cells had detectable FRα protein 
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expression243. SKOV-3 cells expressed high levels of FR-α protein (Figure 34). The 
FR-α expression in MelJuSo-UbG76V-YFP has not been investigated to date, with no 
literature available regarding FR-α expression in this cell line. Interestingly, MelJuSo 
exhibited the highest FR-α expression level. RPE-1 cells also expressed detectable 
levels of FR-α. The current literature suggests that cultured RPE-1 cells exhibit low or 
negligible FR-α expression at mRNA level, so this result was unexpected242,246. 
However, we measured protein expression in contrast to other studies measuring 
mRNA levels. It should be noted that FRα is expressed in mammalian retina, 
specifically located on the choroidal-facing basolateral membrane of the RPE cell. The 
retinal pigment epithelial cells are polarized, having two distinct regions of the plasma 
membrane that are morphologically and functionally different. However, RPE-1 cells 
in culture lose this polarity as they are bound to an impermeable structure and therefore 
lack FRα expression242,246. It could be postulated that the immortalisation process 
alters FRα expression or that culture in folate-depleted medium has induced nutrient 
deprivation, in turn promoting receptor expression. 
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Figure 34: Expression of the Folate Receptor alpha (FR-α) in cell lines. Western blot 
analysis was carried out on 100 µg of total protein isolated from SKOV-3, A549, 
MelJuSo-UbG76V-YFP and RPE-1 cells cultured in folate-free RPMI medium as 
outlined in E.4.1, using an anti-folate receptor alpha antibody. Anti -actin antibody 
was used as a control. Reversible Ponceau red staining was used as a loading control. 
Data represent one of two independent experiments yielding similar results. 
 
Given that SKOV-3 are a commonly used cell model for FR-α overexpressing cells 
and have been well-characterized, SKOV-3 was chosen as the FR-α overexpressing 
cell line for cytotoxicity assays and A549 were used as the FR-α underexpressing cell 
line. In addition, we did not have access to the MelJuSo UbG76V-YFP cell line for initial 
cytotoxicity experiments. Due to the unexpected FR-α expression found in RPE-1 
cells, this cell line was not used as an FR-ve model.  
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As stated previously, folate receptor expression has been shown to vary in cell lines. 
In HeLa cells, FR-expression was shown to be cell cycle dependent, with the highest 
FR levels being observed in the S-phase247. FR levels have also been found to decrease 
as cell confluency increases248. Additional factors such as folate supplementation or 
deprivation in cell culture media may also play a role in the variability of FR-
expression249. Furthermore, as discussed previously regarding the RPE-1 cell line, 
differences in FR-α expression may exist in cultured cells and intact tissues242,246,250. 
While it is clear that various conditions can influence the expression of the FRα in cell 
models, we measured FRα protein expression under folate free media conditions and 
used the same cellular conditions in all other experiments.  
 
D.2.3  [Cu(fol)(phen)(H2O)].3H2O is cytotoxic in eukaryotic cells 
 
Cellular models of SKOV-3 (FR overexpressing) and A549 (FR underexpressing) 
were used to test the cytotoxicity and cytoselectivity of [Cu(fol)(H2O)3].H2O (1) and 
its 1,10-phenanthroline derivative, [Cu(fol)(phen)(H2O)].3H2O (5). Copper(II) bis-
phenanthroline ([Cu(phen)2]
2+ was used as a non-targeted complex. Cells were treated 
with the complexes for 24 hours in folate free RPMI-1640 medium and cell viability 
was measured using the Alamar blue assay. The Alamar Blue assay encompasses an 
oxidation-reduction indicator that both fluoresces and changes colour in response to 
chemical oxidation of growth medium as a result of cell death. A decrease in cell 
viability results in a colour change from pink (reduced, fluorescent) to blue (oxidised, 
non-fluorescent).  
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In a preliminary screen conducted to elucidate if [Cu(fol)(H2O)3].H2O (1) and 
[Cu(fol)(phen)(H2O)].3H2O (5) resulted in any cytotoxic effects and to determine a 
suitable concentration range for subsequent studies, SKOV-3 and A549 cells were 
treated with 2.5 – 100 µM [Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5), 
folic acid, CuCl2, and 1,10-phen for 24 hours. Cisplatin was used as a positive control 
and DMSO/EtOH (0.5%) were used as negative controls.  
 
Results show that complex (1) was non-cytotoxic in A549 cells from 2.5 – 50 µM but 
did show some effect at 100 µM (Figure 35). In SKOV-3 cells, there were effects on 
cell viability (approx. 20% reduction) at concentrations of 50 and 100 µM. In 
comparison, complex (5) appeared to induce a concentration-independent cytotoxic 
effect, reducing cell viability by 90% in both SKOV-3 and A549 cells from 10 µM, 
which did not change further up to 100 µM. Cisplatin was found to be effective in a 
concentration-dependant manner, reducing cell viability by 42% at 10 µM and 68 % 
at 100 µM in A549 cells. A similar effect was observed in SKOV-3 cells, when at 10 
µM, a 44% decrease in viability was observed and a 68% decrease at 100 µM. Folic 
acid exhibited little or no cytotoxicity up to 100 µM in both cell lines as expected, as 
folic acid is an essential component in cell culture media and required for the 
conversion of homocysteine to methionine and DNA synthesis251. However, CuCl2 
significantly reduced A549 viability (52%) when used at 25 µM whereas it only 
reduced SKOV-3 viability by 19% at the same concentration. 1,10-phenanthroline 
induced a concentration-independent cytotoxic effect from 2.5 – 100 µM in both cell 
lines. It is believed that 1,10-phenanthroline is capable of chelating metal ions within 
cell culture media (e.g. Cu2+ ions) to generate biologically active species known to be 
capable of inducing cellular damage203,252. 
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Figure 35: Cytotoxic effects of [Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O 
(5) and starting materials (folic acid, CuCl2, 1,10-phen) in SKOV-3 cells (human 
ovarian adenocarcinoma) and (B) A549 cells (human lung carcinoma). Cells were 
treated with DMSO (0.5%; negative control for [Cu(fol)(H2O)3].H2O (1), 
[Cu(fol)(phen)(H2O)].3H2O (5), folic acid, and cisplatin), EtOH (0.5%; negative 
control for CuCl2 and 1,10-phen) [Cu(fol)(H2O)3].H2O (1), 
[Cu(fol)(phen)(H2O)].3H2O (5), folic acid, CuCl2, 1,10-phen, and cisplatin 
(concentration range 2.5 – 100 μM). Cells were harvested, and cell viability was 
measured using the Alamar Blue assay. Results are representative of three independent 
experiments (n = 3) and show mean ± standard deviation (SD). 
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Based on the results from the preliminary screening (Figure 34), subsequent 
cytotoxicity studies were carried out in the concentration range of 1-10 µM. Cells were 
treated with complex 5, its non-targeted comparator, [Cu(phen)2]
2+, and cisplatin. 
DMSO/EtOH (0.05%) was used as a negative control. As complex 1 was not found to 
be particularly cytotoxic at lower concentrations and even up to 50 µM, it was not used 
in further studies. Results showed that treatment of SKOV-3 cells for 24 hours with 
3.16 µM of complex 5 resulted in a 55 % reduction in cell viability, with 5.62 and 10 
µM reducing viability further to only 6% after 24 hours treatment (Figure 36 (A)). 
 
 In contrast, in A549 cells which express low levels of the folate receptor, treatment 
with 3.16 µM of 5 resulted in only a 10% reduction in cell viability, which was 
significantly different to SKOV-3 cells (p < 0.05). However, at 5.62 and 10 µM, 
complex 5 also reduced viability substantially by 85 and 93% after 24 hours treatment 
(Figure 36 (B)). The EC50 values calculated for complex 5 in SKOV-3 and A549 cell 
lines are 3.13 µM and 3.79 µM respectively. The EC50 values calculated for 
[Cu(phen)2]
2+, which does not contain folate, are 2.00 µM (SKOV-3) and 3.45 µM 
(A549). Treatment of both cell lines with cisplatin did not significantly affect cell 
viability after 24 hours (≤ 20%), although there was slightly more of an effect on 
SKOV-3 cell viability than on A549. The data suggest that there is a difference in cell 
viability of high/low FR expressing cells at concentrations under 5 µM following 
treatment with complex 5 and [Cu(phen)2]
2+, however treatment over 5 µM (5.62 µM 
– 10 µM) resulted in more than a 90% reduction in cell viability in both cells lines. 
This data shows that the effects of complex 5 are only different at 3.16 µM but are not 
different at higher concentrations in SKOV-3 cells expressing significant levels of FR 
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compared to A549 cells with lower expression of FR, suggesting that it is unlikely that 
the folate moiety can increase the cytoselectivity of complex 5.  
 
Figure 36: Cytotoxic effects of [Cu(fol)(phen)(H2O)].3H2O (5) in (A) SKOV-3 cells 
and (B) A549 cells. Cells were treated with DMSO (0.05%; negative control for 
complex 5 and cisplatin), EtOH (0.05%; negative control for [Cu(phen)2]
2+), complex 
5, [Cu(phen)2]
2+, and cisplatin (concentration range 1.00 – 10.00 μM). Cell viability 
was measured using the Alamar Blue assay. Results are representative of three 
independent experiments (n = 3) and show mean ± standard deviation (SD). * shows 
a significant difference between A549 and SKOV-3 cells (p < 0.05). 
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D.2.4  The cytotoxic effect of [Cu(fol)(phen)(H2O)].3H2O is not FR-α 
mediated 
 
The similar EC50 values of both the targeted complex 5 and the non-targeted 
[Cu(phen)2]
2+ against SKOV-3 cells and A549 cells suggest that the FR may not be 
involved in selective cellular uptake. However, to rule out the involvement of the FR-
receptor targeted uptake of complex 5, one population of SKOV-3 cells were cultured 
in folate-depleted RPMI 1640 medium for one week, while another population of 
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic 
acid (FAH2), for the same period to saturate the FR
253. Cell culture media were 
changed every second day for one week. Following one-week incubation, cells were 
treated with 1.00 – 10.00 µM complex 5 for 24 hr and cell viability was measured 
using the Alamar blue assay. The FR has a high affinity for folic acid and the reported 
Kd for folic acid is less than 1 nM
254, therefore, it is expected that folate receptors will 
be fully saturated following treatment with 100 µM folic acid. 
 
The EC50 values calculated for cells treated with complex 5 were as follows: SKOV-3 
(+FAH2) 4.18 µM; SKOV-3 (-FAH2) 3.95 µM, which indicated a similar effect on 
SKOV-3 cell viability in the presence or absence of excess folic acid (Figure 36). Our 
result suggests that the targeting of folate-containing [Cu(fol)(phen)(H2O)].3H2O (5) 
into cells expressing the folate receptor may be folate receptor independent as there 
was no discernible difference between cell viability (uptake of the complex) even when 
the folate receptor was saturated.  
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In comparison to Figure 36 (A), there is an unexpected marked difference in cell 
viability at 3.16 µM in Figure 37 {45% viability (Figure 36 (A)) versus 85% (Figure 
37)}. It is not clear why this difference occurred between experiments but the 
triplicates from each experiment showed similar results. From 5.62 µM to 10 µM, both 
treatments result in similar effects on cell viability {similar to results in Figure 36 (A)}. 
 
 
Figure 37: The effects of complex 5 are not mediated through the folate receptor. 
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic 
acid, and folate free RPMI 1640 medium for one week prior to treatment with 1.00 – 
10.00 μM of complex 5. Cells were incubated for 24 hours and cell viability measured 
using the Alamar Blue assay. Results are representative of three independent 
experiments (n = 3) and results are show as mean ± standard deviation (SD). 
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The crystal structure of the human folate receptor alpha in complex with folic acid was 
resolved in 201326. FRα has a globular structure stabilized by eight disulphide bonds 
and has a deep open folate-binding pocket, with the folate pteroate moiety buried 
inside the receptor. The glutamate moiety sticks out of the pocket entrance, allowing 
it to be conjugated to drugs without adversely affecting FRα binding. It may be 
postulated that the ONO tridentate coordination of complex 5 sterically inhibits 
docking of the pterin moiety into the receptor pocket. However, it is not currently 
known if complex 5 remains intact or dissociates into folic acid and a [Cu(phen)]2+ 
moiety prior to cellular uptake. Stability studies are required to better understand the 
structural integrity of complex 5. 
 
If the complexes are not entering the cell through the FRα, intact or otherwise, they 
may enter the cell by another mechanism such as the human copper transporter, 
hCTR1255,256. Furthermore, the lipophilic nature of 1,10-phenanthroline may aid 
cellular uptake of the copper(II) complex by passive diffusion257. Further work is 
required to determine the mechanism of uptake of these complexes into mammalian 
cells. 
 
D.2.5  Treatment of MelJuSo-UbG76V-YFP cells with [Cu(phen)2]2+ and 
[Cu(fol)(phen)(H2O)].3H2O results in accumulation of ubiquitinated proteins. 
 
Recent studies suggest that copper(II) phenanthroline complexes, such as 
[Cu(IAA)2(phen)] (IAA = Indole-3-acetic acid) and [Cu(IPA)2(phen)] (IPA = indole-
3-propionic acid) may function as proteasome inhibitors due to their inhibition of the 
proteasome and induction of apoptosis in vitro in cell lines122. Previous research by 
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Verma et al showed that 1mM 1,10-phenanthroline inhibited the essential Rpn11 
isopeptidase activity of purified 20S proteasome samples258. Santoro et al investigated 
the effects of copper(II) ions on the 20S proteasome in cell-free conditions and 
suggested that copper(II) ions may induce proteasomal inhibition by affecting the 
gating dynamic of the 20S proteasome through the irreversible closure of α-rings259. 
In the same study, they identified the accumulation of polyubiquitinated proteins in 
HeLa cells following treatment with copper chloride and concluded that Cu(II) ions 
affect proteasome activity at multiple levels. Similar results were reported by Chen et 
al who showed that treatment of breast cancer cell lines MDA-MG-231 with disulfiram 
(which can bind copper and is used clinically to treat alcoholism), when coordinated 
to copper, resulted in inhibition of proteasomal activity260. Zhang et al postulated that 
both copper(II) and 1,10-phenanthroline were required to induce proteasomal 
inhibition and that 1,10-phenanthroline played an important role in the observed 
proteasome inhibition and apoptotic effects of copper(II) complexes122.  
 
The MelJuSo-UbG76V-YFP cell line was used as a dual reporter model of proteasomal 
inhibition and cell survival261. This cell line expresses a ubiquitin-YFP (yellow 
fluorescent protein) fusion protein that is constitutively targeted for proteasomal 
mediated degradation and a nuclear localised red fluorescent (RFP) protein to allow 
quantification of cell number. The accumulation of the Ub-YFP reporter indicates 
inhibition in proteasomal function whereas a reduction in RFP signal indicates reduced 
proliferation or cell death. To examine the effects of copper(II) complexes on 
proteasomal activity, MelJuSo-UbG76V-YFP cells were treated with 0.157 – 5 µM of 
[Cu(fol)(H2O)3].H2O (1), [Cu(fol)(phen)(H2O)].3H2O (5), and [Cu(phen)2]
2+. 
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Bortezomib was used as a positive control at a concentration of 50 nM. DMSO-treated 
or EtOH-treated cells (0.05%) were used as negative controls.  
 
Accumulation of UbG76V-YFP was examined by time-lapse microscopy. As expected, 
cells treated with complex 1 did not display YFP-positivity and remained viable 
throughout the experiment (Figure 38 and 39). Cells treated with complex 5, 
[Cu(phen)2]
2+ (5µM), and Bortezomib (50 nM) rapidly became YFP-positive after 
addition of the complexes and displayed a rounded, apoptotic morphology even after 
12 hours of exposure (Figure 38). Interestingly, a subpopulation of cells treated with 
complex 5 did not become YFP-positive and remained viable over the 72-hour period 
(Figure 38 and 39). In addition, proteasome inhibition correlated with cell death as 
indicated by a decrease in nuclear RFP signal {Figure 39 (A & B)}. Interestingly 
[Cu(phen)2]
2+ resulted in more rapid cell death as a result of proteasomal inhibition 
than treatment with complex 5 {Figure 39 (A & B)}.  
 
These results indicate that complex 5 and [Cu(phen)2]
2+ could both function as 
proteosomal inhibitors and further experimental work was undertaken to identify if 
copper(II) phen was specific as a proteasome inhibitor compared to other 
phenanthroline-containing complexes. 
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Figure 38: Treatment of MelJuSo-UbG76V-YFP cells with complex 5 and [Cu(phen)2]
2+ results in proteasomal inhibition. MelJuSo-
UbG76V-YFP cells treated with 5 µM complex 1, complex 5 and [Cu(phen)2]
2+ and examined by time-lapse microscopy. Data represent 
one of two independent experiments showing similar results.
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Figure 39: Treatment of MelJuSo-UbG76V-YFP cells with complex 5 and 
[Cu(phen)2]
2+ results in proteasomal inhibition. Cells were treated with 5µM complex 
1, complex 5 and [Cu(phen)2]
2+ for 72 hours (A) green fluorescence, and (B) red 
fluorescence. An increase of green fluorescent protein (GFP) and decrease of red 
fluorescent protein (RFP) indicates proteasomal inhibition. Data represent one of two 
independent experiments showing similar results. 
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D.2.6  Copper(II) Phenanthroline is specific as a proteasome inhibitor  
 
To determine if copper(II) phenanthroline was specific as a proteasome inhibitor 
compared to other phenanthroline-containing complexes, MelJuSo-UbG76V-YFP cells 
were treated with [Cu(phen)2]
2+, [Mn(phen)2]
2+, 1,10-Phenanthroline or Bortezomib 
for 72 hours. 
 
Accumulation of UbG76V-YFP was examined by time-lapse microscopy on treated 
cells. Our data show that cells treated with [Cu(phen)2]
2+ (3.14 µM) and those treated 
with Bortezomib (50 nM) became YFP-positive within 24 hours indicative of 
proteasomal inhibition (Figure 40). Cells treated with concentrations greater than 10 
µM of [Cu(phen)2]
2+ were apoptotic before the first image was taken (≤3 hours) 
therefore the YFP signal could not be detected. Both [Mn(phen)2]
2+ and 1,10-
phenanthroline treated cells did not express YFP up to 72 hours of treatment, however 
a decrease in cell viability, evident by a decrease in red fluorescence, and a change in 
morphology was observed from 48 – 72 hours (Figure 40). Our results confirm that 
copper(II) phenanthroline is specific as a proteasomal inhibitor when compared to 
another phenanthroline-containing complex (e.g. manganese(II) bis-phenanthroline or 
1,10 phenanthroline). Previous research demonstrates that although copper chloride 
inhibits chymotrypsin-like activity of purified 20S proteasome with an IC50 value of 
∼7.5 μmol/L, a 95% reduction in its activity is seen in intact MDA-MB-231 cells260. 
Additionally, Zhang et al suggests that phenanthroline encourages the uptake of copper 
into intact cells to induce proteasome inhibition122. Therefore, it is believed that both 
copper(II) and 1,10-phenanthroline are required to induce proteasome inhibition.
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Figure 40: Copper(II) phenanthroline treatment results in proteasomal degradation. MelJuSo-UbG76V-YFP cells were treated with phen, 
[Mn(phen)2]
2+, [Cu(phen)2]
2+ (3.14 µM) and Bortezomib (50 nM). Cells were exposed to 3.14 µM metal phenanthrolines and the free 
ligand, 1,10-phenanthroline, and Bortezomib (50 nM). Cells were treated for 72 hours and imaged using time-lapse microscopy every 3 
hours. Images are from one experiment. 
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D.2.7  Effect of [Cu(fol)(phen)(H2O)].3H2O and [Cu(phen)2]2+ on proteins 
involved in apoptosis and proteasome activity  
 
Our results to date indicated that complex 5 and [Cu(phen)2]
2+ have the potential to act 
as proteasome inhibitors and that these effects were specific for Cu(II) containing 
complexes. To further investigate the mechanism of proteasomal degradation by 
complex 5 and [Cu(phen)2]
2+ complexes, western blot assay was carried out using 
antibodies to key proteins involved in the response to proteasomal inhibition, 
endoplasmic reticulum (ER) stress, reactive oxygen species (ROS) and apoptosis. 
MelJuSo-UbG76V-YFP cells were treated with complex 5, [Cu(phen)2]
2+ (1.58 µM – 5 
µM), or Bortezomib (50 nM) for 6 hours and 18 hours. 
 
Western blot analysis identified that complex 5 and [Cu(phen)2]
2+ induced 
accumulation of K48 (lysine 48) linked polyubiquitin and the Ub-YFP reporter at 2.81 
and 5 µM indicating proteasome inhibition (Figure 41). The K48 antibody identifies 
polyubiquitinated chains linked through the Lys48 residue of ubiquitin, commonly 
associated with proteins targeted for proteosomal degradation262. Regulators of the ER 
stress response, heat shock protein 6 (HSPA6) and glucose-regulating protein 78 
kDa/immunoglobulin heavy chain binding protein (GRP78/BIP), were induced 
following treatment; however, the [Cu(phen)2]
2+ showed a more rapid induction of 
these proteins already after 6 hours compared to complex 5.  
 
Next, we investigated the effect of [Cu(phen)2]
2+ and complex 5 on regulators of cell 
cycle progression and apoptosis. Both compounds induced the accumulation of cell 
cycle regulators p53 and p21, with [Cu(phen)2]
2+ treated cells displaying a more rapid 
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response. Similarly, both compounds also induced the accumulation of activated 
caspase-3 indicating the activation of the intrinsic apoptotic pathways (Figure 41). In 
both experiments of 6 hours and 18 hours, treatment with 5 µM [Cu(phen)2]
2 did not 
result in accumulation of K48 Ub. It is unclear why this occurred as other proteins 
indicating ER stress, proteasomal inhibition and apoptosis were induced, although 
some differences were observed after 18 hours treatment with 5 µM e.g. p21, HMOX-
1 and GFP. Taken together, these results show that treatment with complex 5 and 
[Cu(phen)2]
2+
 result in accumulation of proteins involved in proteasomal inhibition and 
apoptosis, with [Cu(phen)2]
2+ resulting in a more rapid effect.  
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Figure 41: Complex 5 and [Cu(phen)2]
2+ induce proteins involved apoptosis and 
proteasome inhibition. Western blot assay was performed on MelJuSo-UbG76V-YFP 
cell extracts treated with 1.58 – 5 µM complex 5 and [Cu(phen)2]2+, and Bortezomib 
(50 nM) for (A) 6 h and (B) 18 h. Antibodies to HSPA6, Ubiquitin K48, Green 
Fluorescence Protein (GFP), GRP78 BiP, p53, Heme Oxygenase 1 (HMOX-1), 
Caspase3 (Casp-3), and p21 proteins were utilised in western blot as per the 
experimental section. β-actin was used as a loading control. Data represent one of two 
independent experiments with similar results. 
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Both complexes also induced the expression of HMOX-1 within 6 hours of cells 
treated with 5 µM complex 5 and 2.81 - 5 µM [Cu(phen)2]
2+, and HMOX-1 is induced 
by a variety of stimuli including ROS generation. The effect of ROS generation on the 
proteasome is unclear. Both Daniel et al and Santoro et al suggest that oxidative 
damage is not the direct cause of proteasomal inhibition, but that copper directly 
interacts with and inhibits the proteasome127,259. Furthermore, the deubiquitinating 
enzyme, RPN11/POH1, located on the 19S regulatory cap (Figure 42), has been found 
to be particularly sensitive to 1,10-phenanthroline in cell-free conditions in the 
millimolar range (1 – 10 mM)258,263. Considering this, the generation of ROS by 
complex 5 and [Cu(phen)2]
2+ is not believed to be involved in the inhibition of the 
proteasome but may be involved in a concurrent mechanism. 
 
Currently, our hypothesis is that the copper(II) phenanthroline moieties of complex 5 
and [Cu(phen)2]
2+ may directly interact with the deubiquitinating enzyme machinery, 
specifically the metalloprotease RPN11/POH1 which is known to interact with 1,10-
phenanthroline264 to exert their proteasome inhibitory effects (Figure 42). If this is the 
case, these copper(II) phenanthroline complexes may represent a novel class of cell 
permeable RPN11/POH1 proteasome inhibitors.  
 
Attempts to elucidate the precise site of interaction of complex 5 with the proteasome 
were made – competitive labelling experiments using HA-tagged ubiquitin vinyl-
sulphonone (HA-UbVS), an active site probe of cysteine DUBs (USP14 and UCHL5) 
were conducted. The metalloprotease RPN11/POH1 is not labelled by the HA-Ub-VS 
probe, therefore alterations in POH1 activity would not be evident using the probe. 
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Unfortunately, results of these experiments were inconclusive, warranting further 
investigation (see Section C.2) 
 
 
Figure 42: Copper(II) phenanthroline complexes mediate their effects through the 
Ubiquitin-Proteasome system. (1) Ubiquitin (Ub) is conjugated to proteins destined 
for degradation by an ATP-dependent process that involves enzymes E1, E2, and E3 
(2) The copper(II) phenanthroline moiety may interact directly with DUB enzyme 
RPN11/POH1 located on the 19S regulatory cap, and (3) prevent deubiquitination of 
Ub-labelled proteins. (4) Ub-labelled proteins may accumulate in the cell, resulting in 
apoptotic cell death. 
 
 
 
 
107 
 
D.2.8   [Cu(fol)(phen)(H2O)].3H2O and [Cu(phen)2]2+ are cytotoxic in 
multicellular tumour spheroids.  
 
As mentioned previously, current proteasome inhibitors such as Bortezomib are 
ineffective against solid tumours265. Therefore, the potency of copper(II) 
phenanthroline complex 5 and [Cu(phen)2]
2+ against 3D tumour spheroids was 
investigated. Multicellular spheroids are superior to 2D monolayer cultures in 
mimicking in vivo solid tumours266–268. Numerous differences reported between 2D 
and 3D cell models regarding responses to therapeutic agents and pivotal cellular 
processes such as cell morphology, differentiation, signalling pathways, cell-cell 
interactions, and cell-matrix interactions demonstrate the importance of 3D cell 
models in drug screenings 268. In light of this, many clinically used drugs (e.g. Taxol, 
and Bortezomib) that show excellent in vitro activity against monolayer cell models 
show limited potency in spheroids 269,270. 
 
Multicellular tumour spheroids (MCTs) were formed using SKOV-3 cells as described 
in section E.4. Cells were treated with 1.77 – 10 µM complex 5, [Cu(phen)2]2+, and 
Bortezomib (17.70 – 100 nM) for 72 hours and examined by time-lapse microscopy 
(Figure 43). The spheroid volume was also measured for each treatment and is shown 
in Figure 44. Treatment with complex 5 and [Cu(phen)2]
2+ (10 µM) resulted in 
disaggregation of spheroids (Figure 42 (A)). Spheroids treated with Bortezomib (10 – 
100 nM) showed no disaggregation over the duration of the experiment, which 
indicates that Bortezomib is not effective in 3D cellular models in line with previous 
literature.  
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This is the first report on the effects of metal-based proteasome inhibitors against 3D 
tumour spheroids which show promising results in multicellular 3D models. However, 
further studies are required to better understand the cytotoxicity of complex 5 and 
[Cu(phen)2]
2+ in 3D tumour spheroids – i.e. do they still function as proteasome 
inhibitors in 3D models or does the generation of ROS or RNS play a more significant 
role in cell death given the hypoxic environment of the 3D spheroid? 
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Figure 43: Complex 5 and [Cu(phen)2]
2+ cause disaggregation of SKOV-3 spheroids. 
(A) SKOV-3 cells treated with 10 µM complex 5 and [Cu(phen)2]
2+ examined by time-
lapse microscopy. DMSO treated cells (0.1%) were used as a negative control and 
Bortezomib (100 nM) as a positive control. B) SKOV-3 cells treated with 10 µM of 
Complex 5 and [Cu(phen)2]
2+ for 72 hours. DMSO (0.1%) and Bortezomib (100 nM) 
were used as controls. Images taken using an inverted microscope (X40 total 
magnification). Data represent one of three independent experiments with similar 
results. 
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Figure 44: Complex 5 and [Cu(phen)2]
2+ cause disaggregation of SKOV-3 spheroids. 
(A) SKOV-3 cells treated with 10 µM complex 5 and [Cu(phen)2]
2+ examined by time-
lapse microscopy. DMSO treated cells (0.1%) were used as a negative control and 
Bortezomib (100 nM) as a positive control. Spheroid volume was calculated for each 
treatment. Data represent one of three independent experiments with similar results. 
 
D.2.9  Conclusion 
 
Our data suggests that complex 1, [Cu(fol)(H2O)3].H2O does not affect cell viability 
in cell lines up to 50 µM, although there were some effects in A549 and SKOV-3 at 
higher concentrations. In contrast, its 1,10-phenanthroline derivative, 
[Cu(fol)(phen)(H2O)].3H2O (5), showed promising in vitro activity at ≤ 5 µM within 
24 hours treatment. Complex 5 was found to be cytotoxic against both FR 
overexpressing SKOV-3 cells and FR underexpressing A549 cells, suggesting that the 
complex may enter the cell through a mechanism other than transport via the folate 
receptor. Additional folate saturation studies support this. Although the mechanism of 
cellular uptake is unknown at this time, complex 5 was found to induce proteasomal 
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inhibition and subsequent apoptosis. The non-targeted [Cu(phen)2]
2+ complex was also 
found to induce proteasomal inhibition and apoptosis, albeit more rapidly.  
 
Finally, both complex 5 and [Cu(phen)2]
2+ were found to be active in 3D-tumour 
spheroids in the low micromolar range, resulting in their disaggregation. Our overall 
conclusion is that copper(II) phenanthroline complexes have the potential to function 
as potent proteasome inhibitors in the low M range and may be developed into new 
metal-based anticancer agents, showing efficacy in 2D and 3D cell models.  
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D.3  The biological activity of manganese(II) folate and it’s 1,10-
phenanthroline derivative 
 
Having examined the potential effects of novel copper(II) folate complexes, we also 
examined [Mn(fol)(H2O)3].3H2O (2) and [Mn(fol)(phen)(H2O)].4H2O (6) (Figure 44) 
to identify their potential as cytotoxic and cytoselective agents and to establish the 
difference in their biological profiles when compared to [Cu(fol)(H2O)3].H2O (1) and 
[Cu(fol)(phen)(H2O)].3H2O (5).  
 
Physiologically, Cu2+ and Mn2+ are involved in a range of biochemical processes. 
However, copper(II) and manganese(II) differ in their structural properties and their 
biological activities in a number of ways. For example in antioxidant systems such as 
the dismutation of superoxide (O2
•–) to O2 and H2O2 via superoxide dismutase (SOD) 
enzymes, it is noted that manganese(II)-containing SOD enzymes react with O2
•– more 
slowly than the Cu/ZnSOD enzyme271. Additionally, Mn2+ systems are reportedly less 
prone to form the reactive hydroxyl radical (•OH) via Fenton chemistry, but rather 
function via the disproportionation of H2O2 into water and oxygen
203,271. Furthermore, 
as Mn2+ is a d5, high spin, weak field metal, it lacks crystal field stabilisation energy 
(CFSE), resulting in less stable complexes more likely to dissociate from its ligand271. 
 
D.3.1  [Mn(fol)(phen)(H2O)].4H2O is cytotoxic in eukaryotic cells 
 
Similar to section D.2.1, the cytotoxicity and cytoselectivity of [Mn(fol)(H2O)3].3H2O 
(2) and its 1,10-phenanthroline derivative, [Mn(fol)(phen)(H2O)].4H2O (6) (Figure 45) 
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were investigated. Manganese(II) bis-phenanthroline ([Mn(phen)2]
2+ was used as a 
non-targeted complex.  
 
Figure 45: The proposed structures of [Mn(fol)(H2O)3].3H2O (2) and 
[Mn(fol)(phen)(H2O)].4H2O (6) 
 
In a preliminary screen conducted to elucidate if [Mn(fol)(H2O)3].3H2O (2) and 
[M4(fol)(phen)(H2O)].3H2O (6) were cytotoxic and to determine a suitable 
concentration range for subsequent studies, SKOV-3 and A549 cells were treated with 
3 – 100 µM complex 2, complex 6, and the non-targeted [Mn(phen)2]2+ counterpart for 
24 and 48 hours. Cisplatin was used as a positive control and DMSO (0.1%) as a 
negative control. Similar to complex 1, it was found that complex 2 did not induce 
marked cytotoxic effect in either SKOV-3 or A549 cell lines within 24 or 48 hours 
from 3 – 100 µM (Figure 46). At 24 hours, complex 6 (17.73 µM) reduced cell viability 
by 51% in SKOV-3 and 29% in A549. [Mn(phen)2]
2+ induced a similar effect, reducing 
cell viability by 47% in SKOV-3 and 20% in A549 at 17.73 µM. However, at 48 hours, 
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complex 6 induced a 70% reduction in cell viability in SKOV-3 at 17.73 µM and only 
a 45% reduction in A549 at the same concentration. Again, [Mn(phen)2]
2+ induced a 
similar effect. 
 
Figure 46: Cytotoxic effects of [Mn(fol)(H2O)3].3H2O (2), 
[Mn(fol)(phen)(H2O)].4H2O (6) and [Mn(phen)2]
2+ in SKOV-3 cells (A & B) and 
A549 cells (C & D). Cells were treated with DMSO (0.1%), [Mn(fol)(H2O)3].3H2O 
(2), [Mn(fol)(phen)(H2O)].4H2O (6), [Mn(phen)2]
2+, and cisplatin (concentration 
range 3 – 100 μM; Log0.25 dilution) for 24 and 48 hours. Cells were harvested, and cell 
viability was measured using the Alamar Blue assay. Results are representative of 
three independent experiments (n = 3) and show mean ± standard deviation (SD). 
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As complex 2 failed to induce a cytotoxic effect within 48 hours, even at 100 µM, it 
was not used in subsequent studies. However, complex 6 was found to induce a 
significant cytotoxic effect at 48 hours, particularly in FR-overexpressing SKOV-3 
cells (Figure 45 (B)). This delayed cytotoxicity may be due to the reportedly slow 
reaction of Mn2+ with superoxide271. In light of this, subsequent studies were 
performed for 48 and 72 hours in the concentration range of 2 – 20 µM, using complex 
6 and its non-targeted comparator, [Mn(phen)2]
2+. In this case, bortezomib was used 
as a positive control from 20 – 200 nM and DMSO (0.1%) was used as a negative 
control. Cell viability was measured using the Alamar blue assay.  
 
Subsequent studies showed that treatment of SKOV-3 cells with 6.31 µM of complex 
6 resulted in a 49% reduction in cell viability (p <0.005), however an increase in 
concentration up to 20 µM only reduced cell viability by an additional 14% after 48 
hours treatment (Figure 46 (A)). After 72 hours treatment, cell viability was reduced 
by 77% when treated with 6.31 µM complex 6, and by 84 and 93% with 11.24 and 20 
µM complex 6 (Figure 46 (B)). There was a similar effect with Bortezomib and with 
[Mn(phen)2
2+] with [Mn(phen)2
2+] being more effective than Bortezomib even at 2 
µM. After 72 hours treatment, there were notable differences between the triplicates 
in each experiment as evidenced by the large error bars in Figure 47 (B and D). This 
may be due to the 72-hour treatment without a change of culture medium and 
accumulation of potentially toxic compounds.  
 
Interestingly, there was a difference between the effects of complex 6 in SKOV-3 
compared to A549 cells. When comparing Figure 47 (A) and (C), at concentrations 
higher than 2 µM, there was decreased cell viability in SKOV-3 (FR-overexpressing 
116 
 
cells) compared to A549 (FR-underexpressing cells) after 48 hours treatment 
(significant, p <0.005), which was also visible after 72 hours treatment (significant, p 
<0.05; compare panels B and D). These results suggest that the effects of complex 6 
may be mediated via the folate receptor.   
 
In A549 cells which express low levels of the folate receptor, treatment with 6.31 µM 
of complex 6 resulted in only a 15% reduction in cell viability after 48 hours with 50% 
viability remaining even after treatment with 20 µM, (Figure 47 (C)). After 72 hours, 
treatment of A549 cells with concentrations of complex 6 up to 20 µM resulted in an 
80% reduction in cell viability, which was concentration dependent at concentrations 
higher than 3.54 µM . The EC50 values calculated for complex 6 in SKOV-3 and A549 
cell lines are 4.92 µM and 7.63 µM at 48 hours, and 4.50 µM (SKOV-3) and 4.64 µM 
(A549) at 72 hours, respectively. The EC50 values calculated for [Mn(phen)2]
2+, which 
does not contain folate, are 1.59 µM (SKOV-3) and 7.85 µM (A549) at 48 hours. 
Bortezomib has EC50 values of 3.45 nM (SKOV-3) and 9.67 nM (A549) at 48 hours. 
The data suggest that there is a difference in cell viability of high/low FR expressing 
cells when treated with complex 6 at 48 hours. However, the differences in EC50 
between the cell lines with a non-folate containing complex and Bortezomib would 
suggest that these differences may not relate to folate receptor expression. 
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Figure 47: Cytotoxic effects of complex 6 in SKOV-3 cells (human ovarian 
adenocarcinoma) (A & B) and A549 cells (human lung carcinoma) (C & D). Cells 
were treated with DMSO (0.1 %), complex 6, [Mn(phen)2]
2+ (2 – 20 µM), and 
Bortezomib (20 – 200 nM) for 48 and 72 hours. Cells were harvested, and cell viability 
was measured using the Alamar Blue assay. Results are representative of three 
independent experiments (n = 3) and show mean ± standard deviation (SD). Asterisk 
(*) shows (p <0.05) whereas (**) and (***) shows (p < 0.005) and (p <0.001). 
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D.3.2  The cytotoxic effect of [Mn(fol)(phen)(H2O)].4H2O is not FRα 
mediated 
 
The EC50 values of complex 6 against A549 cells is 1.5 times greater than that of 
SKOV-3 cells after 48 hours treatment which could suggest the involvement of the 
FRα in transporting complex 6 into cells. To further investigate if the FR-receptor is 
involved in targeted uptake of complex 6, a similar method described in section D.2.4 
was used. The FR was saturated with folic acid for one week and cells were treated 
with 2 – 20 µM complex 6 for 48 hr (Figure 48) and cell viability was measured using 
the Alamar blue assay.  
 
The EC50 values calculated for cells treated with complex 6 for 48 hours were as 
follows: SKOV-3 (+FAH2) 5.91 µM; SKOV-3 (-FAH2) 5.27 µM, which show a 
similar effect on SKOV-3 cells in the presence or absence of excess folic acid (Figure 
47). This result suggests that the targeting of the [Mn(fol)(phen)(H2O)].4H2O (6) may 
not be through the folate receptor and that the effects seen on cell viability are due to 
other mechanisms. In addition, the effects on cell viability with manganese complexes 
occur after a much longer timeline than those seen with copper complexes. We can 
only speculate at this stage that the complexes are entering the cell via a transport 
mechanism or by passive diffusion. The current literature suggests that manganese(II) 
complexes may enter cells through a number of transport mechanisms, including: the 
divalent metal transporter 1 (DMT1)272, a manganese citrate transporter273,274, a store 
activated Ca2+ channel275, the ZIP8 mechanism276,277, and the ZIP14 mechanism278–280. 
However, DMT1 transports metal ions and therefore its capacity to bind and/or 
transport complex 6 or [Mn(phen)2]
2+ is unknown. 
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Figure 48: The effects of complex 6 are not mediated through the folate receptor. 
SKOV-3 cells were cultured in RPMI 1640 medium supplemented with 100 µM folic 
acid (FAH2), and folate free RPMI 1640 medium for one week prior to treatment with 
2 – 20 μM of complex 6. Cells were incubated for 48 hours and cell viability measured 
using the Alamar Blue assay. Results are representative of three independent 
experiments (n = 3) and results are show as mean ± standard deviation (SD). 
 
D.3.3  [Mn(fol)(phen)(H2O)].4H2O and [Mn(phen)2]2+ do not induce 
proteasome inhibition. 
 
When comparing the activities of Cu and Mn containing complexes, it was previously 
observed that [Mn(phen)2]
2+ did not result in proteasomal inhibition following 
treatment at 3.14 µM for 72 hours (Figure 39). To elucidate its potential proteasomal 
effects, complex 6 was further investigated. MelJuSo-UbG76V-YFP cells were treated 
with 2 – 20 µM of [Mn(fol)(phen)(H2O)].4H2O (6) and [Mn(phen)2]2+ to determine if, 
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like their copper(II) phenanthroline counterparts, they were capable of inducing 
proteasomal inhibition. Bortezomib was used a positive control at a concentration of 
20 - 200 nM. DMSO-treated cells (0.1%) were used as negative controls.  
 
Accumulation of UbG76V-YFP was examined by time-lapse microscopy, which 
indicates inhibition of proteosomal function. Cells treated with bortezomib (20 - 200 
nM) rapidly became YFP-positive after treatment, displaying a rounded, apoptotic 
morphology within 24 hours of exposure (Figure 49). However, cells treated with 
complex 6 and [Mn(phen)2]
2+ did not display YFP-expression throughout the 
experiment, even up to 72 hours treatment. A distinguishing feature of these 
experiments was that within 48 – 72 hours, cell growth/division ceased and changes in 
cell morphology became apparent at a microscopic level as evident in Figure 48 in the 
number of cells evident (compare DMSO treated cells, complex 6 and [Mn(phen)2]
2+ 
at 72 hours). An observed decrease in RFP in cells treated with complex 6 and 
[Mn(phen)2]
2+ also indicated reduced cell viability. 
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Figure 49: Effects of Complex 6 and [Mn(phen)2]2+ on the proteasome. MelJuSo-
UbG76V-YFP cells were treated with complex 6 and [Mn(phen)2]2+ (11.24 µM) and 
Bortezomib (63.10 nM) for 72 hours. DMSO (0.1%) treated cells were used as a 
negative control. Images were collected using time-lapse microscopy every 3 hours. 
Images shown are from one experiment at 72 hours. 
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D.3.4  Treatment of MelJuSo-UbG76V-YFP cells with 
[Mn(fol)(phen)(H2O)].4H2O delays cell migration and proliferation. 
 
The apparent inhibition of cell growth observed in Figure 48 prompted the exploration 
of complex 6’s effects on MelJuSo-UbG76V-YFP cell migration. MelJuSo-UbG76V-YFP 
cells are derived from cutaneous melanomas which are highly metastatic skin tumours 
resulting from the malignant transformation of melanocytes281,282. Late stage 
melanomas (i.e. stage IV melanoma) are characterised by their ability to metastasize 
or migrate to other parts of the body with a mean survival time of 7.5 months from 
diagnosis283. The liver, lungs, bones and brain are most often affected by these 
metastases284,285.  
 
MelJuSo-UbG76V-YFP cells were seeded into 35 mm dishes and allowed to reach 100% 
confluency as a monolayer. A sterile pipette tip was used to scratch a straight line along 
the equator of each dish. One dish was supplemented with folate-depleted RPMI 1640 
media containing [Mn(fol)(phen)(H2O)].4H2O (complex 6) (20 µM). Another dish 
containing 0.1% DMSO was used as a negative control. Both were scratched at time 
of treatment. A third dish was supplemented with folate-depleted RPMI 1640 media 
containing [Mn(fol)(phen)(H2O)].4H2O (6) (20 µM) and was scratched 24 hours after 
treatment. Media was replenished every 24 hours and images of the scratch site were 
taken every 24 hours for a total of 72 hours. 
 
Our results showed that DMSO (0.1%) treated cells almost entirely filled the wound 
site within 72 hours, showing that normal growth and proliferation was occurring 
(Figure 50). In stark contrast, treatment of MelJuSo-UbG76V-YFP cells with complex 
123 
 
6 (20 µM) greatly hindered the mobility/proliferation of these cells and 70 – 80% of 
the wound site remaining unoccupied at 72 h (Figure 50). Pre-treatment of cells with 
complex 6 24 hours prior to scratch resulted in a similar outcome. These results show 
that complex 6 treatment of melanoma cell lines impairs their ability to proliferate as 
well as hindering their mobility.
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Figure 50: Complex 6 (20 µM) hinders mobility of MelJuSo-UbG76V-YFP cells within 48 – 72 hours. A confluent 35 mm dish of MelJuSo-
UbG76V-YFP cells was scratched across the equator and treated with 20 µM complex 6 or DMSO (0.1 %) for 72 hours. A third set of 
MelJuSo-UbG76V-YFP cells were pre-treated with complex 6 (20 µM) 24 hours prior to scratching. Media was replenished every 24 hours 
and images of the scratch site were taken every 24 hours for a total of 72 hours. The experiment was repeated twice yielding the same 
result. Results are presented from one experiment. Total magnification X40.
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D.3.5  [Mn(phen)2]2+ and [Mn(fol)(phen)(H2O)].4H2O may induce cell 
death via ROS induced autophagy. 
 
The generation of reactive oxygen species by manganese(II) complexes is well 
reported203,286,287. However, it is only within the last decade that the mechanism of 
action of manganese(II) complexes in mammalian cells was reported97,98,102,203,288. The 
current literature suggests that manganese(II)-induced ROS results in mitochondrial 
damage, and subsequently leads to both apoptotic and autophagic cell death97,98,102. 
Therefore, to explore the findings in our previous experiments of the inhibition of cell 
growth and proliferation by treatment with Mn-containing complexes, the possibility 
of autophagic cell death in MelJuSo-UbG76V-YFP cells treated with complex 6 was 
investigated using cell morphology analysis, western blot analysis and flow cytometry.  
 
D.3.5.1 Cell morphology 
 
As evidenced in the wound scratch assay experiments on treatment of MelJuSo-
UbG76V-YFP cells with complex 6 (20 µM) (section D.3.4), a distinct visible change in 
cell morphology occurred {Figure 51 (A)}. Between 48 – 72 hours, cell nuclei 
appeared swollen and chromatin were condensed. In addition, granularity of the 
cytoplasm increased greatly. A key morphological change associated with autophagy 
is the development of autophagosomes; double-membraned vesicles that form around 
cellular material to be degraded by autophagy, resulting in the increased cell 
granularity/complexity observed in treated cells289,290. Furthermore, the chromatin 
condensation and enlargement of the nuclei observed is considered a morphological 
hallmark of apoptosis291,292. Similar results were observed in SKOV-3 cells treated 
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with complex 6 (20µM) (Figure 51 (B)). Flow cytometry experiments measuring cell 
size {forward scatter; and complexity {Figure 51 (C) and (D)} using 
tetramethylrhodamine ethyl ester (TMRE)  staining confirmed an increase in SKOV-
3 cell size and complexity {i.e. increased granularity, nuclear condensation and 
enlarged nuclear size as shown in Figure 51 (B)}, in comparison to DMSO (0.1%) 
treated cells. Taken together these results suggest that both autophagic and apoptotic 
pathways are involved in the death of cells treated with complex 6293. 
 
D.3.5.2 Regulation of proteins involved in Autophagy and ROS regulation 
 
Western blot analysis of proteins involved in autophagy, ROS generation, and 
mitochondrial damage was carried out to determine if these proteins were regulated by 
treatment with complex 6. MelJuSo-UbG76V-YFP cells were treated with complex 6, 
[Mn(phen)2]
2+ (6.31 – 20 µM), or Bortezomib (50 nM) for 48 hours and total protein 
was isolated and resolved by SDS-PAGE  
 
Western blot analysis identified that complex 6 (6.31 – 20 µM) and [Mn(phen)2]2+ 
(6.31 – 20 µM) suppressed the expression of p62, a protein reported to be readily 
degraded upon initiation of autophagy294,295 (Figure 52). p62 is a multifunctional 
protein which functions in signal transduction and interacts with ubiquitin and 
polyubiquitin chains and delivers ubiquitinated cargo to autophagy and the 
proteasome296. Cells treated with complex 6 (6.31, 11.23 and 20 µM) and 
[Mn(phen)2]
2+ (6.31, 11.23 and 20 µM) were found to increase in HMOX-1 expression, 
suggesting an increase in ROS. Interestingly, treatment with [Mn(phen)2]
2+ resulted in 
a larger increase in HMOX-1 expression than complex 6, suggesting it may be more 
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effective at increasing intracellular ROS levels. In addition, HSP60 expression was 
suppressed in cells treated with complex 6 (11.23 – 20 µM) and [Mn (phen)2]2+ (6.31 
– 20 µM) at 48 hours.  
 
Figure 51: Treatment of cells with complex 6 causes morphological changes at 
cellular level (A) MelJuSo-UbG76V-YFP cells were treated with Complex 6 (20 µM) 
for 48 hours (B) SKOV-3 cells treated with complex 6 (20 µM) for 48 hours. Cells 
were viewed in an inverted microscope x 200 magnification (C) Flow cytometry was 
carried out on SKOV-3 cells treated with (C) DMSO (0.1 %) and (D) 20 µM complex 
6 for 48 hours. Data represent results from one experiment. 
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HSP60 is a mitochondrial chaperone that is commonly upregulated in cancer cell lines, 
orchestrating a cytoprotective pathway via the stabilisation of survivin levels and 
suppressing p53297,298. A decrease in HSP60 expression may suggest ROS induced 
damage to the mitochondria. DMSO (0.1%) treated cells maintained high expression 
of both p62 and HSP60 at 48 hours, but showed no expression of HMOX-1, as 
expected. Cells treated with Bortezomib (50 nM), which is active within 24 hours, 
were non-viable at 48 hours and therefore no protein expression was observed (Figure 
52). 
 
Figure 52: Complex 6 and [Mn(phen)2]
2+ suppress expression of proteins involved in 
autophagy and mitochondrial damage. Western blot assay was performed on MelJuSo-
UbG76V-YFP cell extracts treated with 6.31, 11.23 and 20 µM complex 6 and 
[Mn(phen)2]
2+, and Bortezomib (50 nM) for 48 hr. Antibodies to HSP60, p62, and 
Heme Oxygenase 1 (HMOX-1) were utilised in western blot as per the experimental 
section. α-Tubulin was used as a loading control. Data represent results from one 
experiment. 
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D.3.5.3 Mitochondrial depolarisation 
 
As chromatin condensation, a key morphological change associated with apoptosis, 
was observed, we investigated the possibility of apoptosis in treated cells. This was 
carried out by monitoring changes in mitochondrial transmembrane potential (ΔΨm). 
During apoptosis, the pro-apoptotic Bcl-2 family proteins Bax and Bak are activated 
and insert into the outer mitochondrial membrane, increasing mitochondrial 
permeability. Proteins such as cytochrome C (cyt-C), apoptosis-inducing factor (AIF), 
Smac/DIABLO and Omi/HrtA2299–303 are released to form the apoptosome. 
Apoptosome formation results in the activation of effector caspases that are 
responsible for most of the biochemical and morphological changes during 
apoptosis304. 
 
SKOV-3 cells were used in this experiment as MelJuSo-UbG76V-YFP cells contained 
fluorescent proteins which would likely interfere with fluorescent measurements. 
SKOV-3 cells were treated with complex 6 (20 µM) or 0.1% DMSO for 48 hours. 
Depolarisation measurements were obtained using flow cytometry and the fluorogenic 
dye TMRE. Using flow cytometry, it was found that complex 6 induced 6.74% 
depolarisation (Figure 53) – a marginal value in comparison to values reported 
elsewhere (e.g. carbonyl cyanide m-chlorophenyl hydrazine (CCCP), an established 
protonophore and known uncoupler of ΔΨm, was found to depolarise 55.3% of the 
sample population (SKOV-3 cells)102. Although this experiment was only carried out 
once due to time constraints, this result shows that complex 6 does not directly activate 
apoptosis as the primary mechanism of cell death to account for the 63% decrease in 
cellular viability {Figure 47 (A)}. 
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Figure 53: Complex 6 does not depolarise the mitochondrial membrane. SKOV-3 
cells were treated with complex 6 (20 µM) (black) or DMSO (0.1 %) (red) for 48 
hours. Cells treated with DMSO (0.1%) without TMRE were used as a negative 
control. TMRE was measured using flow cytometry. Data represent results from one 
experiment. 
 
Although further clarification of the role of autophagy and/or apoptosis in complex 6-
induced cell death is required, current results are intriguing and are supported by the 
current literature. To fully understand the mechanisms at work, additional 
investigation is needed. For example, examining the expression of LC3, a protein 
directly bound to p62 and involved in autophagic flux, would further support our 
hypothesis of autophagy305. Markers of autophagy are available commercially and will 
be used to confirm autophagy in future studies. In addition, treatment of cells with 
autophagic inhibitors such as 3-methyladenine (3-MA) and/or inducers (rapamycin 
and suberoylanilide hydroxamic acid) could also be used to confirm our hypothesis102. 
Examination of apoptotic proteins such as p53 and caspases may offer additional 
insight. 
131 
 
D.3.6  Cell cycle analysis 
 
The eukaryotic cell cycle is divided into four distinct phases – mitosis (M), gap 1 (G1), 
DNA synthesis (S), and gap 2 (G2). The M phase of the eukaryotic cell cycle 
corresponds to mitosis; the period of cell division. This phase is followed by G1, the 
period between mitosis and initiation of DNA replication. It is during this time that 
cells are metabolically active and continue to grow without DNA replication occurring. 
The S phase follows, during which DNA replication takes place. The completion of 
DNA synthesis is followed by the G2 phase, when cells continue to grow and protein 
synthesis initiates in preparation for mitosis306. 
 
In order to investigate the toxicity mechanism of complex 6, the effects on SKOV-3 
cell cycle phase distribution was examined. Again, SKOV-3 cells were used in this 
experiment as MelJuSo-UbG76V-YFP cells contained fluorescent proteins which would 
likely interfere with results. SKOV-3 cells were treated with complex 6 (20 µM) or 
0.1% DMSO for 48 hours. Cell cycle analysis was conducted using propidium iodide 
(PI) to stain DNA. Using flow cytometry, it was found that complex 6 induces a 
decrease (8.9%) in the G2/M phase and slight increase within the S (synthesis) phase 
(3.4%) when compared to DMSO (0.1%) treated cells {Figure 54 (A) & (B)}. This 
may suggest that treatment with complex 6 over 48 hours induces cell cycle arrest in 
SKOV-3 cells in S phase and prevents cells progressing to G2/M phase. 
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Figure 54: Effects of Complex 6 (20 µM) on SKOV-3 cell cycle after 48 hours 
treatment. A) SKOV-3 cells were treated with DMSO (0.1%) and Complex 6 (20 µM) 
for 48 hours and cell cycle analysis was performed using PI staining for DNA content. 
Flow cytometry was carried out on a Beckman Coulter Gallios flow cytometer and 
data was analysed using the FlowJo software (version 10). B) Bar graphs show relative 
percent of cells in each phase. The data shown represents two experiments with similar 
results.  
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D.3.7  The effect of [Mn(fol)(phen)(H2O)].4H2O on 3D spheroids 
 
Multicellular tumour spheroids were formed using SKOV-3 cells as described in 
section E.4.4. Cells were treated with 2 – 20 µM complex 6, [Mn(phen)2]2+, and 
Bortezomib (17.73 – 100 nM) for 72 hours and examined by time-lapse microscopy 
(Figure 54). The spheroid volume was also measured for each treatment and is shown 
in Figure 55.  
 
Treatment with complex 6 and [Mn(phen)2]
2+ (20 µM) did not result in disaggregation 
of spheroids nor change in spheroid volume when compared to the untreated cells 
(Figure 55 (A)). Bortezomib-treated spheroids (100 nM) appear to show an increased 
spheroid volume in comparison to spheroids treated with Complex 6 and 
[Mn(phen)2]
2+, however show no disaggregation over the duration of the experiment 
(Figure 55 & 56). These results suggest that manganese(II) complexes 6 and 
[Mn(phen)2]
2+ are ineffective against spheroids. However, it should be noted that as 
complex 6 and [Mn(phen)2]
2+ require 48 hours to induce an effect in 2D monolayer 
systems (Figures 45 and 46), it may be that a longer treatment time is required to see 
an effect against spheroids, although experiments were carried out for 72 hours. 
However, it is clear from our results that there are different mechanisms of action 
between copper(II) and manganese(II) complexes, with copper(II) complexes 
affecting 3D models and manganese(II) complexes having no effect after 72 hours. 
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Figure 55: Complex 6 and [Mn(phen)2]
2+ do not cause disaggregation of SKOV-3 
spheroids. (A) SKOV-3 cells treated with 20 µM complex 6 and [Mn(phen)2]
2+ 
examined by time-lapse microscopy. DMSO (0.1%) and Bortezomib (100 nM) were 
used as controls. B) SKOV-3 cells treated with 20 µM of Complex 6 and 
[Mn(phen)2]
2+ for 72 hours. DMSO (0.1%) and Bortezomib (100 nM) were used as 
controls. Images taken using an inverted microscope (X40 total magnification).  
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Figure 56: Complex 6 and [Mn(phen)2]
2+ treatment do not result in disaggregation of 
SKOV-3 spheroids. (A) SKOV-3 cells treated with 20 µM complex 6 and 
[Mn(phen)2]
2+ examined by time-lapse microscopy. DMSO treated cells (0.1%) were 
used as a negative control and Bortezomib (100 nM) as a positive control. Spheroid 
volume was calculated for each treatment. Data represent one of three independent 
experiments with similar results.  
 
D.3.8  Conclusion 
 
This study suggests that complex 2, [Mn(fol)(H2O)3].3H2O, is inactive in the range 3 
– 100 µM, whereas the 1,10-phenanthroline derivative, [Mn(fol)(phen)(H2O)].4H2O 
(6), showed in vitro activity at ≤ 8 µM within 48 hours against both FR-overexpressing 
SKOV-3 cells and FR-underexpressing A549 cells. Folate saturation studies suggest 
that complex 6 enters the cell through a mechanism other than by direct uptake through 
the folate receptor. 
 
Treatment with complex 6 and [Mn(phen)2]
2+ was found to affect expression of 
proteins involved in autophagy and mitochondrial damage (p62 and HSP60), while 
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also inducing ROS generation, supporting the hypothesis of ROS induced autophagy. 
Increased granularity observed in treated cells may indicate formation of 
autophagosomes, formed during autophagy, while chromatin condensation may 
suggest an additional apoptotic component in the observed cell death. However, a 
marker of autophagy is required to confirm the presence of autophagosomes. 
  
The inability of complex 6 to depolarise the mitochondrial membrane of treated cells 
may suggest that complex 6 does not activate apoptosis as the primary mode of cell 
death. Consequently, it is postulated that the manganese(II) complex 6 induces ROS 
generation and potential mitochondrial damage, resulting in a sequential cell death that 
involves autophagic and possibly apoptotic pathways. However, the exact sequence 
and details of this mechanism remain unclear and warrant further experimental 
investigation. Complex 6 was found to be ineffective against 3D tumour spheroids at 
20 µM. 
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D.4  Conjugates of folic acid with imidazole-phenanthroline derivatives 
 
As well as its ability to act as a ligand in its own right, folic acid can also be conjugated 
to small or large biologically active metal complexes through either direct folate 
coupling or folate coupling via a spacer to create potentially FR-selective cytotoxic 
compounds (Tables 2 and 3). Although not always required, the inclusion of a spacer 
allows for effective unhindered binding of the folate moiety to the FR and control over 
the lipophilicity of the folate conjugate, which are requirements for cellular 
internalization of the entire molecule through endocytosis (Figure 4). It should be 
noted that the synthesis, purification and characterisation of metal complex-folate 
conjugates are quite often difficult, presenting problems in relation to biomedical 
applications. This section describes the attempts to synthesise folate-phen conjugates, 
using a range of potential spacer moieties, as potential alternative ligands to the 1,10-
phenathroline. 
     
D.4.1  The “first generation” targeted folate-imidazole-phenanthroline 
ligand and its copper(II) and manganese(II) complexes 
 
The two novel metal-folate complexes [Cu(FIMP-1)2](ClO4)2.2H2O (9) and 
[Mn(FIMP-1)3](ClO4)2.2H2O (10) (FIMP-1 = the ‘first generation’ folate-imidazole-
phenanthroline) were synthesised using the method developed previously by this 
group (P. Mc Carron, M. McCann and M. Devereux, unpublished results) (Figure 57). 
The FIMP-1 ligand consists of an imidazole-phenanthroline moiety conjugated 
directly to folic acid via amide linkage while the metal centre {copper(II) or 
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manganese(II)} is coordinated through the chelating phenanthroline moiety (Figure 
56).  
 
 
Figure 57: Structures of [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO-
4)2.2H2O (10) 
 
Preliminary biological studies were performed on the ‘first generation’ FIMP-1 ligand, 
[Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO4)2.2H2O (10), using the FR-
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overexpressing cell line, SKOV-3, and the FR-underexpressing cell line, A549, to 
explore their FR selective capabilities. 
 
Folic acid and 1,10-phenathroline are the key components of the ‘first generation’ 
FIMP-1 ligand and exert their own autonomous cell activity. Folic acid is an essential 
component in cell culture media due to its role in cell development and in the 
conversion of homocysteine to methionine251 and is therefore not expected to have a 
cytotoxic effect on cell lines SKOV-3 and A549. Figure 58 shows that treatment with 
folic acid did not significantly affect cell viability; however, some effects could be 
seen at higher concentrations (100 μM). 
 
The FIMP-1 ligand contains a 1,10-phenanthroline moiety which is also capable of 
coordinating metal ions within cell culture medium. Furthermore, the ligand may also 
compete with folic acid for FR binding, in turn preventing the necessary uptake of folic 
acid into cells. These actions may account for the cytotoxicity observed in SKOV-3 
cells when treated with 50 and 100 μM of the metal-free FIMP ligand, resulting in a 
reduction of cell viability by approximately 50% which again appeared to be non-
concentration dependent. However, it was found that the FIMP-1 ligand also exerted 
a significant effect on the viability of A549, particularly at the higher concentration of 
100 μM.  
 
In contrast, cells treated with 1,10-phenanthroline showed ~50% viability (SKOV-3) 
with A549 cells retaining only 20% viability. Furthermore, it was evident that the 
cytotoxic effects exerted by 1,10-phenanthroline were concentration independent. It is 
believed that 1,10-phenanthroline is capable of chelating metal ions within cell culture 
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media (e.g. Cu2+ ions) to generate biologically active species known to be capable of 
inducing such cellular damage203,252. 
 
Figure 58: Cell viability following treatment with complexes 9 and 10. A549 (FR-
underexpressing) and SKOV-3 (FR-overexpressing) cells were grown to 80% 
confluency as described in Section E.9. Cells were treated for 48 hrs with 10, 50 and 
100 μM of complexes 9 and 10, FIMP-1 ligand, folic acid and 1,10-phenanthroline. 
Cell viability was measured using the Alamar Blue assay. The experiment was 
repeated three times and the data shown are Mean ± SD. 
 
A similar result was observed when cells were treated with [Cu(FIMP-
1)2](ClO4)2.2H2O (9), which caused a greater reduction in the cell population of FR-
underexpressing A549 than FR-overexpressing SKOV-3. It may be postulated that the 
‘first generation’ FIMP-1 ligand and [Cu(FIMP-1)2](ClO4)2.2H2O (9) can exert a 
cytotoxic response through a mechanism other than endocytosis via the FR. However, 
further investigation is required. 
 
141 
 
Although the activity for [Mn(FIMP-1)3](ClO4)2.2H2O (10) is very similar at 10 µM 
concentration in both the FR-overexpressing and FR-underexpressing cell lines 
(approximately 50% - equivalent to the EC50 value), significant differences were 
observed when the concentration was increased to 50 and 100 μM (with reductions in 
viability from 23% to 14% observed in FR-overexpressing cells and from 49% to 45% 
in FR-underexpressing cells, respectively). The effects observed in the FR+ve SKOV-
3 cells may be concentration dependent, unlike the effect observed in A549 cells 
treated with [Mn(FIMP-1)3](ClO4)2.2H2O (10) which reduced all viability to ~50%, 
regardless of concentration. Although preliminary results suggest that the Mn(II) 
complex [Mn(FIMP-1)3](ClO4)2.2H2O (10) effect may be mediated via the FR, work 
is required to further elucidate both the cytotoxicity and cytoselectivity of this 
complex.  
 
The solubilities of [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-1)3](ClO4)2.2H2O 
(10) were a particular issue in their biological assessments but the results obtained 
were encouraging and prompted the pursuit of more appropriate complexes 
incorporating ligands similar to this “first generation” FIMP-1 molecule.  
 
D.4.2  The synthesis of novel “second generation” functionalised folate- 
imidazole-phenanthroline (FIMP) ligands 
 
Building on the observed preliminary results for the “first generation” FIMP-1 ligand 
and its copper(II) and manganese(II) complexes, the synthesis of a series of three novel 
“second generation” FIMP ligands was undertaken. All three novel second generation 
FIMP-2 ligands differ from the ‘first generation’ analogue in that they contain a linker 
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intended to increase the distance between the targeted folate group and the metal-
binding IMP moiety in the molecules (Figure 59). To achieve this, three different types 
of linkers were chosen: (1) the first contains an ethylenediamine linker intended to 
simply reduce steric hindrance; (2) the second contains an ethereal oxygen chain to 
improve water solubility; and (3) the third possesses a disulphide bond which can be 
cleaved within the cell to release the cytotoxic cargo. A brief summary of the synthetic 
steps required are listed in Table 9 and a proposed synthetic route to the ‘second 
generation’ FIMP-2 ligands is shown in Scheme 5.  
 
 
Figure 59: The structures of the ‘first generation’ FIMP-1 ligand and the proposed 
‘second generation’ FIMP-2 ligands (functionalised linkers highlighted in red). (A) 
ethylenediamine linker (B) ethereal oxygen linker (C) disulphide bond. 
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Table 9: A summary of the synthetic steps undertaken for the attempted synthesis of 
the novel ‘second generation’ functionalised folate-imidazole-phenanthroline (FIMP-
2) ligands.  
Step Synthetic Steps 
Step 1 Synthesis of 1,10-phenanthroline-5,6-dione. 
Step 2 
Synthesis of four imidazo-phenanthroline ligands 
(IMPs). 
Step 3 
N-Boc protection of three diamine functional 
linkers. 
Step 4a Conjugation of N-boc-diamine linkers to folic acid. 
Step 4b 
Conjugation of N-boc-diamine linkers to IMP-
COOH. 
Step 5 Deprotection of N-boc-ethylenediamine-IMP 
Step 6 Conjugation of folic acid and ethylenediamine-IMP 
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Scheme 5: A simplified schematic of the proposed synthesis of the novel functionalised FIMP-2 ligand A (based on similar synthetic 
procedures from the literature). The synthesis of FIMP-2 ligands B and C were attempted using a similar approach.
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D.4.3  Synthesis of 1,10-phenanthroline-5,6-dione {Step 1} 
 
Until recently, 1,10-phenanthroline-5,6-dione (phendione) was synthesised under 
severe conditions, involving reflux of 1,10-phenanthroline with an excess of potassium 
bromide in a mixture of concentrated sulfuric acid and nitric acid307. Although initial 
yields were promising (86%), attempts to scale up resulted in a sharp decrease in 
product yield308,309. 
 
 In 2010, Zheng et al reported the novel synthetic method which involved the room 
temperature reaction of 1,10-phenanthroline and potassium bromate in a 60% sulfuric 
acid solution on a 20 gram scale310. Phendione was recovered in high yield (90%) and 
pure form. As phendione is essentially used as a starting material in the synthesis of 
the FIMP-1 and FIMP-2 ligands, the ability to work on a large scale, and obtain a high 
yielding, high purity product was imperative. Consequently, using the synthetic 
method described by Zheng et al, phendione (11) was obtained as yellow crystalline 
needles in high yield (83%) and pure form. The synthetic route to phendione (11) is 
presented in Scheme 6. 
 
 
Scheme 6: The synthetic route to 1,10-phenanthroline-5,6-dione (11) 
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Phendione (11) was characterised using IR and NMR spectroscopy. The 1HNMR 
spectrum of 11 (Appendix 8) shows three distinct doublets of doublets (dd) peaks in 
the aromatic region at 7.57, 8.48 and 9.10 ppm respectively. These three peaks 
correspond to the six protons present on the symmetrical molecule (Figure 60). The 
peaks representing H1 are located furthest downfield as H1 is deshielded by the 
neighbouring nitrogen atoms. The peaks corresponding to H2 are furthest upfield at 
7.57 ppm due to the shielding effects of H1 and H3. Finally, the peaks corresponding 
to H3 are positioned at 8.48 ppm. The IR spectrum of 11 (Appendix 8) contains 
characteristic peaks at 817 cm-1 and 740 cm-1 due to C-H bending.  
 
Figure 60: 1,10-phenanthroline-5,6-dione (11) illustrating numbering scheme for 1H-
NMR analysis.  
 
D.4.4  Synthesis of imidazo-phenanthrolines (IMP) {Step 2} 
 
A key step in the synthesis of the first and second generation FIMP ligands is the 
synthesis of the imidazo-phenanthroline precursors IMP-NO2 (12) and IMP-COOH 
(13), respectively (Figure 61). 
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Figure 61: Structures of IMP ligands (12 - 15) 
 
The reported synthesis of 12 and 13 is dependent on the acid catalysed reaction of 
1,10-phenanthroline-5,6-dione (11) with excess ammonium acetate to provide a stable 
1,10-phenanthroline-5,6-di-imine intermediate. This subsequently reacts with the 
desired aldehyde to undergo an aldol-type condensation reaction, forming a second, 
unstable intermediate. Finally, a two hydrogen shift resulting in the loss of a water 
molecule causes the formation of the final imidazo-phenanthroline conjugate311 
(Scheme 7). This method requires extended reflux times and leads to low-to-moderate 
yields311,312.  
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Scheme 7: The mechanism illustrating the formation of the imidazole-phenanthroline 
ligand (modified from Steck et al)311 
 
To improve the overall outcome for the synthesis of this class of IMP compound it was 
decided to explore the use of microwave technology. To test the suitability of this 
novel approach, imidazole-phenanthroline-phenyl {IMP-phenyl (14)} was first 
synthesised as shown in Scheme 8. This reaction was very successful, indicated by a 
product in high yield (87%) and with excellent purity. The method was subsequently 
applied to the syntheses of the IMP-NO2 (12) and IMP-COOH (13), which are required 
for the synthesis/attempted synthesis of the first and second generation FIMP ligands. 
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The microwave synthetic method deployed is novel, resulting in an accelerated 
reaction time, reducing the previously reported 3 hour reflux311,312 to a fifteen minute 
reaction. Furthermore, the products were obtained with minimal work up in very high 
yield and excellent purity. This improvement is attributed to the “superheating” which 
can occur at ambient pressure through the high efficiency conversion of microwave 
radiation to heat. 
 
Scheme 8: Synthetic route to IMP ligands 12 - 14. (R = H, COOH, NO2) 
 
IMP-COOH (13) is required for the attempted synthesis of the three novel “second 
generation” functionalised FIMP ligands, in which the COOH group is used to form 
an amide bond with an unprotected NH2 group of a diamine linker. The IMP-NO2 (12) 
is the precursor of IMP-NH2 (15) (Figure 61) which is required to produce the “first 
generation” FIMP-1 ligand via amide bond formation between the amine functionality 
of 15 and the COOH group of folic acid. The conversion of IMP-NO2 (12) into IMP-
NH2 (15) is via a hydrogenation reaction, involving a 10% palladium/carbon catalyst 
and hydrazine monohydrate as the hydrogen source. The synthetic route is shown in 
Scheme 9.  
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Scheme 9: Synthetic route for IMP-NH2 (15). 
 
Table 10 presents the full 1H NMR data for compounds 12 - 15. The R-groups (Figure 
62) differ in their electron donating and electron withdrawing properties. As a result, 
the protons that show the most significant change in chemical shift are located on the 
phenyl ring. Both the NO2 and COOH groups are electron withdrawing and draw 
electron density away from nearby protons; in turn, deshielding protons on the phenyl 
ring result in a downfield chemical shift. The electron donating NH2 group of 15 has 
lone pairs adjacent to the phenyl ring which increase the electron density on the ring, 
leading to an upfield shift of the phenyl protons. In all 1HNMR spectra, the chemical 
shifts of protons on the nitrogen atom present on the imidazole ring were not observed. 
This may be because the protons are highly active and readily exchangeable between 
the two nitrogens of the imidazole ring in solution313,314. 
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Figure 62: IMP-R ligand illustrating numbering scheme for 1H-NMR analysis. 
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Table 10: 1HNMR resonances for IMP-R ligands with various functional groups carried out in DMSO-d6. The integration and peak 
splitting are shown in brackets.  
Proton 
12 
(ppm) 
Proton 
13 
(ppm) 
Proton 
14 
(ppm) 
Proton 
15 
(ppm) 
H1 & H11 9.00 (d, 2H) H1 & H11 8.91 (d, 2H) H1 & H11 9.00 (d, 2H) H1 & H11 8.99 (d, 2H) 
H3 & H9 8.81 (d, 2H) H3 & H9 8.90 (d, 2H) H3 & H9 8.89 (d, 2H) H3 & H9 8.89 (d, 2H) 
H5 & H6 
H7 & H8 
8.40 (m, 4H) H6 & H7 8.42 (d, 2H) H2 & H10 8.27 (d, 2H) H5 & H8 7.98 (d, 2H) 
H2 & H10 7.79 (d, 2H) 
H5 & H8 8.33 (d, 2H) H5 & H8 7.79 (d, 2H) H2 & H10 7.82 (d, 2H) 
H2 & H10 7.76 (dd, 2H) 
H6 & H7 7.59 (d, 2H) H6 & H7 6.74 (d, 2H) 
H9 7.50 (t, 1H) NH2 5.63 (s, 2H) 
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D.4.5  The N-Boc protection of diamine linkers {Step 3}  
 
Di-tert-butyl dicarbonate (Boc) is a commonly used protecting group used in organic 
synthesis315,316. The general route for N-Boc protection of diamines is shown in 
Scheme 10. The diamines ethylenediamine and 2,2′-(ethylenedioxy)bis(ethylamine) 
were N-Boc-protected in a similar fashion, following methods previously published to 
produce 16 and 17, respectively (Figure 63). A ten-fold excess of the diamine was 
reacted against Boc to reduce di-Boc product formation. Reactions were clean and 
high-yielding (> 88%), producing a stable colourless oil. The N-Boc protection of 
cystamine (18) (Figure 63) proved slightly less advantageous, producing a product in 
moderate yield (approx. 40%). Published data are quite similar, with yields of 43-45% 
obtained317–319.  
 
This particular synthetic step proved to be a key limiting factor in the overall synthesis 
of FIMP-2 ligands. The excess of diamine required proved problematic (particularly 
in the case of compounds 17 and 18) and attempts to reduce the ratio of Boc:diamine 
resulted in the increased formation of the undesirable di-Boc protected products and a 
decrease in N-boc-protected diamines. Furthermore, attempts to scale-up reactions 
resulted in reduced product yields. These limitations resulted in a knock-on effect 
throughout the synthesis of FIMP-2 ligands, particularly those incorporating the 2,2′-
(ethylenedioxy)bis(ethylamine) and the cystamine as linkers. 
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Figure 63: N-Boc protected diamines 16 - 18. 
 
 
Scheme 10: The N-Boc protection of diamines where R = (CH2)2NH2, 
(CH2)2O(CH2)2O(CH2)2NH2 and (CH2)2SS(CH2)2NH2
320 
 
N-Boc diamines 16 - 18 were characterised primarily by NMR (1HNMR and 13CNMR) 
and mass spectrometry. In 1HNMR spectra, the shielded Boc group, consisting of three 
methyl branches, is the furthest upfield in all spectra, appearing from 1.08 – 1.47 ppm 
respectively (Table 11). In the spectrum of 17, the singlet peak representing the 
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unprotected NH2 appears to merge with that of the Boc group, increasing integration 
from nine to eleven. In 1HNMR spectra of 16 and 18 (Appendices 12 and 14), the NH2 
peak can be observed as a singlet at 1.22 ppm and 1.49 ppm. In all N-Boc protected 
diamines, the NH group is observed as a singlet between 5.39 and 5.84 ppm, 
respectively. The remaining peaks are associated with the aliphatic CH2 groups. 
Similar results have been published elsewhere316,318,321. 
 
Table 11: 1HNMR resonances for N-Boc protected diamines 16 - 18. The integration 
and peak splitting are shown in brackets.  
Compound 
Chemical Shifts (ppm) 
Boc group NH NH2 CH2 groups 
16 1.36 (s, 9H) 5.84 (s, 1H) 1.22 (s, 2H) 
3.07 (d, 2H)  
2.70 (d, 2H) 
 
17 1.19 (s, 11H)*  5.39 (s, 1H)  
*Peak hidden 
under Boc peak 
at 1.19 ppm 
3.37 (s, 4H) 
3.27 (dd, 4H) 
3.04 (d, 2H) 
 2.61 (t, 2H) 
18 1.44 (s, 9H) 5.57 (s, 1H) 1.49 (s, 2H) 
3.43 (d, 2H) 
3.00 (t, 2H)  
2.78 (dd, 4H) 
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D.4.6  Conjugation of N-Boc-diamine linkers with folic acid {Step 4 (a)} 
 
The conjugation of N-Boc protected diamine(s) 16 - 18 with folic acid was undertaken 
with a view to generating compounds 19 - 21 (Figure 64). The method described by 
Trindade et al is the basis for the folate-amine conjugation used in this project (Scheme 
11)322. This involves the generation of an activated-folate ester via N-
hydroxysuccinimide (NHS) and the coupling agent, N,N’-dicyclohexylcarbodiimide 
(DCC). The newly formed activated ester cleanly reacts with amines under mild 
conditions allowing for simple amide formation. The by-product of the DCC mediated 
coupling, dicyclohexylurea (DCU) is highly insoluble in all organic solvents, allowing 
for easy removal via filtration. 
 
In the same paper, Trindade et al reported that only γ conjugates have medicinal 
relevance due to their higher affinity towards the FR322. Within the FR structure, the 
glutamate residue is stabilized by six hydrogen bonds, four of which interact with the 
α carboxylic acid. Therefore, it is apparent that only γ folate conjugates may retain the 
fully effective affinity toward the receptor,322 although this is a controversial subject 
in the literature. Previous publications have proven that γ conjugates are inherently 
obtained as the major product (from 55 to 90% selectivity)62,172,322–325 using 
carbodiimide chemistry. Furthermore, the markedly different pKa values of the 
carboxylate groups contribute to their different reactivities25,326. 
 
 157 
 
 
Figure 64: The proposed structures of N-Boc amine-folate conjugates 19 – 21  
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Scheme 11: The conjugation of N-Boc protected diamine(s) to folic acid322. 
 
The primary methods used to elucidate the structures of folate conjugates 19 - 21 
(Figure 65) were mass spectrometry and NMR spectroscopy (1HNMR and 13CNMR). 
However, characterisation did prove difficult due to the poor solubility of compounds 
(hot DMF and hot DMSO only); and the presence of broad solvent peaks in the NMR 
spectra. 
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In order to determine if conjugation was successful, 1HNMR spectra were analysed to 
identify peaks associated with folic acid as well as the characteristic peak associated 
with the Boc protection group. In all spectra (Appendices 15 - 17), peaks related to 
methylene groups of the diamine linkers were observed but could not be adequately 
integrated due to distortion by the broad solvent peaks at 2.50 and 3.30 ppm327. Peaks 
corresponding to aromatic CH groups (Figure 65: H1, H4, and H5) and NH groups 
appeared within the region of 6 – 9 ppm. The peaks corresponding to the hydrogen 
bound to a carbonyl carbon (H7; Figure 65) was typically observed at 4.35 ppm, while 
its neighbouring peak at 4.50 ppm was identified as a CH2 (H2). Two aliphatic 
methylene groups (H8 and H9; Figure 65) appeared as three peaks between 1.90 – 2.30 
ppm respectively. The peak which corresponds to H8 appears to be split into two, due 
to the neighbouring hydrogen bound to the carbonyl carbon. Finally, the large peak at 
approximately 1.35 ppm relates to the Boc protection group (H12).  
 
 
Figure 65: N-Boc-amine-folate conjugate illustrating numbering scheme for 1H-NMR 
analysis. 
 
Mass spectra were also recorded for compounds 19 - 21 in addition to NMR 
spectroscopy (Table 12). Results for both 19 and 20 were as expected and complement 
structural data determined through NMR analysis. However, the data derived through 
mass spectrometric analysis of compound 21 do not support the structure assumed on 
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the basis of the NMR analysis, instead pointing towards a molecule in which two N-
Boc cystamine linkers were conjugated to folic acid (Figure 66). In 2011, Omran et al 
published a paper detailing the synthesis of a folate-prodrug of cystamine in which the 
final product contained two cystamine chains bound to both the α and γ carboxylate 
groups of folic acid. The 1HNMR results published by the group are similar to those 
obtained in this project, however, no mass spectrometric data were presented in their 
paper328. Further investigation is required to understand how and why the α 
carboxylate group is involved in this reaction. This problem coupled with the relatively 
poor solubility of compounds 19 and 20 (leading to difficulties in their 
characterisation) presented as significant problems for this approach to synthesising 
the FIMP-2-type ligands and it was decided to approach the challenge from a different 
direction. 
 
Table 12: Mass spectrometry results of folate-amine conjugates 19 - 21 
Folate-Amine Conjugate [M+H]+ Calc [M+H]+ Found 
19 584.2576 584.2601 
20 672.3100 672.3098 
21 676.2336 910.3257 
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Figure 66: The possible structure of 21 reported by Omran et al328 and supported by 
mass spectrometric data from the current study. 
 
D.4.7  Conjugation of N-Boc-diamines linkers with IMP-COOH {Step 4 
(b)} 
 
Given the problematic solubility of the folate-amine conjugates 19 and 20 and the 
potential amide formation at both α and γ carboxylate groups encountered with the 
synthesis of 21, it was decided to approach the generation of the FIMP-2 ligands 
differently. The N-Boc protected diamines were reacted with IMP-COOH to produce 
the alternative diamine-IMP conjugated compounds 22 - 24 (Figure 67). 
 
The synthetic path to compounds 22 - 24 is shown in Scheme 12. It has been reported 
that activated esters such as aromatic esters are usually easier to hydrolyse than alkyl 
esters and that they are prone to react with a wide range of nucleophiles due to the 
increased electrophilicity of the carbonyl centre. However, all attempts to activate 
IMP-COOH (13) via the DCC/NHS method described in Scheme 11 were 
unsuccessful. This may be due to the undesirable formation of the unreactive N-
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acylurea. To correct this issue, the fast reacting nucleophile, hydroxybenzotriazole 
(HOBt), was added (Scheme 12). HOBt reduced this side reaction by reacting faster 
than competing acyl transfers and generating an active intermediate capable of 
coupling with the amine329. The protocol was adjusted further by replacing the 
coupling agent DCC with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 
ensuring its addition was performed at 0 oC (Scheme 13). 
 
Using this method, the N-boc-ethylenediamine-IMP (22) was isolated in high yield, 
while both the N-boc-(ethylenedioxy)bis(ethylamine)-IMP (23) and the N-boc-
cystamine-IMP (24) were only recovered in low to moderate yield. Table 13 presents 
the resonances and shifts of 22 - 24 and the relevant proton numbering scheme is 
shown in Figure 68. The peaks showing the greatest downfield shift correspond to H1 
in all compounds, appearing at 9.04 – 9.02 ppm; this is due to the deshielding 
properties of the adjacent nitrogen atoms. H6 in all conjugates are neighbours to a 
carbonyl carbon which again has a deshielding effect, forcing the peaks corresponding 
to H6 downfield to 8.92 ppm respectively. H7 and H8 represent NH groups; H8 is bound 
to an ester functional group and is forced further downfield because of this. H7 exhibits 
a similar effect although to a lesser extent. H2 as well as H5 exhibit little or no 
deshielding and sit in the aromatic region of 7.80 – 8.08 ppm. H9 are situated on the 
Boc protection group and appear in spectra as a singlet at 1.35 to 1.39 ppm. Methylene 
groups along the alkyl chains of the diamine linkers appear within the region of 2.80 
– 3.40 ppm, although the methylene groups of compound 23 experience greater 
deshielding due to the ethereal oxygens present in the chain. Mass spectrometric 
results are in agreement with structures elucidated through the NMR analysis. 
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Figure 67: Structure of the N-Boc protected diamine-IMP conjugates 22 – 24. 
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Scheme 12: Synthetic route to the N-Boc protected diamine-IMP conjugates 22 – 24.  
 
 
 165 
 
 
Scheme 13: Use of HOBt to minimise the formation of unreactive N-acylurea329. 
 
 
Figure 68: N-Boc diamine-IMP conjugate illustrating numbering scheme for 1H-NMR 
analysis. 
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Table 13: 1HNMR resonances for compounds 22 - 24, carried out in DMSO-d6. The 
integration and peak splitting are shown in brackets. 
Proton 22 (ppm) Proton 23 (ppm) Proton 24 (ppm) 
H1  9.04 (dd,2H) H1 9.02 (d, 2H) H1 9.02 (d, 2H) 
H6  
8.92 (dd, 
2H) 
H6 8.91 (d, 2H) H6 8.92 (d, 2H) 
H8 8.60 (s, 1H) H8 8.81 (s, 1H) H8 8.67 (s, 1H) 
H3  8.34 (d, 2H) H3 8.35 (d, 2H) H3 8.35 (d, 2H) 
H5 8.05 (d, 2H) H5 8.07 (d, 2H) H5 8.08 (d, 2H) 
H2 
7.83 (dd, 
2H) 
H2 
7.87 – 7.78 
(m, 2H) 
H2 7.83 (d, 2H) 
H7 6.97 (s, 1H) H7 6.99 (s, 1H) H7 6.74 (s, 1H) 
H4 4.11 (s, 1H) H4 - H4 - 
Methylene 
groups 
 
3.16 (d, 4H) 
Methylene 
groups 
 
3.61 (dd,2H) 
3.24 (dd, 2H) 
2.96 (t, 2H) 
2.80 (t, 2H) 
 
Methylene 
groups 
 
3.40 – 3.27 
(m, 10H) 
3.07 (d, 2H) 
H9 1.39 (s, 9H) H9 1.37 (s, 9H) H9 1.35 (s, 9H) 
 
D.4.8  Deprotection of N-Boc ethylenediamine-IMP {Stage 5} 
 
As previously mentioned in section D.4.5, the problem of low yield when undertaking 
the N-Boc protection of the diamines 2,2′-(ethylenedioxy)bis(ethylamine) and 
cystamine to form compounds 17 and 18 proved to be a key limiting factor in achieving 
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the synthesis of their corresponding FIMP-2 ligands. Furthermore, subsequent 
difficulties experienced when attempting to conjugate 17 and 18 with folic acid further 
compromised progression towards the end-state FIMP-2 compounds (see section 
D.4.6) and unfortunately consumed scarce supplies of both of these N-Boc protected 
compounds. The limited quantities of 17 and 18 that remained could only be used to 
synthesise enough of the novel N-Boc-(ethylenedioxy)bis(ethylamine)-IMP (23) and 
the novel N-Boc-cystamine-IMP (24) compounds for their characterisation. The 
synthesis of N-Boc-ethylenediamine (16), on the other hand, was much more 
successful enabling access to the N-Boc-ethylenediamine-IMP (22) in high enough 
yield to facilitate its deprotection and subsequently conjugation with folic acid to yield 
the final ‘second generation’ folate-ethylenediamine-IMP (FIMP-et) ligand. 
 
N-Boc-ethylenediamine-IMP (22) was deprotected to yield the relatively soluble 
compound 25 (Figure 69). This involved the deprotonation of the Boc group with 
trifluoroacetic acid (TFA), resulting in the loss of the tert-butyl cation (this will either 
be deprotonated to form isobutylene gas, or it will polymerize to form isobutylene 
oligomers). The remaining carbamic acid is quickly decarboxylated to produce a free 
amine. In the presence of excess TFA, the product may be present as a TFA salt which 
can be neutralised with a base such as triethylamine to give the free amine as a stable 
product (Scheme 14)320. 
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Figure 69: The structure of N-Boc Ethylenediamine-IMP (25) 
 
 
Scheme 14: The Boc deprotection of an amine 
 
Analysis of the 1HNMR spectrum of 25 (Appendix 22) indicates the successful 
removal of the N-Boc protection group which is typically observed as a singlet at 1.35 
ppm. Peaks in the aromatic region of 7 – 9 ppm represent CH groups present in the 
phenanthroline and benzene ring of the compound. A singlet at 8.25 represents the NH 
group involved in the amide bond between IMP-COOH and ethylenediamine. As 
discussed previously, a peak representing the imidazole proton is not observed due to 
its tendency to readily exchange between the two nitrogens of the imidazole ring in 
solution313. Peaks which represent the methylene groups of ethylenediamine can be 
observed at 3.22 and 3.60 ppm. Mass spectrometric data confirms the proposed 
structure of 25 depicted in Figure 69. 
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D.4.9 Conjugation of ethylenediamine-IMP with folic acid {Stage 6} 
 
The final step of this FIMP-2 ligand synthesis involved the conjugation of 
ethylenediamine-IMP (25) with folic acid to attempt the generation of the novel γ-
conjugate of the FIMP-ethylenediamine ligand (26) (FIMP-et; Figure 70). The 
conjugation was undertaken using the method described by Trindade et al (Scheme 
15) and involves the generation of an activated-folate ester via N-hydroxysuccinimide 
(NHS) and the coupling agent, N,N’-dicyclohexylcarbodiimide (DCC) as described in 
Section D.4.6322. Compound 26 was obtained as a yellow powder in good yield (> 
70%) and it was soluble only in warm DMSO and warm DMF. 
 
 
Scheme 15: The amide conjugation of imidazole-phenanthroline-ethylenediamine and  
acid322. 
 
The conjugation of ethylenediamine-IMP (25) with folic acid to generate the novel 
FIMP-ethylenediamine ligand (26) has the potential to yield three possible isomers 
(Figure 70). The current literature suggests that γ conjugates (Figure 70) are inherently 
obtained as the major product (from 55 to 90% selectivity) of folate-based 
carbodiimide conjugations, based on results obtained from reverse phase high pressure 
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liquid chromatography (RP-HPLC)62,172,322–325. Furthermore, Trindade et al reported 
that folic acid was conjugated with N‐Boc-ethylenediamine almost exclusively at the 
terminal γ carboxylic acid as confirmed by RP‐HPLC (95% selectivity)322. Similar 
results have been reported elsewhere330,331. It has also been suggested that this may be 
due to hydrogen bonding of the α-carboxylic group to the neighbouring amide group, 
resulting in limited access to bulky conjugates to the α-position332.  
 
To throw light on the isomeric from of compound 26 it was analysed using infrared 
spectroscopy, mass spectrometry, NMR spectroscopy (1HNMR and 13CNMR) and 
reverse phase high pressure liquid chromatography (RP-HPLC).  
 
Figure 70: Possible isomeric structures of FIMP-et (26) 
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The relevant proton numbering scheme of compound 26 is shown in Figure 71 and the 
1H NMR spectrum is shown in Figure 72. Due to poor solubility, NMR spectra were 
obtained using 24000 scans. Additionally, a water-suppression protocol was 
implemented to remove the broad water peak at 3.33 ppm associated with d6-DMSO 
which can be seen in Appendix 24.  
 
 The 1HNMR (Figure 72 and Appendix 24) and 13CNMR (Appendix 24) spectra of 26 
were analysed to identify peaks associated with folic acid as well as the characteristic 
peaks associated with the imidazole phenanthroline moiety. Peaks corresponding to 
the aromatic CH groups of folic acid were observed at 6.66 and 7.70 ppm (H6 & H7; 
para-aminobenzoic acid; Figure 70) and 8.67 ppm (H3) while peaks related to the 
amide NH groups in folic acid (H5
 & H8) were observed at 6.89 and 8.34 ppm. Peaks 
corresponding to H4 and H9 were found at 4.36 – 4.56 ppm. The peaks which 
correspond to the aromatic CH groups of imidazole-phenanthroline were observed at 
7.83, 8.34, 8.92, and 9.03 (H17, H19, H18, H16 and H20; benzoic acid and 
phenanthroline). Additionally, peaks relating to methylene groups of glutamic acid and 
ethylenediamine were found in the aliphatic region of 1.90 – 2.95 ppm. The presence 
of the methylene groups was further supported by the 13C NMR DEPT 135 spectrum 
(Appendix 24). A small broad peak at 11.5 ppm indicated the presence of a free 
carboxyl OH group. Additional spectral evidence of successful conjugation was found 
in the IR spectrum of 26 where prominent peaks corresponding to C=O groups (1604 
and 1641 cm-1) of folic acid and C-H bending of phenanthroline (740 and 836 cm-1) 
were observed. 
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Figure 71: FIMP-et ligand 26 illustrating numbering scheme for 1H-NMR analysis. 
 
Figure 72: 1HNMR spectra of 26 
 
Mass spectrometric analysis was also performed on 26 in addition to NMR and IR 
spectroscopy. The mass spectrum of 26 (Appendix 23) contains a [M+H]+ peak at 
806.29 (expected m/z 806.28) in low abundance (10% approximately). A peak at 
776.27 m/z may be due to α-cleavage of the α-carboxyl group (m/z 776.31). It has 
previously been reported that folic acid fragments readily to release the glutamate tail, 
resulting in a peak at m/z 295 [M+H-Glu]+333. A similar trend is observed in the mass 
spectrum of 26 where a peak at 295.10 m/z is observed, which may correspond to 
[M+H– C27H26N7O2]. A subsequent peak at 416.10 m/z may correspond to this 
fragment with solvent adducts [M – C27H26N7O2 + DMSO + acetonitrile + H]+ (m/z 
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416.15). The remaining fragment (Glu-et-IMP) may correspond to the peak at m/z 
465.16 ([M+H–C14H12N7O2]; m/z 465.20). The peak with highest abundance (m/z 
585.71) may relate to [M – C14H12N7O2 + DMSO + acetonitrile + H]+ (m/z 585.71), 
indicating solvent adducts. 
 
In an attempt to establish the purity of 26, RP-HPLC was performed using a Waters 
2998 HPLC and Photodiode Array Detector using a Poroshell 120, EC-C8 column. A 
gradient solvent system of 95% TFA/water (solvent A) and 5% TFA/acetonitrile 
(solvent B) to 100% TFA/acetonitrile was used. However, various mobile phases were 
trialled but were found to be inappropriate due to elution capabilities and poor 
solubility of compound 26, these included: pet ether/ethyl acetate/acetone (82:18:1), 
water/acetonitrile (1:1), methanol/acetonitrile (1:1), ethanol:acetonitrile (1:1), 0.1% 
TFA in water and 0.1% TFA in acetonitrile). A similar gradient solvent system 
including TFA/H2O and TFA/ACN has been used successfully to separate folate-
conjugates previously172,181. An initial elution timeframe of 20 minutes was used 
without success, with only the DMSO solvent peak observed {elution time: 2 min; 2.6 
absorption units (AU)}. Upon extension of the runtime to 45 min, a very small peak 
with low absorbance could be seen (elution time 33 minutes; 0.5 AU) (Figure 73). It 
would appear that compound 26 is a highly non-polar molecule which may be 
adsorbed onto the C-18 column. However, it is noteworthy that no impurities such as 
unreacted folic acid were observed in the chromatogram. Furthermore, given the 
presence of a peak at 11.5 ppm in the 1H NMR spectrum of 26 which indicates the 
presence a free OH group (COOH functionality) and the relatively good C,H and N 
elemental analysis values (available in section E.3.8.), it is believed that the γ-
conjugate of the FIMP-et ligand has been obtained with good purity.  
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Figure 73: The chromatogram of compound 26 
 
D.4.10  Copper(II) and manganese(II) complexes incorporating the novel 
second generation FIMP-ethylenediamine ligand 
 
The FIMP-ethylenediamine ligand (FIMP-et) (26) reacted with Cu(ClO4)2.6H2O and 
Mn(ClO4)2.6H2O to yield complexes 27 and 28, respectively. The synthetic route to 
the FIMP-et complexes 27 and 28 is shown in Scheme 16. The complexes were 
obtained as green/brown (27) and yellow (28) powders, were soluble in DMSO and 
DMF, and they formulated on the basis of elemental analysis (Table 14) as [Cu(FIMP-
et)2(H2O)2].(ClO4)2.4.5H2O (27) [Mn(FIMP-et)3].(ClO4)2.9H2O (28), respectively.  
 
 
 
Scheme 16: The synthetic route for complexes 27 and 28  
 
The IR spectra for the FIMP-et ligand and complexes 27 – 28 are shown in and 
Appendix 25. Complexes 27 and 28 have very similar spectra which reflect similar 
structural characteristics for the two complexes. As well as the expected features 
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associated with the FIMP-et ligand the spectra of the two complexes both have strong 
broad peaks at 1084 – 1100 cm-1 characteristic of the presence of the perchlorate 
anions229. Both complexes exhibit similar UV-Vis spectra (Appendix 25), with 
absorbance bands from 254 – 258, 330 – 335, and 400 - 402 nm, respectively. In 
comparison to the UV-Vis spectrum of the free FIMP-et ligand (26) which contains a 
small shoulder at 272 nm, the UV-Vis spectra of complexes 27 and 28 contain much 
more pronounced peaks from 254 – 258 nm which may suggest coordination to the 
phenanthroline moiety of FIMP-et (Appendix 25). Structures that fit the physico-
chemical data for complexes 27 and 28 are shown in Figure 74 and they are believed 
to have structures similar to those of their FIMP-1 analogues (Figure 57). 
 
 Table 14: The formulation, yields and elemental analytical data for complexes 27 and 
28. 
Complex 
Mw 
(g/mol) 
Yield 
(%) 
Found (Calc) % 
C H N M 
[Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O 
(27) 
1991.2 75 
49.14 
(49.46) 
3.78 
(4.20) 
18.23 
(17.73) 
4.16 
(3.39) 
[Mn(FIMP-et)3].(ClO4)2.9H2O (28) 2833.8 77 
52.52 
(52.14) 
3.98 
(4.38) 
19.47 
(19.28) 
1.00 
(1.94) 
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Figure 74: The proposed structures of complex 27 and 28  
 
Attempts were also made to generate mixed-ligand complexes containing FIMP-et and 
1,10-phenanthroline (proposed structure shown in Figure 75). Following a method 
previously reported for similar mixed-ligand reactions copper(II) perchlorate, 
phenanthroline, and FIMP-et (ratio of 1:1:1) were reacted in one-pot334,335. This 
approach yielded only impure [Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O (27) as a 
precipitate along with [Cu(phen)2].(ClO4)2 which was isolated from the filtrate. A 
similar outcome was achieved for the manganese reaction.  
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Figure 75: The intended structure of the mixed FIMP-et/phen metal complexes. 
 
D.4.10  Conclusion 
To date, one of three novel “second generation” FIMP-2 ligands (Figure 63) has been 
successfully synthesised and characterised. For all ligands, stages 1 and 2 proceeded 
without difficulties. Stage 3 proved to be a limiting step in the overall synthesis, due 
to large ratios required and poor scalability, particularly regarding N-Boc-2,2′-
(ethylenedioxy)bis(ethylamine) (17) and N-Boc-cystamine (18). Issues regarding 
conjugation of N-Boc-diamines with folic acid, experienced in Stage 4(a), were 
overcome through the conjugation of the N-boc diamine linkers with IMP-COOH 
{Stage 4(b)}, thus allowing for the isolation of all three desired compounds and better 
solubility with easier characterisation. However, due to issues encountered in stage 3 
and 4(a), only small quantities of N-Boc-2,2′-(ethylenedioxy)bis(ethylamine)-IMP 
(23) and N-Boc-cystamine-IMP (24) could be synthesised and characterised but could 
not be further deprotected or conjugated to folic acid. Nonetheless, the N-Boc-
ethylenediamine-IMP product 22 was successfully deprotected to generate the 
corresponding ethylenediamine-IMP derivative 25 {Stage 5} and subsequently 
conjugated to folic acid using the DCC/NHS method to produce the novel “second 
generation” FIMP-et ligand 26 {Stage 6}. The reaction of the FIMP-et ligand (26) with 
copper(II) and manganese(II) perchlorate yielded the novel mononuclear complexes 
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[Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O (27) and [Mn(FIMP-et)3].(ClO4)2.9H2O (28) in 
good yield (> 75%). Attempts to generate mononuclear mixed phenanthroline complex 
{[M(FIMP)(phen)x] (M= Cu
2+ and Mn2+)} via a reaction between metal(II) 
perchlorate, 1,10-phenanthroline, and (26) (1:1:1) yielded only an impure metal-FIMP 
complex and [M2+(phen)X](ClO4)2. 
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CONCLUSION & FUTURE 
PERSPECTIVES 
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C.1 Conclusion 
 
This work focused on interdisciplinary research in chemistry and biology with a view 
to generating novel folate complexes with 1,10-phenanthroline ligation and novel 
folate-phenanthroline conjugates and to elucidate their targeting capabilities and 
mechanisms of action in-vitro. The synthesis work in this thesis, particularly in 
generating the FIMP-2 was complex and challenging. However, despite the difficulties 
encountered, the work resulted in the generation of one novel second generation FIMP-
2 ligand, two novel metal complexes with FIMP-2 ligation and eight novel simple 
metal-folate complexes. Subsequent biological testing could be performed on four of 
the simple metal folate complexes generated in this project, in addition to some basic 
cytotoxicity studies performed on first generation FIMP-1 complexes. 
 
All attempts to generate a series of simple binuclear metal folate complexes (where M 
= Cu2+, Mn2+, Fe3+, and Zn2+), using methods previously published, did not yield the 
expected products. Instead the di-sodium salt of folic acid reacted with the relevant 
metal chlorides to yield the novel mononuclear complexes [Cu(fol)(H2O)3].H2O (1), 
[Mn(fol)(H2O)3].3H2O (2), [Fe(fol)(H2O)2(Cl)].4H2O (3) and [Zn(fol)(H2O)3].3H2O 
(4). Complexes 1 – 4 (Figure 28) were characterised using IR, solid-state UV 
spectroscopy, thermogravimetric analysis, magnetic susceptibility measurements and 
elemental analysis. 13C NMR evidence in conjunction with the IR data, indicate that 
the folate ligand is present in the complexes in a tridentate ONO {α-COO-, γ-COO-, and 
Namide} binding mode.  
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Regardless of the amount of 1,10-phenanthroline employed (up to four equivalents) 
all reactions with complex 1 yielded only [Cu(fol)(phen)(H2O)].3H2O (5). All attempts 
to react 1,10-phenanthroline with complexes 2 – 4 were unsuccessful. Attempts to 
generate the binuclear metal complexes [{M(phen)2}2(folate)] (M = Cu
2+, Mn2+, Fe3+ 
and Zn2+) via a reaction between the chlorides of [Cu(phen)2]
2+, [Mn(phen)2]
2+, 
[Fe(phen)3]
3+, and [Zn(phen)]2+ and disodium folate yielded the novel mononuclear 
complexes [Cu(fol)(phen)(H2O)].3H2O (5), [Mn(fol)(phen)(H2O)].4H2O (6), 
[Fe(fol)(phen)(Cl)].5H2O (7), [Zn(fol)(phen)(H2O)].4H2O (8), in good to high yield. 
Complexes 5 – 8 were characterised using IR, solid-state UV spectroscopy, 
thermogravimetric analysis, magnetic susceptibility measurements and again all of the 
products formulate as having just one phen ligand present in their structure and it is 
believed that the folate is again acting as a tridentate ONO ligand.  
  
The successful synthesis of complexes 1 - 8 allowed the biological effects to be 
investigated in cellular models. The solubility of these complexes proved challenging 
and most were only partly soluble in hot DMSO. This highlights some of the 
challenges that face medicinal chemists in developing novel complexes with 
therapeutic potential and their suitability for in-vitro testing. A further challenge is 
identifying a suitable cellular model for these studies. There are conflicting results in 
the literature regarding folate receptor expression in cell lines and to overcome this 
challenge, we investigated folate receptor expression directly using western blot 
analysis. It was concluded that SKOV-3 (FR-overexpressing) and A549 (FR 
underexpressing) were suitable models for further work. Studies conducted using 
complexes 1, 2, 5 and 6 showed that [Cu(fol)(H2O)3].H2O (1) and 
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[Mn(fol)(H2O)3].3H2O (2) were not cytotoxic against either cell line up to 50 µM and 
these were not further investigated.  
The copper-phen complex [Cu(fol)(phen)(H2O)].3H2O (5) was found to be cytotoxic 
within 24 hours in both FR-overexpressing SKOV-3 and FR-underexpressing A549 
cells, with EC50 values of 3.13 µM (SKOV-3) and 3.79 µM (A549). Saturation studies 
with folic acid (100 µM) allowed us to conclude that the cytotoxic effect was not FR-
mediated, suggesting complex 5 enters cells via a different mechanism. Complex 5 
was an attractive complex for further investigation given its activity in the low 
micromolar range. Complex 5 (5 µM) induced proteasome inhibition within 18 hours 
in MelJuso-UbG76V-YFP cells, evident by live cell analysis and western blot analysis, 
with key proteins upregulated and an accumulation of ubiquinated proteins evident. It 
was concluded that the copper phenanthroline moiety may be responsible for the 
inhibitory effects on the proteasome as neither complex 1, the free phen ligand or 
[Mn(phen)2]
2+ induced the effect. Attempts to elucidate the precise region of complex 
5 interaction with the proteasome was unsuccessful and needs to be revisited.  
 
As mentioned previously, current proteasome inhibitors such as Bortezomib are 
ineffective against solid tumours. Given that copper phenanthroline complexes were 
effective proteasome inhibitors, their effects against 3D tumour spheroids were 
investigated. Our results identified that copper(II) phenanthroline complexes induced 
significant disaggregation of SKOV-3 spheroids at 10 µM within 72 hours. This is the 
first report on the effects of metal-based proteasome inhibitors against 3D tumour 
spheroids which show promising results and warrants further research. Taken together, 
these results suggest that complex 5 is a novel cell permeable proteasome inhibitor 
which is active against spheroids which holds promise for future investigations. 
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Interestingly, the manganese folate phen [Mn(fol)(phen)(H2O)].4H2O (6), although 
cytotoxic in SKOV-3 and A549 cells, was not a proteasome inhibitor. Again, the EC50 
values calculated for complex 6 in SKOV-3 and A549 cell lines were in the low 
micromolar range (4.92 µM (SKOV-3) and 7.63 µM (A549) at 48 hours, and 4.50 µM 
(SKOV-3) and 4.64 µM (A549) at 72 hours. A novel finding of this study was that 
complex 6 can inhibit/halt migration of MelJuso melanoma cells in-vitro. 
Morphological changes in treated MelJuso-UbG76V-YFP cells were apparent at 48 – 72 
hr (chromatin condensation, enlarged nuclei, and increased cell granularity), as 
confirmed by flow cytometry. Additional experimental evidence gained suggests that 
complex 6 induces cell death via ROS induced autophagy which is an exciting new 
possibility for metal complexes. 
 
Novel first generation FIMP-1 ligands were synthesized outside the scope of this 
project but formed the basis for the development of FIMP-2 ligands, which was a 
major part of the chemistry undertaken in this PhD. Basic cytotoxicity studies were 
undertaken on the FIMP-1 ligand, [Cu(FIMP-1)2](ClO4)2.2H2O (9) and [Mn(FIMP-
1)3](ClO4)2.2H2O (10). It was found that the free ligand induced a 50% reduction in 
SKOV-3 cell viability at 50 and 100 μM and exerted a significant effect on the viability 
of A549, particularly at the higher concentration of 100 μM. Cells treated with 
[Cu(FIMP-1)2](ClO4)2.2H2O (9) caused a greater reduction in the cell population of 
FR-ve A549 than FR+ve SKOV-3. [Mn(FIMP-1)3](ClO4)2.2H2O (10; 50 and 100 µM) 
induced a far greater cytotoxic effect against FR+ve SKOV-3 at 48 hr (with reductions 
in viability from 23% to 14%) in comparison to FR-ve A549 cells (49% to 45%, 
respectively). Further investigation is required into the role of the FR in these effects. 
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In order to overcome issues associated with solubility and potential steric hinderance 
encountered with complexes 1, 2, 5, 6, 9 and 10, the synthesis of novel second 
generation FIMP-2 ligands with functional linkers was attempted. The synthesis of 
FIMP-2 ligands was multistep, beginning with the large-scale synthesis of phendione 
(11) which was generated in high yields and high purity. Step two involved the novel 
microwave synthesis of imidazole-phenanthroline compounds 12 – 14, which again 
were generated in high yield and purity. IMP-NO2 (12) was further reacted to generate 
IMP-NH2 (15), which is required for the synthesis of the FIMP-1 ligand. Step three 
involved the N-Boc protection of diamine linkers ethylenediamine, 2,2'-
(ethylenedioxy)bis(ethylamine), and cystamine to yield compounds 16 – 18. This step 
proved limiting due to the excess of diamine required, and the inability to scale up the 
reaction. Step four (a) was the amide conjugation of compounds 16 – 18 to folic acid 
using DCC/NHS to yield compounds 19 – 21. N-Boc-ethylenediamine-folate (19) and 
N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-folate (20) were isolated in moderate 
yields, and were characterised using IR, 1H NMR, 13C NMR, elemental analysis and 
mass spectrometry. However, due to poor solubility and complexity of the molecules, 
NMR spectra were difficult to accurately integrate. The reaction of folic acid with 
compound 18 resulted in the a,γ folate conjugate, N-Boc-cystamine-folate (21), which 
is undesirable. Given the issues encountered in step 4 (a), conjugation of compounds 
16 – 18 with IMP-COOH (13) was performed to yield N-Boc-diamine-IMP 
compounds 22 - 24 {step 4 (b)}. 22 – 24 were obtained in good yield and purity and 
allowed for easy characterisation due to improved solubility and decreased molecular 
complexity. Due to issues encountered in steps 3 an 4(a), only compound N-Boc-
ethylenediamine-IMP (22) was generated in high enough quantities to allow 
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subsequent deprotection and conjugation with folic acid. However, N-Boc-2,2'-
(ethylenedioxy)bis(ethylamine)-IMP (23) and N-Boc-cystamine-IMP (24) are novel 
and they were characterised by IR and NMR spectroscopy, mass-spectrometry and 
elemental analysis. In light of this, compound 22 was deprotected using trifluoroacetic 
acid (step 5) to yield compound IMP-ethylenediamine (25) in good yield and purity. 
The final synthetic step (step 6) involved the conjugation of folic acid and compound 
25 to yield the novel second generation, folate-ethylenediamine-imidazole-
phenanthroline ligand (FIMP-et; 26). The ligand was characterised using IR, UV, mass 
spectrometry, elemental analysis and NMR.  
 
Novel FIMP-et complexes [Cu(FIMP-et)2(H2O)2].(ClO4)2.4.5H2O (27) and 
[Mn(FIMP-et)3].(ClO4)2.9H2O (28) were generated by reacting FIMP-et (26) with the 
relevant metal perchlorates. Both complexes were obtained in good yield and purity. 
Physico-chemical data suggests that complex 27 is a mononuclear copper(II) complex 
with two FIMP-et ligands, while complex 28 is a mononuclear complex with three 
FIMP-et ligands.  
 
In conclusion, this study has established that folic acid does not act as a traditional 
dicarboxylate ligand, precluding the generation of binuclear metal-phen complexes 
analogous to those previously generated using simple dicarboxylic acids. However, 
the novel mononuclear complexes 1 – 8 are extremely interesting in their own right, 
shedding light on the coordination chemistry of the folate ligand. The biological 
studies carried out on the copper (1 and 5) and manganese (2 and 6) complexes 
revealed that the phen-based complexes (5 and 6) exhibit cytotoxicity at in-vivo 
relevant concentrations in the low micromolar range and that they do not require a 
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folate receptor mediated transport for efficacy. The copper-phen complex 5 has a 
notably different mechanism of action compared to that of its manganese analogue 
complex 6. These differences are highlighted in Table 15. 
 
The preliminary biological studies on the copper and manganese complexes of the first 
generation folate-imidazole-phen (FIMP-1) ligands ([Cu(FIMP-1)2](ClO4)2.2H2O (9) 
and [Mn(FIMP-1)3](ClO4)2.2H2O (10)) revealed that, whereas both complexes 
displayed a cytotoxic profile, only the manganese-FIMP-1 complex [Mn(FIMP-
1)3](ClO4)2.2H2O (10) may be acting via a folate receptor mediated uptake. A synthetic 
route to the second-generation folate-imidazole-phen (FIMP-2) ligands has been 
developed via a challenging multi-step approach. The synthesis of the FIMP-et ligand, 
which contains an ethylenediamine spacer between the imidazole-phen and the folate 
moieties has been successful. Although attempts to make the mixed ligand FIMP-
et/phen complexes were not successful, the novel complexes [Cu(FIMP-
et)2(H2O)2].(ClO4)2.4.5H2O (27) and [Mn(FIMP-et)3].(ClO4)2.9H2O (28) were isolated 
and characterised.  
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Table 15: Comparison of the effects of copper(II) or manganese(II) containing complexes on SKOV-3, A549 or MelJuSo-UbG76V-YFP cells  
Complex 
Folate 
Targeting 
Cytotoxicity 
Proteasome 
Activity 
Effect on 3D 
Spheroids 
Mitochondrial 
Depolarisation 
Cell Cycle 
Activity 
Wound 
Scratch 
Assay 
Proposed 
mechanism 
of action 
[Cu(fol)(H2O)3].H2O 
 (1) 
Not targeted via 
the FR 
Cytotoxic at 100 
µM in both SKOV-
3 and A549 cells 
(24 hr) 
No 
proteasomal 
activity 
Ineffective 
against 3D 
spheroids 
Not tested Not tested Not tested - 
[Mn(fol)(H2O)3].3H2O  
(2) 
Not targeted via 
the FR 
Not cytotoxic in 
SKOV-3 or A549 
cells up to 100 µM 
(48 hr) 
No 
proteasomal 
activity 
Ineffective 
against 3D 
spheroids 
Not tested Not tested Not tested - 
[Cu(fol)(phen)(H2O)].3H2O 
(5) 
Not targeted via 
the FR 
Cytotoxic below 5 
µM in both SKOV-
3 and A549 cells 
(24 hr) 
Proteasome 
inhibitor 
Causes 
disaggregation 
of spheroids 
within 72 hr (10 
µM) 
Not tested Not tested Not tested 
Cell 
permeable 
DUB 
inhibitor 
[Mn(fol)(phen)(H2O)].3H2O 
(6) 
Not targeted via 
the FR 
Cytotoxic below 8 
µM in both SKOV-
3 and A549 cells 
(48 hr) 
No 
proteasomal 
activity 
Ineffective 
against 3D 
spheroids 
No 
mitochondrial 
depolarisation 
Causes 
arrest in S 
phase 
Inhibits cell 
proliferation 
and migration 
ROS induced 
autophagy 
[Cu(phen)2]2+ - 
Cytotoxic below 5 
µM in both SKOV-
3 and A549 cells 
(24 hr) 
Proteasome 
inhibitor 
Causes 
disaggregation 
of spheroids 
within 72 hr (10 
µM) 
Not tested Not tested Not tested 
Cell 
permeable 
DUB 
inhibitor 
[Mn(phen)2]2+ - 
Cytotoxic below 8 
µM in both SKOV-
3 and A549 cells 
(48 hr) 
No 
proteasomal 
activity 
Ineffective 
against 3D 
spheroids 
Not tested Not tested Not tested 
ROS induced 
autophagy 
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C.2 Future work 
 
This body of work has identified exciting potential for the development of novel 
cytotoxic agents. While the use of folic acid as a means of targeting complexes to cells 
via the FR does not appear to function in simple metal complexes, this did not prevent 
these complexes exhibiting cytotoxic effects in the low micromolar range, at 
concentrations that would be considered relevant in-vivo. Future proposed work is 
detailed below and provides useful information to assist chemists in the search for 
folate targeted metal complexes: 
 
• The potential of [Cu(fol)(phen)(H2O)].3H2O (5) to inhibit the proteasome is 
novel. There are a number of deubiquitinating enzymes (DUBs) associated 
with the proteasome located at the 19S cap. To identify which deubiquitinases 
are inhibited by complex 5, a competitive labelling experiment using 
hemagglutinin-tagged ubiquitin vinylsulphonone (HA-UbVS), an active-site 
directed probe that irreversibly reacts with cysteine deubiquitinases, should be 
performed. Using this labelling process, cysteine proteases such as UCHL5 and 
USP14, which form part of the 19S cap, will be labelled. By a process of 
elimination, these experiments would clarify if complex 5 can directly interact 
with the 19S cap of the proteasome and which DUB enzyme it can interact 
with. 
 
• The effect of complex 5 in the disaggregation of 3D spheroids warrants further 
investigation. 3D spheroids contain a hypoxic centre and the clinical drug 
Bortezomib is ineffective in 3D spheroids and solid tumours. 3D spheroids 
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more closely represent in-vivo tissues and the microenvironment. Does 
complex 5 inhibit cell aggregation by affecting the extracellular matrix or cause 
disaggregation through cell death? 
 
• Further investigation into the relationship between manganese(II) complex 
[Mn(fol)(phen)(H2O)].4H2O (6) and ROS-induced autophagy is required. To 
confirm that complex 6 does induce ROS generation, ROS levels should be 
measured in treated cells.  
 
• The potential for manganese containing complex 6 to induce autophagy can be 
confirmed using markers of autophagy and confocal microscopy e.g. 
quantitation of LC3B protein on autophagic vesicles using commercially 
available autophagy assays. Known autophagic inducers {e.g. rapamycin 
(Rapa) and suberoyanilide hydroxamic acid (SAHA)} and autophagic 
inhibitors {e.g. 3-methyladenine (3-MA) and chloroquine (CQ)} could also be 
used experimentally. 
 
• Studies using animal models could be considered to determine the efficacy of 
complexes 5 and 6 in vivo. Mouse or guinea pig models could be suitable for 
studies on absorption, metabolism, distribution, and excretion of the 
complexes. Furthermore, such studies allow for safety aspects such as adverse 
effects and drug-drug interactions to be evaluated336. Given the poor solubility 
of both complexes, administration of the complexes to animals would be 
challenging and oral administration would be the most suitable route of 
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administration. Improvement in solubility is a key priority to advance the 
research to in vivo models. 
 
• Deprotection and conjugation of N-Boc-2,2'-(ethylenedioxy)bis(ethylamine) 
and N-Boc-cystamine with folic acid to yield novel FIMP-2,2'-
(ethylenedioxy)bis(ethylamine) and FIMP-cystamine ligands remains. The 
proposed improved solubility of FIMP-2,2'-(ethylenedioxy)bis(ethylamine) 
may allow for analysis by RP-HPLC. Furthermore, these ligands with 
functional linkers (improved solubility and cleavage in the acidic endosome) 
may offer advantageous biological activity and improved FR selectivity. 
 
• Although the novel FIMP-1 ligands showed promise, investigation of the 
cytotoxicity, cytoselectivity, and mechanism of action of the novel FIMP-et 
ligand and its copper(II) and manganese(II) complexes in FR cell models is 
required. 
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EXPERIMENTAL 
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E.1  Experimental Methods and Instrumentation  
   
Chemicals and reagents were purchased from Sigma Aldrich Ireland, ACROS Ireland 
and Fluorochem and used without further purification. 
 
Infrared (IR) spectra were recorded in the region 4000 – 600 cm-1 on a Perkin Elmer 
Spectrum GX FT-IR Microscope using Attenuated total reflectance (ATR) 
 
UV-Vis spectra were recorded on a Unicam UV-500 spectrometer. Soluble samples 
were analysed in a 1 cm-1 quartz cuvette with a path length of 1 cm with a spectral 
range of 200 – 800 nm unless otherwise specified. The background was corrected for 
blank solvent absorbance prior to each measurement and was collected at room 
temperature. Samples with poor solubility were analysed as solids using an integrating 
sphere attachment and a quartz slide. The background was corrected for blank quartz 
slide absorbance prior to each measurement and was collected at room temperature 
 
All Nuclear magnetic resonance (NMR) characterisation was performed on a Bruker 
Ascend 500 MHz or a Bruker Avance 400MHz spectrometer using deuterated DMSO-
d6, deuterated chloroform or deuterium oxide unless otherwise stated. Peak positions 
are relative to trimethylsilane (TMS; 0 ppm chemical shift). All NMR spectra were 
processed and analysed using MestReNova NMR software. 
 
1H NMR and 13C NMR of folic acid/copper chloride mixtures were performed on a 
Bruker Avance 400MHz spectrometer. Samples were prepared in 1 ml D2O (99.95 %) 
and the final concentration was 40 mM for proton and carbon spectra. NMR spectra 
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were recorded for folate and Cu(II)–folate system at pH 7 by adding a small volume 
of 1M NaOH. Measurements were made for Cu(II)–folate at a molar ratio of 1:100 
(Metal:Ligand).  
 
Inductively coupled plasma - optical emission spectrometry (ICP-OES) was performed 
on a Varian Liberty 150 ICP-Emission spectrometer. Standard curves were generated 
using 1 – 10 mg/L solutions of Centipur ICP-multi-element standard solution (contains 
1000 mg/L Cu2+, Mn2+, and Fe3+) 
 
Magnetic susceptibility measurements were performed using a Johnson Matthey 
magnetic susceptibility balance. Hg[Co(SCN)4] was used as a reference standard.  
 
Mass Spectroscopy were carried out by the Analytical Chemistry Laboratory, 
Maynooth University, Kildare, Ireland and University of Southern Denmark, Odense, 
Denmark. 
 
Elemental analyses were performed by the Microanalytical Laboratory, University 
College Dublin. Ireland and the Analytical Chemistry Laboratory, Maynooth 
University, Kildare, Ireland. 
 
Thermogravimetric analysis (TGA) was carried out using a TGA – Q50 TA Instrument 
by the Technological University Dublin (TU Dublin), Tallaght Campus. Scanning was 
performed from ambient temperature to 800oC in the presence of nitrogen gas with the 
sample purge flow of 30 ml min-1. The sample was loaded in a platinum pan and 
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analysis was carried out at a heating rate of 10oC min-1. The percentage of weight loss 
versus temperature was examined. 
 
RP-HPLC analysis was performed on a Waters 2998 HPLC and Photodiode Array 
Detector, (Waters, USA), using a Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 
μm, (Agilent Technologies, UK). Gradient elution was carried out at a flow rate of 1 
mL/min, column temperature 25 ± 5.0 °C. The gradient running was 5% A/95% B to 
100% A over 45 min where A is 0.1% TFA in acetonitrile and B is 0.1% TFA in water. 
Samples were monitored according to their UV absorbance at 280 nm. 
 
Microscopy and cell imaging were performed using an Olympus IX73 inverted 
microscope in Linkoping University. 
 
Live cell analysis was performed using an IncuCyte S3 live cell analysis system in 
Linkoping University. A 10X objective was used for spheroid cultures and a 20X 
objective was used for monolayer cultures. 
 
Fluorescence was measured using a Perkin Elmer Victor 3V 1420 Multilabel Plate 
Counter from 560 – 590 nm in Linkoping University. 
 
Absorbance was measured using a Molecular Devices Versa Max Microplate 
Spectrophotometer at 570 nm in Linkoping University. 
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E.2  The synthesis of simple metal folates and their 1,10-phenanthroline 
derivatives 
 
E.2.1   The general procedure for the synthesis of simple metal folate 
complexes. 
 
Simple metal folate complexes were synthesised according to El-Wahed et al147. A 
methanolic suspension of folic acid (0.441 g, 1.0 mmol, 50 ml) was neutralised using 
a sodium hydroxide solution (0.1 M). To this, a 10 ml solution of metal chloride was 
added (1.0 mmol). The mixture was heated to approximately 80 oC and refluxed for 
two hours. The coloured suspension cooled and centrifuged at 3000 rpm for 5 min. 
The coloured pellet was washed with excess amounts of distilled water to remove 
residual chloride ions and centrifugation was repeated in methanol and diethyl ether. 
The product was dried overnight at 50oC. 
 
[Cu(fol)(H2O)3].H2O (1)  
Yield: 0.38 g (68%); Appearance: Brown solid; Solubility: Insoluble in all solvents; 
µeff: 1.78 B.M.; ƛmax (nm): 235, 335, 417 nm; Elemental Analysis (Calc): C, 39.76; 
H, 4.21; N, 17.38; Cu, 11.07; Elemental Analysis (Found): C, 39.65; H, 3.80; N, 17.42; 
Cu, 11.29; TG Analysis: 9.36 % (calculated: 9.71 %; 4 H2O); IR: 3252, 3164, 2790, 
2102, 2047, 1686, 1603, 1568, 1510, 1450, 1404, 1334, 1299, 1259, 1125, 1105, 991, 
969, 838, 818, 766, 736, 675 cm-1. 
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[Mn(fol)(H2O)3].3H2O (2) 
Yield:  0.35 g (63 %); Appearance: Yellow solid; Solubility: Insoluble in all solvents: 
µeff: 6.11 B.M; λmax (nm): 292, 397; Elemental Analysis (Calc): C, 37.95; H, 4.69; N, 
16.30; Mn, 9.13; Elemental Analysis (Found): C, 37.85; H, 4.20; N, 16.08; Mn, 9.37; 
TG Analysis: 17.36 % (calculated: 17.97 %; 6 H2O); IR: 3250, 3166, 3126, 2783, 
1691, 1603, 1561, 1526, 1507, 1501, 1408, 1335, 1298, 1188, 1124, 1055, 986, 970, 
952, 855, 821, 768, 734, 697, 670 cm-1.  
 
[Fe(fol)(H2O)2(Cl)].4H2O (3)  
Yield: 0.38 g (61.29 %); Appearance: Red-brown solid; Solubility: Insoluble in all 
organic solvents; λmax: 287, 393 nm; µeff: 2.71 B.M.; Elemental Analysis (Found): C, 
35.99; H, 4.42; N, 15.45; Fe; 9.05; Elemental Analysis (Calc): C, 35.78; H, 4.43; N, 
15.37; Fe, 8.76; TG Analysis: 16.54 & (calculated: 16.93 %; 6 H2O); IR: 3340, 1687, 
1641, 1607, 1511, 1448, 1408, 1337, 1303, 1191, 1130, 1105, 946, 840, 823, 768, 736, 
584, 516 cm-1.  
 
[Zn(fol)(H2O)3].3H2O (4)   
Yield: 0.38 g (62.20 %); Appearance: Yellow solid; Solubility: Insoluble in all organic 
solvents; Elemental Analysis (Found): C, 38.10; H, 4.99; N, 16.42; Zn, 10.69; 
Elemental Analysis (Calc): C, 37.70; H, 4.61; N, 16.02; Zn, 9.74; TG Analysis: 16.15 
% (calculated: 17.68 %; 6 H2O); IR: 3320, 3178, 2942, 2859, 2788, 1601, 1547, 1509, 
1449, 1398, 1341, 1309, 1274, 1184, 1133, 1106, 838, 822, 770 cm-1.  
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E.2.2  The Synthesis of 1,10-Phenanthroline derivatives of simple metal 
folate complexes  
 
E.2.2.1 The coordination of 1,10-phenanthroline and simple metal folates 
 
1,10-phenanthroline (0.15 g, 0.8 mmol) was added to a stirred suspension of metal 
folate (0.3 g, 0.4 mmol) in 40 ml methanol. The suspension was refluxed for 4 hr. The 
resulting precipitate was centrifuged at 3000 rpm for 5 min and the pellet was washed 
with methanol and diethyl ether. The green powder was dried overnight at room 
temperature.  
 
[Cu(fol)(phen)(H2O)].3H2O (5)  
Yield: 0.27 g (87.10 %); Appearance: Green solid; Solubility: Partially soluble in hot 
DMF and DMSO; µeff: 1.82 B.M.; λmax: 259, 386, 712 nm; Elemental Analysis 
(Calc): C, 49.37; H, 4.28; N, 16.71; Cu, 8.43; Elemental Analysis (Found): C, 49.45; 
H, 3.78; N, 17.70; Cu, 7.35; TG Analysis: 9.94 % (calculated: 9.54 %, 4 H2O); IR: 
3255, 3081, 2973, 2795, 1724, 1687, 1605, 1561, 1517, 1450, 1427, 1400, 1341, 1299, 
1254, 1192, 1147, 1127, 1107, 1053, 970, 850, 769, 723, 675 cm-1. 
 
E.2.2.2 The coordination of folic acid with metal bis phenanthroline 
complexes 
 
To a neutralised solution of folic acid (0.44 g, 1 mmol) in methanol, two molar 
equivalents of the metal-bis phenanthroline was added. The resulting coloured mixture 
was refluxed for 4 hr. The suspension was centrifuged at 3000 rpm for 5 min and the 
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pellet was washed with methanol and diethyl ether. The yellow powder was dried 
overnight at room temperature.  
 
[Mn(fol)(phen)(H2O)].4H2O (6) 
Yield: 0.74 g (97.56 %); Appearance: Yellow solid; Solubility: Partially soluble in hot 
DMF and DMSO; µeff; 5.32 B.M; λmax (nm): 258, 291, 389; Elemental Analysis 
(Calc): C, 48.76; H, 3.92; N, 16.51; Mn, 7.19; Elemental Analysis (Found): C, 48.49; 
H, 3.65; N, 16.66; Mn, 8.15; TG Analysis: 10.31 % (calculated: 11.79 %, 5 H2O); IR: 
3302, 3062, 2971, 2845, 2796, 1725, 1688, 1604, 1514, 1449, 1424, 1409, 1341, 1302, 
1189, 1145, 1120, 1106, 1050, 969, 951, 865, 847, 822, 767, 730, 670 cm-1.  
 
[Fe(fol)(phen)(Cl)].5H2O (7) 
Yield: 0.35 g (44.31 %); Appearance: Red solid; Solubility: Partially soluble in hot 
DMF and DMSO; µeff: 2.71 B.M.; Elemental Analysis (Calc): C, 46.54; H, 4.28; N, 
15.76; Fe, 6.98; Elemental Analysis (Found): C, 46.42; H, 4.31; N, 16.73; Fe, 7.15; 
TG Analysis: 10.74 % (calculated: 11.25 %, 5 H2O); IR: 3329, 3107, 1690, 1602, 1515, 
1454, 1426, 1406, 1335, 1299, 1262, 1185, 1130, 1106, 845, 725 cm-1.  
 
[Zn(fol)(phen)(H2O)].4H2O (8)  
Yield: 0.65 g (84.42 %); Appearance: Yellow solid; Solubility: Partially soluble in hot 
DMF and DMSO; Elemental Analysis (Calc): C, 48.10; H, 4.43; N, 16.29; Zn, 8.45; 
Elemental Analysis (Found): C, 48.38; H, 3.97; N, 16.59; Zn, 7.95; TG Analysis: 9.94 
% (calculated: 7.14 %, 5 H2O); IR: 3318, 3070, 2942, 2837, 1690, 1606, 1544, 1509, 
1452, 1428, 1393, 1338, 1306, 1274, 1190, 1127, 1110, 852, 822, 770, 730 cm-1. 
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E.2.2.3 The general method for the synthesis of metal phenanthroline 
chloride complexes 
 
The method described by McCann et al was used to synthesise metal phenanthroline 
chloride complexes225. To a solution of the relevant metal chloride (1 gram) in 
methanol (20 ml) was added a solution of 1,10-phenanthroline in methanol (2 molar 
equivalent; 20 ml). The resulting suspension was stirred for 2 hr at room temperature. 
The coloured solid was filtered off, washed with methanol and dried in vacuo. 
Recrystallisation was performed in minimal amounts of methanol and crystals 
developed over the period of weeks. 
 
[Cu(phen)2Cl2].CH3OH.4.5H2O 
Yield: 2.90 g (81.46 %); Appearance: Blue crystal; Solubility: Soluble in hot methanol, 
ethanol, DMSO, and DMF; µeff: 1.78 B.M; Elemental Analysis (Calc): C, 49.28; H, 
4.48; N, 9.58; Elemental Analysis (Found): C, 49.69; H, 4.30; N, 9.49; IR: 3360, 3059, 
1628, 1586, 1519, 1427, 1341, 1228, 1145, 1039, 852, 784, 721 cm-1. 
 
[Mn(phen)2Cl2] 
Yield: 1.80 g (73.47 %); Appearance: Yellow crystal; Solubility: Soluble in hot 
methanol, ethanol, DMSO, and DMF; µeff: 5.75 B.M; Elemental Analysis (Calc): C, 
59.28; H, 3.32; N, 11.52; Elemental Analysis (Found): C, 59.07; H, 3.24; N, 11.26; 
IR: 3048, 2994, 1623, 1578, 1515, 1426, 1224, 1144, 1093, 1028, 988, 845, 779, 722 
cm-1. 
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[Fe(phen)3]Cl3.CH3OH.5.5H2O 
Yield: 1.77 g (57.28 %); Appearance: Red crystal; Solubility: Soluble in hot methanol, 
ethanol, DMSO, and DMF; µeff: 2.41 B.M; Elemental Analysis (Calc): C, 53.29; H, 
4.71; N, 10.08; Elemental Analysis (Found): C, 52.82; H, 3.23; N, 10.09; IR: 3436, 
,3057, 1619, 1582, 1515, 1421, 1340, 1305, 1216, 1144, 1102, 847, 776, 720, 640 cm-
1. 
 
[Zn(phen)Cl2] 
Yield: 1.36 g (58.62 %); Appearance: Colourless solid; Solubility: Soluble in hot 
methanol, ethanol, DMSO, and DMF; Elemental Analysis (Calc): C, 45.54; H, 2.55; 
N, 8.58; Elemental Analysis (Found): C, 46.03; H, 2.07; N, 3.69; IR: 3050, 1584, 1519, 
1425, 1342, 1224, 1105, 1035, 979, 851, 780, 723 cm-1. 
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E.3  The synthesis of novel second generation folate-imidazole ligands 
 
E.3.1  Synthesis of 1,10-phenanthroline-5,6-dione (phendione; 11) 
 
Phendione was synthesised as previously described310. 10 g (55.49 mmol) of 1,10-
phenathroline was dissolved in 130 ml 60% H2SO4 in a 500 ml round bottom flask. 
Over a period of 1 hr, 10.19 g (61.04 mmol) KBrO3 was added in small quantities. A 
colour change ranging from red to orange to yellow was observed upon increasing 
concentrations of KBrO3. The solution was left uncovered for 1 hr to facilitate the 
removal of bromine gas before the yellow solution was gently stoppered and left to stir 
for 20 – 24 hr. The solution was poured over 400 ml of ice and the pH recorded as pH 
1. To raise the pH to pH 7, approximately 100 ml of saturated NaOH solution was 
added, inducing a colour change from yellow solution to tan suspension. The product 
was extracted with three 100 ml aliquots of dichloromethane (DCM) and the combined 
organic layers removed in vacuo. The yellow product was recrystallized in minimal 
quantities of methanol, filtered, washed with cold methanol and air-dried. Yield: 9.70 
g (83.19 %); Appearance: yellow crystalline solid; Solubility: MeOH, acetone, 
DMSO, DMF, ACN, DCM, THF and CHCl3; λmax: 258 and 299 nm; LC-MS (ESI) 
calcd for C12H6N2O2 211.0502 [M+H]
+, found 211.0500; Elemental Analysis (Found) 
C, 68.52; H, 2.74; N, 13.48; Elemental Analysis (Calc): C, 68.57; H, 2.88; N, 13.33; 
1H NMR (500 MHz, CDCl3) δ 9.09 (dd, J = 4.6 Hz, 2H), 8.48 (dd, J = 7.9 Hz, 2H), 
7.57 (dd, J = 7.8 Hz, 2H); 13C NMR (126 MHz) δ 178.72, 156.51, 153.02, 137.40, 
128.19, 125.64; IR: 3350, 3061, 2914, 2849, 1995, 1704, 1685, 1577, 1561, 1463, 
1458, 1414, 1317, 1293, 1205, 1184, 1115, 1060, 1011, 925, 817, 817, 740, 735, 668 
cm-1. 
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E.3.2 The general procedure for the synthesis of imidazo-phenanthrolines 
(IMP) compounds 
 
To 0.30 g of phendione (1.43 mmol) in 10 ml methanol, was added a 10 ml methanolic 
solution of ceric ammonium nitrate (0.04 g, 0.07 mmol). An excess of ammonium 
acetate (1.10 g, 143 mmol) was added and the suspension was heated until soluble. 
1.43 mmol of the chosen aldehyde was added and the reaction vessel was sealed. The 
reaction continued in a microwave synthesiser, with parameters set as follows: 15 min 
at 70 oC/3 bar/300 watt with constant stirring. The product was submerged in 150 ml 
distilled water and stirred for an additional 30 min. The mixture was filtered, washed 
with acetone or diethyl ether and allowed to dry at 70 oC overnight. 
 
IMP-NO2 (12) 
Yield: 0.39 g (72.91%); Appearance: Orange solid; Solubility: DMF and DMSO, 
partially soluble in acetone, hot MeOH & EtOH; LC-MS (ESI) calcd for C19H12N5O2 
342.0986 [M+H]+, found 342.1009; Elemental Analysis (Found) C, 60.52; H, 4.34; N, 
18.48; Elemental Analysis (Calc): C, 60.47; H, 4.01; N, 18.56; 1H NMR (500 MHz, 
DMSO) δ 9.05 (dd, J = 4.2, 1.5 Hz, 2H), 8.91 (d, J = 8.0 Hz, 2H), 8.49 (q, J = 9.0 Hz, 
4H), 7.85 (dd, J = 7.9, 4.2 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 149.93, 148.33, 
143.97, 132.48, 130.14, 129.59, 128.54, 123.41; IR: 3385, 3176, 3097, 3076, 3037, 
1603, 1567, 1515, 1454, 1399, 1343, 1299, 1108, 1072, 854, 805, 738, 708 cm-1 
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IMP-COOH (13) 
Yield: 0.46 g (94.05%); Appearance: Yellow solid; Solubility: Partially soluble in hot 
DMSO and DMF; λmax: 282, 337 nm; LC-MS (ESI) calcd for C20H13N4O2 341.1033 
[M+H]+, found 341.10.35; Elemental Analysis (Found) C, 63.91; H, 4.51; N, 14.87; 
Elemental Analysis (Calc): C, 63.82; H, 4.28; N, 14.89; 1H NMR (500 MHz, DMSO) 
δ 8.91 (d, J = 1.2 Hz, 2H), 8.90 (d, J = 1.1 Hz, 2H), 8.42 (d, J = 8.2 Hz, 2H), 8.33 (d, J 
= 23.7 Hz, 2H), 7.76 (dd, J = 8.0, 4.3 Hz, 2H); 13C NMR (126 MHz, DMSO) δ 172.42, 
168.24, 166.57, 159.16, 157.50, 151.56, 150.21, 149.21, 148.17, 144.12, 137.62, 
136.59, 133.93, 130.53, 130.13, 129.76, 126.68, 125.32, 123.66, 123.23; IR: 3374, 
3060, 1931, 1679, 1602, 1536, 1479, 1380, 1317, 1254, 1182, 1114, 1070, 1015, 958, 
862, 807, 735, 711 cm-1  
 
IMP-Phenyl (14) 
Yield: 0.37 g (87.08 %); Appearance: Pale yellow solid; Solubility: MeOH, DMSO, 
DMF and CHCl3; LC-MS (ESI) calcd for C19H13N4 297.1135 [M+H]
+, found 
297.1144; Elemental Analysis (Found) C, 72.32; H, 4.27; N, 17.88; Elemental 
Analysis (Calc): C, 72.60; H, 4.49; N, 17.82; 1H NMR (500 MHz, DMSO) δ 9.00 (s, 
2H), 8.89 (d, J = 7.8 Hz, 2H), 8.27 (d, J = 7.6 Hz, 2H), 7.79 (s, 2H), 7.59 (t, J = 7.6 
Hz, 2H), 7.50 (t, J = 7.3 Hz, 1H); 13C NMR (126 MHz) δ 150.54, 147.76, 143.63, 
130.03, 129.64, 129.02, 126.20, 123.27; IR: 3062, 1950, 1882, 1603, 1562, 1546, 
1505, 1514, 1476, 1458, 1428, 1398, 1351, 1297, 1190, 1158, 1134, 1105, 1069, 1030, 
969, 952, 918, 803, 775, 739, 694, 666, 643, 621 cm-1 
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E.3.3  Synthesis of IMP-NH2 (15) 
 
IMP-NH2 was synthesised as previously described
314. To a 300 ml solution of 12 (0.80 
g, 2.34 mmol), 0.2 g of 10% Palladium/Carbon catalyst was added. The mixture was 
refluxed for 2 hr in the absence of light before 1.25 ml (0.026 mmol) hydrazine 
monohydrate was added in one portion and the mixture was refluxed for 3 hr. The 
resulting dark mixture was allowed to cool to room temperature and filtered through a 
bed of celite to product a yellow filtrate. The solvent was removed under reduced 
pressure to yield an orange solid. Yield: 1.53 g (74.88 %); Appearance: Orange solid; 
Solubility: H2O, EtOH, MeOH, DMSO, DMF; LC-MS (ESI) calcd for C19H14N5 
312.1244 [M+H]+, found 312.1252; Elemental Analysis (Found) C, 65.11; H, 4.26; N, 
20.66; Elemental Analysis (Calc): C, 65.69; H, 4.93; N, 20.16; 1H NMR (500 MHz, 
DMSO) δ 8.99 (s, 2H), 8.89 (d, J = 3.1 Hz, 1H), 7.98 (d, J = 5.4 Hz, 2H), 7.82 (d, J = 
20.0 Hz, 2H), 6.74 (d, J = 7.9 Hz, 2H), 5.63 (s, 2H); 13C NMR (126 MHz, DMSO) δ 
151.59, 149.95, 146.82, 142.66, 128.96, 128.33 , 127.12, 122.69, 116.84, 113.17; IR: 
3324, 3198, 1608, 1561, 1523, 1482, 1451, 1427, 1350, 1295, 1180, 1067, 1029, 834, 
798, 735, 694, 645, 620 cm-1 
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E.3.4  The N-Boc protection of diamines 
 
E.3.4.1 The N-Boc protection of ethylenediamine (16) 
 
Ethylenediamine was protected as previously described316. To a cooled solution of 
ethylenediamine (9.359 ml, 140 mmol) in anhydrous DCM (20 ml), a solution of di-
tert-butyl dicarbonate (3.055 g, 14 mmol) in 50 ml anhydrous DCM was added drop-
wise over a period of 2 hours. The reaction was stirred for 24 hr at room temperature 
under nitrogen. The solvent was removed under reduced pressure and replaced with 
water. The aqueous suspension was filtered to remove the di-boc protected by-product 
and the filtrate was washed with three portions of DCM (50 ml). The combined organic 
layers were dried over Na2SO4 and evaporated to yield a viscous oil. Yield: 3.96 g 
(88.19%); Appearance: Viscous oil, ranging in colour from colourless to pale yellow; 
Solubility: H2O, MeOH, EtOH, Et2O, Acetone, EtOAc, DCM, ACN, CHCl3, DMF and 
DMSO; λmax: 216 nm; LC-MS (ESI) calcd for C7H17N2O2 161.1285 [M+H]+, found 
161.1297; 1H NMR (500 MHz, CDCl3) δ 5.84 (s, 1H), 3.07 (d, J = 5.3 Hz, 2H), 2.70 
(t, J = 5.9 Hz, 2H), 1.36 (s, 9H), 1.22 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 156.30, 
78.63, 43.38, 41.78, 28.30; IR: 3368, 2866, 1702, 1522, 1454, 1390, 1364, 1275, 1250, 
1170, 1105, 1042, 999, 967, 916, 864, 815, 781 cm-1. 
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E.3.4.2 The N-Boc protection of 2,2'-(ethylenedioxy)bis(ethylamine) (17) 
 
2,2'-(ethylenedioxy)bis(ethylamine) was protected as previously described321. To a 
cooled solution of 2,2-(ethylenedioxy)bis(ethylamine) (20.44 ml, 140 mmol) in 20 ml 
anhydrous chloroform, a solution of di-tert-butyl dicarbonate (3.06 g, 14 mmol) in 50 
ml anhydrous chloroform was added drop-wise over a period of 2 hours. The reaction 
was stirred for 24 hr at room temperature under nitrogen. The solvent was removed 
under reduced pressure and the residue dissolved in DCM (50 ml), washed with three 
50 ml portions of distilled water, dried over Na2SO4 and evaporated to yield a 
colourless, viscous oil. Yield: 3.22 g (92.72 %); Appearance: Colourless viscous oil; 
Solubility: H2O, MeOH, EtOH, Acetone, EtOAc, DCM, ACN, CHCl3, DMF and 
DMSO. LC-MS (ESI) calcd for C11H25N2O4 249.3272 [M+H]
+, found 249.1815; 1H 
NMR (500 MHz, CDCl3) δ 5.52 (s, 1H), 3.26 (s, 4H), 3.16 (d, J = 15.1 Hz, 4H), 2.92 
(s, 2H), 2.50 (s, 2H), 1.08 (s,11H); 13C NMR (126 MHz) δ 155.42, 77.96, 72.81, 69.51, 
41.08, 39.64, 27.77. IR: 3354, 2975, 2932, 2869, 1686, 1518, 1543, 1391, 1364, 1272, 
1248, 1165, 1041, 953, 870, 779 cm-1 
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E.3.4.3 The N-Boc protection of cystamine dihydrochloride (18) 
 
Cystamine bis-hydrochloride was N-Boc protected as previously described319. To a 
cooled solution of cystamine bis-hydrochloride (8.0 g, 36 mmol) in methanol (200 ml), 
14.9 ml (107 mmol) of triethylamine was added. A solution of di-tert-butyl dicarbonate 
(7.70 g, 36 mmol) in 100 ml methanol was added drop wise over a period of 2 hours. 
The reaction was stirred for 24 hr at room temperature. The solvent was removed under 
reduced pressure and the white residue dissolved in 80 ml of 1 M aqueous NaH2PO4. 
The aqueous solution was extracted twice with diethyl ether to remove di-Boc-
cystamine and subsequently basified to pH 10 with 1 M NaOH. The aqueous layer was 
then extracted three times with ethyl acetate. The combined ethyl acetate layers were 
washed twice with distilled water, dried with Na2SO4 and evaporated in vacuo to yield 
a yellow, viscous oil. Yield: 3.56 g (39.99 %); Appearance: Yellow viscous oil; 
Solubility: MeOH, EtOH, Acetone, Et2O, EtOAc, DCM, CHCl3, DMF, DMSO & 
ACN; LC-MS (ESI) calcd for C9H21N2O2S2 253.1044 [M+H]
+, found 253.1050; 1H 
NMR (500 MHz, CDCl3) δ 5.57 (s, 1H), 3.42 (s, 2H), 3.00 (t, J = 5.9 Hz, 2H), 2.78 
(dd, J = 13.5, 6.7 Hz, 4H), 1.47 (d, J = 24.0 Hz, 11H); 13C NMR (126 MHz, CDCl3) δ 
155.41, 78.73, 41.93, 40.19, 38.92, 37.90, 27.95; IR: 3357, 2974, 2928, 2865, 1691, 
1513, 1453, 1390, 1364, 1270, 1299, 1163, 1043, 1006, 947, 919, 865, 777 cm-1 
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E.3.5  The general procedure for the conjugation of N-Boc protected 
diamines with folic acid 
 
The method for amide conjugation described by Trindade et al was used322. To a 
solution of folic acid (0.893 g, 2 mmol) dissolved in 60 ml anhydrous dimethyl 
sulfoxide (DMSO), N,N′-dicyclohexylcarbodiimide (DCC; 0.826 g; 4 mmol) and N-
hydroxysuccinamide (NHS; 0.465 g; 4 mmol) were added successively. The reaction 
mixture was stirred in the absence of light for 24 hr at room temperature, after which 
time a colourless precipitate, dicyclohexylurea, was removed by vacuum filtration. To 
the orange filtrate, 0.523 ml (3.8 mmol) of triethylamine and 0.784 g (3.8 mmol) DCC 
were added, followed by 3.8 mmol of the selected N-Boc protected diamine dissolved 
in 5 ml DMSO. The mixture was stirred overnight at room temperature, in the absence 
of light before a mixture of 20% acetone in diethyl ether was added (100 ml). The fine, 
yellow precipitate was filtered and washed thoroughly with excess acetone/diethyl 
ether mix (20% v/v) and dried in a 60oC oven overnight. 
 
N-Boc-ethylenediamine-folate (19) 
Yield: 0.981 g (84.06 %); Appearance: Yellow solid; Solubility: DMF, DMSO (hot);; 
LC-MS (ESI) calcd for C26H33N9O7 584.2576 [M+H]
+, found 584.2601; Elemental 
Analysis (Found) C, 50.88; H, 6.34; N, 19.81; Elemental Analysis (Calc): C, 50.40; H, 
6.02; N, 20.34; 1H NMR (500 MHz, DMSO) δ 8.77 – 8.54 (m, 2H), 8.02 (d, J = 7.2 
Hz, 1H), 7.94 – 7.58 (m, 4H), 7.42 (d, J = 8.7 Hz,1H), 7.21 (d, J = 5.9 Hz, 1H), 7.09 – 
6.51 (m, 8H), 4.64 – 4.38 (m, 3H), 3.06 (dd, J = 10.7, 5.6 Hz, 2H), 3.01 – 2.91 (m, 
2H), 2.36 (t, J = 6.8 Hz, 1H), 2.16 – 2.05 (m, 1H), 1.99 (d, J = 5.9 Hz, 1H), 1.87 (dd, 
J = 26.0, 8.4 Hz, 1H), 1.45 – 1.23 (m, 11H). 13C NMR (126 MHz, DMSO) δ 172.38 
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(s), 166.70 (s), 157.13 (s), 156.08 (s), 154.26 (s), 151.21 (s), 149.11 (s), 129.53 (s), 
111.64 (s), 78.11 (s), 53.51 (s), 47.97 (s), 46.36 (s), 40.87 (s), 40.47 (s), 40.30 (s), 
40.12 (s), 39.95 (s), 39.79 (s), 39.71 – 39.15 (m), 33.79 (s), 32.47 (s), 28.66 (s), 25.76 
(s), 24.90 (s); IR: 3324, 2929, 2852, 2791, 2720, 1693, 1624, 1602, 1536, 1509, 1435, 
1366, 1273, 1246, 1172, 1128, 1018, 952, 892, 818, 768, 730, 705, 639 cm-1 
 
N-Boc-2 2'-(ethylenedioxy)bis(ethylamine)-folate (20) 
Yield: 1.26 g (98.82 %); Appearance: Yellow solid; Solubility: DMF, DMSO (hot); 
LC-MS (ESI) calcd for C30H42N9O9 672.3100 [M+H]
+, found 672.3098; Elemental 
Analysis (Found) C, 53.27; H, 6.62; N, 17.71; Elemental Analysis (Calc): C, 53.64; H, 
6.15; N, 18.70; 1H NMR (500 MHz, DMSO) δ 8.66 (d, J = 14.4 Hz, 1H), 8.05 – 7.80 
(m, 3H), 7.73 – 7.59 (m, 2H), 6.92 (d, J = 4.9 Hz, 2H), 6.72 (s, 1H), 6.64 (d, J = 8.7 
Hz, 2H), 4.53 (dd, J = 37.6, 4.9 Hz, 2H), 4.32 (dd, J = 13.2, 8.3 Hz, 1H), 3.38 – 3.31 
(m, 6H), 3.27 – 3.13 (m, 3H), 3.05 (d, J = 5.2 Hz, 3H), 2.25 – 2.07 (m, 2H), 1.97 (dd, 
J = 13.3, 5.7 Hz, 1H), 1.91 – 1.79 (m, 1H), 1.35 (s, 11H); 13C NMR (126 MHz) δ 
171.98, 166.21, 155.64, 153.94, 150.78, 149.26 – 148.48, 148.34, 129.04, 127.95, 
121.48, 111.23, 77.64, 69.33, 68.99, 53.17, 45.95, 32.04, 28.25, 27.68; IR: 3311, 3154, 
2930, 2863, 2773, 1703, 1645, 1603, 1524, 1488, 1365, 1331, 1295, 1270, 1178, 1124, 
1015, 948, 836, 822, 766, 643, 607, 509, 442 cm-1  
 
N-Boc-cystamine-folate (21) 
Yield: 1.54 g (60.01%); Appearance: Yellow solid; Solubility: DMF, DMSO (hot); 
LC-MS (ESI) calcd for C28H38N9O7S2 676.2336 [M+H]
+, found 910.3257; Elemental 
Analysis (Found) C, 48.23; H, 5.39; N, 18.68; Elemental Analysis (Calc): C, 48.47; H, 
5.67; N, 18.17; 1H NMR (500 MHz, DMSO) δ 8.64 (s, 1H), 8.01 (dd, J = 10.6, 6.6 Hz, 
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2H), 7.66 (d, J = 8.6 Hz, 2H), 6.94 (s, 3H), 6.70 – 6.58 (m, 2H), 4.49 (d, J = 5.6 Hz, 
2H), 4.32 (dd, J = 13.1, 8.5 Hz, 1H), 3.19 (dd, J = 12.2, 6.0 Hz, 2H), 2.73 (dd, J = 8.4, 
5.0 Hz, 6H), 2.15 (dd, J = 14.4, 6.9 Hz, 2H), 1.99 (d, J = 6.4 Hz, 1H), 1.93 – 1.78 (m, 
1H), 1.35 (s, 11H); 13C NMR (126 MHz) δ 171.60, 165.94, 155.29, 153.64, 150.45, 
128.81, 127.62, 110.88, 77.59, 45.62, 39.69, 39.44, 39.19, 39.02, 38.77, 37.75, 37.32, 
36.87, 31.75, 27.90, 27.23; IR: 3294, 3148, 3087, 2980, 2924, 1695, 1606, 1505, 1413, 
1390, 1365, 1334, 1295, 1270, 1248, 1166, 1124, 1041, 1018, 945, 856, 817, 766, 733, 
607, 509 cm-1 
 
E.3.6 The general procedure for the conjugation of N-Boc protected diamines 
with IMP-COOH 
 
N-Boc protected diamines were conjugated with IMP-COOH using a similar method 
to one previously described by Pu et al337 . To 25 ml dimethylformamide (DMF), IMP-
COOH (11) (0.40 g, 1.17 mmol) and hydroxybenzotriazole (HOBt; 0.36 g; 2.34 mmol) 
were added. The suspension was cooled to 0 oC and 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC; 0.45 g; 2.34 mmol) was added and stirred 
for 20 min. The final addition of N-Boc diamine (2.34 mmol) in 10 ml DMF was 
performed at room temperature. The reaction was left to stir for 24 hr at room 
temperature. To the orange solution, 100 ml distilled water was added to produce a 
fine yellow precipitate. The crude product was washed well with water and 
subsequently recrystallized in minimal quantities of methanol, filtered, washed with 
cold diethyl ether and air-dried. 
 
 
 211 
 
N-Boc-ethylenediamine-IMP (22) 
Yield: 0.50 g (89.05 %); Appearance: Pale yellow solid; Solubility: MeOH, DMF, 
DMSO (hot); λmax: 227, 278, 325 nm; LC-MS (ESI) calcd for C27H27N6O3 483.2145 
[M+H]+, found 483.2158; Elemental Analysis (Found): C, 60.35; H, 5.51; N, 15.92; 
Elemental Analysis (Calc): C, 60.44; H, 6.01; N, 15.66; 1H NMR (500 MHz, DMSO) 
δ 9.04 (d, J = 4.1 Hz, 2H), 8.94 (d, J = 8.1 Hz, 2H), 8.60 (s, 1H), 8.36 (d, J = 8.2 Hz, 
2H), 8.06 (d, J = 8.1 Hz, 2H), 7.85 (dd, J = 8.0, 4.3 Hz, 2H), 6.95 (s, 1H), 4.11 (s, 1H), 
3.17 (s, 4H), 1.39 (s, 9H); 13C NMR (126 MHz) δ 166.02, 156.00, 150.00, 148.18, 
143.91, 135.19, 132.49, 129.88, 126.03, 123.57, 78.10, 48.73, 28.53; IR: 3648, 3363, 
3314, 3078, 2978, 2944, 1693, 1638, 1544, 1528, 1480, 1448, 1395, 1367, 1351, 1330, 
1303, 1278, 1250, 1235, 1171, 1032, 978, 856, 807, 740, 699, 676, 644, 623 cm-1 
 
N-Boc-2 2'-(ethylenedioxy)bis(ethylamine)-IMP (23) 
Yield: 0.29 g (44.93 %); Appearance; Yellow solid; Solubility: MeOH, DMSO, DMF; 
LC-MS (ESI) calcd for C29H31N6O3S2, 575.1894 [M+H]
+, found 575.1873; 1H NMR 
(500 MHz, DMSO) δ 9.02 (d, J = 2.9 Hz, 2H), 8.91 (d, J = 7.7 Hz, 2H), 8.81 (s, 1H), 
8.35 (d, J = 8.4 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.87 – 7.78 (m, 2H), 6.99 (s, 1H), 
3.61 (dd, J = 12.6, 6.3 Hz, 2H), 3.24 (dd, J = 12.8, 6.3 Hz, 2H), 2.96 (t, J = 6.9 Hz, 
2H), 2.80 (t, J = 6.9 Hz, 2H), 1.37 (s, 9H); 13C NMR (126 MHz, DMSO) δ 155.29, 
149.29, 147.68, 143.26, 134.53, 131.98, 129.52, 127.65, 125.70, 123.23, 123.03, 
77.40, 37.39, 36.87, 27.93; IR: 3213, 2976, 2929, 1688, 1637, 1519, 1480, 1451, 1396, 
1365, 1308, 1278, 1252, 1166, 1069, 1029, 953, 856, 805, 775, 741, 705, 644, 622 cm-
1 
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N-Boc-cystamine-IMP (24) 
Yield: 0.29 g (43.22 %); Appearance: Yellow solid; Solubility: EtOH, MeOH, CHCl3, 
DCM, DMSO, DMF; LC-MS (ESI) calcd for C31H35N6O5, 571.2663 [M+H]
+, found 
571.2637; 1H NMR (500 MHz, DMSO) δ 9.02 (d, J = 1.6 Hz, 2H), 8.92 (d, J = 7.7 Hz, 
2H), 8.67 (s, 1H), 8.35 (d, J = 7.7 Hz, 2H), 8.08 (d, J = 7.7 Hz, 2H), 7.83 (d, J = 2.9 
Hz, 2H), 6.74 (s, 1H), 3.40 – 3.27 (m, 10H), 3.07 (d, J = 5.3 Hz, 2H), 1.35 (s, 9H); 13C 
NMR (126 MHz, DMSO) δ 166.03, 155.87, 149.92, 148.22, 143.88, 135.18, 132.47, 
129.96, 128.19, 127.01, 126.20, 124.51, 123.62, 119.20, 110.03, 77.88, 69.77, 69.42, 
69.14, 28.44. IR: 3310, 3071, 2974, 2868, 1691, 1639, 1518, 1480, 1452, 1396, 1365, 
1281, 1250, 1169, 1100, 1031, 1017, 969, 952, 860, 806, 776, 741, 712, 675, 644, 621 
cm-1. 
 
E.3.7  The deprotection of N-Boc-ethylenediamine-IMP (25)  
 
N-Boc-ethylenediamine-IMP was deprotected as described by Trindade et al322. N-
Boc-ethylenediamine-IMP (0.2 g, 0.4 mmol) was added to cooled trifluoroacetic acid 
(TFA; 5 ml) and stirred at room temperature for two hours. The TFA was removed in 
vacuo with the aid of DCM (50 ml) and a minimal volume of DMF was used to 
dissolve the residue. The addition of 200 µl triethylamine (TEA) resulted in 
precipitation of a yellow product. A 70:30 mixture of diethyl ether and acetone was 
used to wash the product. The product was filtered and washed with an excess of 
acetone and diethyl ether and dried at 60oC overnight. Yield: 0.108 g (71.05%); 
Appearance: Yellow solid; Solubility: MeOH, DMF, DMSO; λmax: 225. 278, 327 nm; 
LC-MS (ESI) calcd for C22H19N6O 383.1615 [M+H]
+, found 383.1620; Elemental 
Analysis (Found): C, 68.56; H, 4.26; N, 22.22; Elemental Analysis (Calc): C, 69.10; 
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H, 4.74; N, 21.98; 1H NMR (500 MHz, DMSO) δ 9.01 (d, J = 5.6 Hz, 2H), 8.92 (d, J 
= 7.6 Hz, 2H), 8.25 (s, 1H), 7.89 (dd, J = 12.8, 8.3 Hz, 4H), 7.36 (d, J = 7.0 Hz, 2H), 
3.66 – 3.52 (m, 2H), 3.34 – 3.00 (m, 2H), 2.08 (s); 13C NMR (126 MHz, DMSO) δ 
165.51, 158.34 – 158.18 (m), 149.64, 148.09, 143.32, 133.38, 131.93, 130.47 – 130.11 
(m), 127.03, 125.17, 123.60, 121.82, 38.33; IR: 3373, 1677, 1553, 1520, 1481, 1454, 
1399, 1309, 1203, 1134, 1073, 1034, 859, 837, 802, 739, 721, 674, 645, 625 cm-1  
 
E.3.8 The conjugation of folic acid with IMP-ethylenediamine (26) 
 
Folic acid was conjugated with IMP-ethylenediamine as previously described by 
Trindade et al322. To a solution of folic acid (0.447 g, 1 mmol) dissolved in 30 ml 
anhydrous DMSO, DCC (0.413 g, 2 mmol) and NHS (0.233 g, 2 mmol) were added 
successively. The reaction mixture was stirred in the absence of light for 24 hr at room 
temperature, after which time, a colourless precipitate, dicyclohexylurea, was removed 
by vacuum filtration. To the orange filtrate, 0.279 ml (2 mmol) of triethylamine and 
0.413 g (2 mmol) DCC were added, followed by compound 25 (0.57 g, 2 mmol) 
dissolved in 5 ml DMSO. The mixture was stirred overnight at room temperature, in 
the absence of light before a mixture of acetone in diethyl ether (20% v/v; 100 ml) was 
added. The fine, yellow precipitate was centrifuged at 3000 RPM for 10 minutes. 
Centrifugation was repeated in methanol, acetone and diethyl ether. The product was 
dried in a 60oC oven overnight. Yield: 0.508 g (71.05%); Appearance: Yellow solid; 
Solubility: DMSO (hot), DMF (hot); λmax: 283, 333 nm; LC-MS (ESI) calcd for 
C41H35N13O6 806.28 [M+H]
+, found 806.28; Elemental Analysis (Found): C, 54.52; H, 
4.19; N, 20.00; Elemental Analysis (Calc): C, 54.97; H, 5.06; N, 20.33; 1H NMR (400 
MHz, DMSO) δ 8.98 (d, J = 42.2 Hz, 23H), 8.77 – 8.51 (m, 12H), 8.34 (s, 12H), 8.05 
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(s, 21H), 7.82 (s, 13H), 7.67 (td, J = 21.2, 10.5 Hz, 10H), 6.89 (d, J = 3.3 Hz, 11H), 
6.76 – 6.52 (m, 11H), 4.46 (ddd, J = 33.4, 30.9, 15.1 Hz, 11H), 2.93 (s, 6H), 2.80 (s, 
5H), 2.67 (s, 3H), 2.58 (d, J = 11.3 Hz, 5H), 2.33 (s, 6H), 2.20 (s, 8H), 2.08 (s, 7H), 
1.93 (s, 6H). 13C NMR (101 MHz, DMSO) δ 176.36, 174.20, 172.22, 166.60, 166.42, 
166.00, 165.91, 165.55, 161.00, 154.32, 153.93, 150.80, 149.68, 148.50, 147.99, 
143.70, 135.04, 133.46, 132.24, 130.46, 129.74, 129.15, 127.98, 125.94, 123.39, 
121.45, 118.42, 112.50, 111.20, 53.28, 45.90, 45.72, 45.54, 40.15, 39.94, 39.52, 39.52, 
39.31, 39.10, 38.89, 32.72, 32.15, 30.72, 29.27, 27.55; IR: 3318, 3077, 2937, 1641, 
1605, 1571, 1532, 1516, 1480, 1453, 1397, 1300, 1273, 1180, 1126, 1073, 1031, 1016, 
995, 969, 953, 878, 858, 836, 821, 809, 768, 740, 713, 696, 676 cm-1  
 
E.3.9  The coordination of copper(II) and manganese(II) to the folate-
ethylenediamine-imidazole-phenanthroline (FIMP-et) ligand 
 
To a stirred solution of compound 26 (0.1 g, 0.1 mmol) in methanol (20 ml), a 
methanolic solution of metal(II) perchlorate hexahydrate (0.03 mmol) was added. The 
suspension was refluxed for four hours, after which the suspension was cooled and 
centrifuged at 3000 rpm for five minutes. Centrifugation was repeated in deionised 
water, methanol and diethyl ether. The product was dried at room temperature 
overnight. 
 
Special caution is advised when handling or working with metal perchlorates due to 
their potentially oxidising and explosive nature. 
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[Cu(FIMP-et)(H2O)2].(ClO4)2.4.5H2O (27) 
Yield: 0.11 g (75.21 %); Appearance: Green-brown solid; Solubility; partially soluble 
in DMSO and DMF; λmax: 212, 253, 401 nm; Elemental Analysis (Found): C, 49.14; 
H, 3.78; N, 18.23; Cu. 3.39; Elemental Analysis (Calc.): C, 49.46; H, 4.20; N, 18.29; 
Cu, 3.19; IR: 3330, 3078, 2939, 1641, 1604, 1566, 1553, 1532. 1481, 1457, 1403, 
1360, 1304, 1278, 1186, 1100, 1079, 1023, 953, 862, 840, 813, 771, 738, 712 cm-1. 
 
[Mn(FIMP-et)].(ClO4)2.9H2O (28) 
Yield: 0.091 g (77.45 %); Appearance: Yellow solid; Solubility; partially soluble in 
DMSO and DMF; λmax: 213, 254, 283, 399 nm; Elemental Analysis (Found): C, 
52.52; H, 3.95; N, 19.47; Mn, 1.00; Elemental Analysis (Calc.): C, 52.14; H, 4.38; N, 
19.28; Mn, 1.94; IR: 3265, 3083, 2939, 2808, 1688, 1637, 1606, 1561, 1524, 1478, 
1453, 1399, 1305, 1277, 1180, 1101, 1076, 953, 859, 817, 811, 772, 737, 712 cm-1. 
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E.4 The cytotoxicity and mechanism of action of simple copper(II) 
and manganese(II) folate complexes and their 1,10-phenanthroline derivatives. 
 
E.4.1  Cell culture 
 
E.4.1.1 Cell culture conditions 
 
SKOV-3 (human ovarian adenocarcinoma cells), A549 (human lung carcinoma cells) 
and RPE-1 (non-malignant retinal epithelial cells) were purchased from American 
Type Culture Collection. MelJuSo-UbG76V-YFP (human melanoma cells) were 
generated as previously described338. Briefly, MelJuso cells were transfected with a 
UbG76V‐GFP reporter plasmid for 48 hours and subsequently cultured in the presence 
of G418 (Sigma) to select for stably transfected cells. SKOV-3, A549, RPE-1 and 
MelJuSo-UbG76V-YFP were grown in folate-free RPMI 1640 medium (Gibco), 
supplemented with 10% foetal bovine serum and 5% penicillin/streptomycin (Life 
Technologies). Cells were cultured in 5% CO2 at 37
oC.  
 
E.4.1.2 Folate saturation experiments in SKOV-3 
 
For folate saturation experiments, SKOV-3 cells were plated in two separate 25ml 
flasks (Sarstedt) at 37oC in 5% CO2 and grown for 1 week before treatment. One flask 
was then cultured in folate-free RPMI 1640 media, while the other was cultured in 
RMPI-1640 media supplemented with 100 µM folic acid for one week. Cells were 
harvested, and cell viability was measured using the Alamar Blue Assay as described 
in section E.4.3 
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E.4.2  Western blot analysis 
 
E.4.2.1 Western blot analysis of folate receptor expression 
 
SKOV-3 (human ovarian adenocarcinoma), A549 (human lung carcinoma), RPE-1 
(retinal epithelial) and MelJuSo-UbG76V-YFP (human melanoma expressing UbG76V-
YFP and nuclear red) cells were seeded at 200,000 cells per well in folate-free RPMI 
1640 medium and grown to 80% confluency. Cells were lysed in RIPA buffer (140 
mM NaCl, 10 mM Tris-Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 
0.1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (Sigma 
Aldrich). Protein concentrations of cell lysates were determined using the detergent 
compatible (DC) protein assay (Bio-Rad) at 570 nm. 15 µg/well total protein were 
resolved on 4-12% Bis-Tris PAGE gels (Invitrogen) in MES buffer (pH 7.3) and 
transferred onto a nitrocellulose membrane (Bio-Rad) for Western blotting. Equal 
protein loading was confirmed using reversible Ponceau staining. Blots were 
developed with enhanced chemiluminescence reagents (Bio-Rad) on a Chemi-DocTM 
Imaging system (Bio-Rad). Primary antibody anti-FRα (Thermofisher Scientific) was 
used at a 1:1000 dilution and secondary antibody, anti-rabbit-horseradish peroxidase 
(HRP) (Thermofisher Scientific) was used at a 1:1000 dilution. 
 
E.4.2.2 Western blot analysis of [Cu(fol)(phen)(H2O)].3H2O mechanism of 
action 
 
Western blots were prepared as described in Section E.4.2.1 with the following 
deviations: 
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MelJuSo-UbG76V-YFP cells were cultured as per section E.4.1 and treated with 1.57-5 
µM of [Cu(fol)(phen)(H2O)].3H2O, and [Cu(phen)2]
2+ in folate-free RPMI 1640 
medium. Bortezomib (50 nM) was included as a positive control and DMSO-treated 
(0.05%) cells were used as a negative control for [Cu(fol)(phen)(H2O)].3H2O and 
ethanol-treated (0.05%) cells were used as a negative control for [Cu(phen)2]
2+. Cells 
were harvested following 6 hr and 18 hr treatments. 15 µg/well protein was resolved 
for each sample. Proteins with molecular weight greater than 40 kDa (K48 Ub, GFP, 
HSPA6, BIP, and p53) were resolved on 3-8% Tris-Acetate PAGE gels (Invitrogen) 
in tris-acetate buffer (pH 8.3). Proteins with molecular weights less than 40 kDa 
(HMOX-1, Casp-3, and p21) were resolved on 4-12% Bis-Tris PAGE gels (Invitrogen) 
in MES buffer (pH 7.3). 
 
Antibodies used in this study were as follows (Table 16): β actin (Sigma Aldrich), 
HSPA6 (Sigma Aldrich); Ubiquitin K48 (Apu2) (Millipore); Green Fluorescence 
Protein (Cell Signalling); GRP78/BiP (Cell Signalling); Tumour Suppressor p53 
(Santa Cruz Bio); Heme Oxygenase 1 (BD Biosciences), Caspase 3 (BD Biosciences); 
and CDK-interacting protein 1 (Cell Signalling). All primary antibodies were used at 
a 1:5000 dilution. Secondary antibodies, mouse-IgG-HRP (Cell Signalling), and 
rabbit-IgG-HRP (Cell Signalling) were used at a 1:1000 dilution. Blots were developed 
on a Chemi-DocTM Imaging system (Bio-Rad). 
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Table 16: Antibodies used, including molecular weight, target of interest and protein 
function in the cell 
Antibody 
Molecular Weight 
(kDa) 
Protein Target Function 
Anti-β-actin 42 Actin 
Housekeeping 
protein (loading 
control) 
Anti-heat shock 
protein HSPA6 
71 HSPA6 
Mitochondrial 
chaperone 
Anti-ubiquitin K48 Various Ubiquitin Protein degradation 
Anti-green 
fluorescent protein 
27 
GFP-linked 
Ubiquitin 
Protein degradation 
Anti-GRP78/BiP 78 GRP78/BiP 
Chaperone - 
Endoplasmic 
reticular stress 
Anti-p53 53 p53 
Tumour suppressor 
Apoptosis 
Anti-Heme 
Oxygenase 1 
32 HMOX-1 
Anti-oxidase 
(Oxidative stress) 
Anti-caspase 3 32/17 (cleaved) Caspase-3 
Death protease 
Apoptosis 
Anti-CDK-
interacting protein 1 
21 p21 
Kinase 
Apoptosis 
 
E.4.2.3 Western blot analysis of [Mn(fol)(phen)(H2O)].4H2O mechanism of 
action  
 
Western blots were prepared as described in Section E.4.2.1 with the following 
deviations: 
 
MelJuSo-UbG76V-YFP-NR cells were cultured as per section E.4.1 and treated with 6 
- 20 µM of [Mn(fol)(phen)(H2O)].4H2O, and [Mn(phen)2]
2+ in folate-free RPMI 1640 
medium. Bortezomib (50 nM) was included as a positive control and DMSO- and 
ethanol-treated (0.1%) cells were used as negative controls. Cells were harvested 
following 48 hr treatment. 10.5 µg/well protein was resolved for each sample. Proteins 
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with molecular weight greater than 40 kDa (HSP60 and p62) were resolved on 3-8% 
Tris-Acetate PAGE gels (Invitrogen) in tris-acetate buffer (pH 8.3). HMOX-1 protein 
was resolved on 4-12% Bis-Tris PAGE gels (Invitrogen) in MES buffer (pH 7.3). 
 
Antibodies used in this study were as follows (Table 17): Anti-α tubulin (Sigma 
Aldrich), anti-heat shock protein HSP60 (Cell Signalling), anti-p62 (Cell Signalling), 
anti-Heme Oxygenase 1 (BD Biosciences). All primary antibodies were used at a 
1:5000 dilution. Secondary antibodies, mouse-IgG-HRP (Cell Signalling), and rabbit-
IgG-HRP (Cell Signalling) were used at a 1:1000 dilution. 
 
Table 17: Antibodies used, including molecular weight, target of interest and protein 
function in the cell 
Antibody 
Molecular Weight 
(kDa) 
Protein Target Function 
Anti-α tubulin 51 Tubulin 
Housekeeping 
protein (loading 
control) 
Anti-heat shock 
protein HSP60 
60 HSP60 
Mitochondrial 
chaperone 
Anti-p62 62 p62 Autophagic flux 
Anti-Heme 
Oxygenase 1 
32 HMOX-1 
Anti-oxidase 
(Oxidative stress) 
 
E.4.3 Cell viability assay 
 
The Alamar Blue assay encompasses a fluorometric/colorimetric growth indicator 
based on the detection of metabolic activity. The system incorporates an oxidation-
reduction indicator that both fluoresces and changes colour in response to chemical 
oxidation of growth medium as a result of cell death. A decrease in cell viability results 
in a colour change from pink (reduced, fluorescent) to blue (oxidised, non-fluorescent).  
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E.4.3.1 Effects of [Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O 
in 2D monolayer cell culture  
 
The Alamar Blue assay (Invitrogen) was used to measure cell proliferation effects of 
[Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O against SKOV-3 and A549 
cells. Cells were grown to 80% confluency and seeded at a density of 5000 cells per 
well in triplicate in 96-well plates (Corning). Preliminary studies were conducted in 
the range of 2.5 – 100 µM using [Cu(fol)(H2O)3].H2O and [Cu(fol)(phen)(H2O)].3H2O 
and starting materials (folic acid, 1,10-phenanthroline, and copper(II) chloride). 
Cisplatin was used as a positive control (2.5 – 100 µM) and DMSO-treated cells (0.5%) 
and ethanol treated cells (0.5%) were used as negative controls. After 24 h incubation 
at 37oC in 5% CO2, cell viability was measured by fluorescence using a Tecan Spark 
microplate reader from 560 – 590 nm. Cell viability was calculated as a percentage of 
solvent-treated control cells and expressed as a percentage of the control. 
 
Following preliminary studies above, subsequent cell viability studies testing 
[Cu(fol)(phen)(H2O)].3H2O and its non-targeted complex, [Cu(phen)]
2+, were 
performed in the concentration range 1 – 10 µM on SKOV-3 and A549 cell lines. 
Cisplatin was used as a positive control (1 – 10 µM) and DMSO-treated cells (0.05%) 
and ethanol treated cells (0.05%) were used as negative controls. In both studies, after 
24 h incubation at 37oC in 5% CO2, cell viability was measured by fluorescence using 
a Tecan Spark microplate reader from 560 – 590 nm. Cell viability was calculated as 
a percentage of solvent-treated control cells and expressed as a percentage of the 
control. Significance values were calculated using multiple t-tests (Prism V8.1) 
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E.4.3.2 Effects of folate saturation on cytotoxicity of 
[Cu(fol)(phen)(H2O)].3H2O  
 
SKOV-3 cells were cultured as described in section E.4.1. Cells were then treated with 
1 – 10 µM [Cu(fol)(phen)(H2O)].3H2O for 24 hrs in the presence or absence of 100 
µM folic acid (FAH2). DMSO (0.05%) was used as a negative control. Cell viability 
was measured by fluorescence using a Tecan Spark microplate reader from 560 – 590 
nm and calculated as a percentage of solvent-treated control cells and expressed as a 
percentage of the control. 
 
E.4.3.3 Effects of [Mn(fol)(H2O)3].3H2O and [Mn(fol)(phen)(H2O)].4H2O  
in 2D monolayer cell culture 
 
The Alamar Blue assay was used as described in Section E.4.3.1 with the following 
deviations: 
Preliminary studies were conducted in the range of 3 – 100 µM using 
[Mn(fol)(H2O)3].3H2O, [Mn(fol)(phen)(H2O)].4H2O, and [Mn(phen)2]
2+. Cisplatin 
was used as a positive control (3 – 100 µM) and DMSO-treated cells (0.5%) and 
ethanol treated cells (0.5%) were used as negative controls. Cells were treated for 24 
and 48 hours at 37oC and 5% CO2. 
 
Following preliminary studies, subsequent cell viability studies using 
[Mn(fol)(phen)(H2O)].4H2O and its non-targeted comparator, [Mn(phen)]
2+, were 
performed in the concentration range 2 – 20 µM against SKOV-3 and A549 cell lines. 
Bortezomib was used as a positive control (20 – 200 nM) and DMSO-treated cells 
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(0.1%) and ethanol treated cells (0.1%) were used as negative controls. Cells were 
treated for 48 and 72 hours at 37oC in 5% CO2. In both studies, cell viability was 
measured by fluorescence using a Tecan Spark microplate reader from 560 – 590 nm. 
Significance values were calculated using multiple t-tests (Prism V8.1) 
 
 
E.4.3.4 Effects of folate saturation on cytotoxicity of 
[Mn(fol)(phen)(H2O)].4H2O 
 
SKOV-3 cells were cultured as described in section E.4.1. Cells were then treated with 
2- 20 µM [Mn(fol)(phen)(H2O)].4H2O for 48 hrs in the presence or absence of 100 
µM folic acid. DMSO (0.1%) was used as a negative control. Cell viability was 
measured by fluorescence using a Tecan Spark microplate reader from 560 – 590 nm 
and calculated as a percentage of solvent-treated control cells and expressed as a 
percentage of the control. 
 
E.4.4  Cytotoxicity of [Cu(fol)(phen)(H2O)].3H2O and    
  [Mn(fol)(phen)(H2O)].4H2O against 3D tumour spheroids 
 
SKOV-3 cells were seeded at 10,000 cells per well in an ultra-low adherence, round 
bottomed 96-well plate (Corning, Costar) in folate-free RPMI 1640 medium 
supplemented with 10% FBS and 5% Penicillin/streptomycin. Cells were allowed to 
settle at the bottom of each well at room temperature for one hour before being cultured 
at 37oC for five days in a 5% CO2 humidified incubator without interference.  
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Cells were treated with [Cu(fol)(phen)(H2O)].3H2O, and [Cu(phen)2]
2+ at 
concentrations ranging from 1 – 10 µM, and [Mn(fol)(H2O)3].3H2O, and 
[Mn(phen)2]
2+ at concentrations ranging from 2 – 20 µM. Bortezomib was used as a 
positive control at concentrations between 30 - 100 nM. DMSO-treated cells (0.1%) 
were used as a negative control. Spheroids were treated for 72 hr and imaged every 
three hours using an IncuCyte-FLR 10X phase contrast/fluorescence microscope 
(Essen Instruments, Ann Arbor, MI). Spheroid volume was calculated using ImageJ 
software. Spheroid volume (V = 0.5 * Length * Width2) 
 
E.4.5 Quantification of UbG76V-YFP fluorescence 
 
MelJuSo-UbG76V-YFP cells were treated with 0.157 – 5 µM of [Cu(fol)(phen)(H-
2O)].3H2O, and [Cu(phen)2]
2+. Bortezomib, a clinically used proteasome inhibitor, was 
used as a positive control (100 nM). Cells were treated with DMSO (0.05%) and 
ethanol (0.05%) as negative controls. Fluorescence of treated MelJuSo-UbG76V-YFP 
cells in 96-well plates (Corning) was recorded every three hours using an IncuCyte-
FLR 20X phase contrast/ fluorescence microscope (Essen Instruments, Ann Arbor, 
MI).  
 
E.4.6  Wound scratch assay 
 
MelJuSo-UbG76V-YFP cells (300,000) were seeded into two 35 mm dishes and allowed 
to reach 100% confluency as a monolayer. A sterile 1000 µL pipette tip was used to 
gently scratch a straight line along the equator of each dish. After scratching, the dish 
was washed carefully twice with 1X PBS to remove detached cells. To the negative 
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control dish, 4 ml fresh media with 0.1% DMSO was added. To the other, 4 ml fresh 
media containing 20 µM [Mn(fol)(H2O)3].3H2O was added. Media (containing either 
0.1% DMSO or 20 µM [Mn(fol)(H2O)3].3H2O was replenished every 24 hours and 
images of the scratch site were taken every 24 hours using an Olympus inverted 
microscope for a total of 72 hours. 
 
E.4.7  Mitochondrial membrane potential  
 
SKOV-3 cells (500,000) were seeded into four 35 mm dishes. After 24 hours, cells in 
two of the dishes were treated with 20 µM [Mn(fol)(H2O)3].3H2O, while the remaining 
two dishes were replenished with media containing 0.1% DMSO. After 48 hours 
treatment, cells were trypsinised, washed and fixed in 70% ice-cold ethanol for 12 h. 
Cells were resuspended in 25 nM TMRE (tetramethylrhodamine, ethyl ester; 
Invitrogen) in PBS for 30 min. Changes in mitochondrial membrane potential (DC) 
were monitored by fluorescence using a Beckman Coulter Gallios flow cytometer. 
Data was analysed using FlowJo V10 software. 
 
E.4.8  Cell cycle analysis 
 
SKOV-3 cells (500,000) were seeded into four 35 mm dishes. After 24 hours, cells in 
two of the dishes were treated with 20 µM [Mn(fol)(H2O)3].3H2O, while the remaining 
two dishes were replenished with media containing 0.1% DMSO. After 48 hours 
treatment, cells were trypsinised, washed and fixed in 70% ice-cold ethanol for 12 h. 
Cells were resuspended in staining solution containing propidium iodide (50 µg/ml) 
and RNAse A (0.5 µg/ml) in PBS. Samples were run on Beckman Coulter Gallios flow 
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cytometer. The percentage of cells in each phase of the cell cycle was determined using 
FlowJo V10 software. 
 
E.5  The Cytotoxicity of Copper(II) and Manganese(II) FIMP 
Complexes 
The structures of these complexes can be found in section D.4.1 
 
E.5.1  Cell culture 
 
Cells were cultured as described in Section E.4.1 
 
E.5.2  Cell viability assay 
 
The Alamar Blue assay was conducted as described in Section E.4.3.1 with the 
following deviations: 
 
A549 cells were seeded at a density of 4000 cells/well while SKOV-3 were seeded at 
a density of 3000 cells/well. Cells were treated with [Cu(FIMP)2](ClO4)2.2H2O, 
[Mn(FIMP)3](ClO4)2.2H2O, or the free FIMP ligand from 10 – 100 μM. Cisplatin (100 
μM) was used as a positive control and DMSO-treated cells (1.80 %) were used as a 
negative control. Complexes were suspended or dissolved in either ethanol or DMSO 
and diluted in culture media to the concentrations specified in Table 16. After 48 hours, 
cell viability was measured by fluorescence using a Perkin Elmer Victor 3V 1420 
Multilabel Plate Counter from 560 – 590 nm.  
 
Table 18: Solvent concentration for each test compound in cell culture media. 
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Compound Solvent Concentration in Media (%) 
Folic acid DMSO (0.25 %) 
1,10-Phenanthroline Ethanol (0.03 %) 
Fol-Im-Phen (FIMP) DMSO (0.20 %) 
[Mn(FIMP)3](ClO4)2.2H2O DMSO (1.80 %) 
[Cu(FIMP)2](ClO4)2.2H2O DMSO (1.50 %) 
 
E.6. Statistical analysis of data 
Cells were treated with complexes as described in Sections 4.3.1 and 4.3.3. Data was 
obtained from three replicate wells on each plate. Each experiment was performed 
three times (three independent plates n=3). All statistical analysis was performed using 
multiple t-test, with the exception of EC50 and standard deviation. GraphPad Prism (V 
8.1) was used to calculate the EC50 concentrations for each complex. The EC50 value 
represents the concentration required to induce a 50% reduction in cell viability. The 
standard deviation was calculated using Excel. Standard deviation was used to measure 
the variability of the data set and provide information regarding the precision of the 
experiment.  
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A.2 1,10-Phenanthroline 
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A.3 Metal phenanthroline complexes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum - [Cu(phen)2Cl2].CH3OH.4.5H2O 
 
 
IR Spectrum – [Mn(phen)2Cl2] 
 
 
IR Spectrum - [[Fe(phen)3]Cl3.CH3OH.5.5H2O 
 
 
 
IR Spectrum – [Zn(phen)Cl2] 
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A.4: Complexes 1 – 2 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
IR Spectrum - [Cu(fol)(H2O)3].H2O (1) 
 
IR Spectrum - [Mn(fol)(H2O)3].3H2O (2) 
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A.5: Complexes 3 – 4 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
IR Spectrum - Fe(fol)(H2O)2Cl].4H2O (3) 
 
IR spectrum - [Zn(fol)(H2O)3].3H2O (4) 
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A.6 Complex 5 – 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum - [Cu(fol)(phen)(H2O)].3H2O (5) 
 
 
IR Spectrum - [Mn(fol)(phen)(H2O)].4H2O (6) 
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A.7 Complex 7 – 8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum - [Fe(fol)(phen)Cl].5H2O (7) 
 
 
 
 
IR Spectrum - [Zn(fol)(phen)(H2O)].4H2O (8) 
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A.8 1,10-Phenanthroline-5,6-dione (11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum 
 
 
 
 
Mass Spectrum 
 
 
 
 
1H NMR Spectrum – CDCl3 
 
 
 
 
13C NMR Spectrum – CDCl3 
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13C NMR Spectrum (DMSO) 
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A.13 N-Boc ethylenediamine (16) 
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A.14 N-Boc 2,2'-(ethylenedioxy)bis(ethylamine) (17) 
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A.15 N-Boc cystamine (18) 
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A.16 N-Boc-ethylenediamine-folate (19) 
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A.17 N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-folate (20)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum 
Mass Spectrum 
1H NMR Spectrum (DMSO) 
13C NMR Spectrum (DMSO) 
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A.18 N-Boc-cystamine-folate (21) 
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A.19 N-Boc-ethylenediamine-IMP (22) 
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13C NMR Spectrum (DMSO) 
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A.20 N-Boc-2,2'-(ethylenedioxy)bis(ethylamine)-IMP (23) 
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A.21 N-Boc-cystamine-IMP (24) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum (DMSO; water peak at 3.33 ppm removed) 
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A.22 Ethylenediamine-IMP (25) 
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A.23 Folate-ethylenediamine-IMP (26) 
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A.24 Folate-ethylenediamine-IMP (26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum (DMSO) 
1H NMR Spectrum (DMSO) (water 
13C NMR Spectrum (DMSO)  
13C NMR DEPT 135 Spectrum (DMSO)  
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A.25 Complexes 27 and 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum - [Cu(FIMP-et)(H2O)2].(ClO4)2.4.5H2O (27) 
 
 
 
 
 
IR Spectrum - [Mn(FIMP-et)].(ClO4)2.9H2O (28) 
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UV Vis spectra (200 – 700 nm) 
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